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Chapter 1
Introduction
All information a cell needs to live 
and survive is stored in the DNA and 
therefore nothing is more important 
than the maintenance of an intact and 
uncompromised genome. Unfortunately, 
endogenous as well as exogenous damaging 
agents such as reactive oxygen species, 
UV light and ionizing radiation constantly 
attack the genome. These agents cause 
DNA lesions, which can block transcription 
and replication and thereby impair protein 
production and cell division. If the DNA 
lesions are not repaired properly they can 
lead to mutations and even large-scale 
genomic rearrangements. These changes 
in the genome can result in for example 
oncogene activation or tumor suppressor 
inactivation and thereby increase cancer 
risk. To counteract these constant threats to 
genome stability, several specialized DNA 
damage recognition and repair pathways 
have evolved. These pathways are commonly 
known as the DNA damage response (DDR).
Types of DNA damage and their 
repair pathways
Nucleotide excision repair
UV light from the sun damages the DNA, 
causing mainly cyclobutane–pyrimidine 
dimers (CPDs) and 6–4 pyrimidine–
pyrimidone photoproducts (6–4PPs). These 
lesions, as well as interstrand crosslinks and 
other bulky lesions caused by numerous 
chemicals or reactive oxygen species (ROS), 
are repaired via the nucleotide excision 
repair pathway (NER). NER consist of two sub-
pathways: transcription-coupled and global 
genome nucleotide excision repair (TC-NER 
and GG-NER). Both pathways culminate in the 
same repair steps, but differ in the proteins 
involved in damage recognition. 
Global genome NER is a surveillance 
mechanism detecting helix-distorting 
lesions throughout the genome. Lesions 
such as 6-4 photoproducts are detected by 
XPC in complex with RAD23 and Centrin 2 
(CETN2)2,3. CPDs, on the other hand, only 
mildly distort the helix and are a poor XPC 
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Figure 1 Types of DNA damage 
Common DNA-damaging agents cause many different types of damage. Each type of damage requires 
one or more of the indicated pathways for repair. BER, base excision repair; CPD, cyclobutane–pyrimidine 
dimers; HR, homologous recombination; ICL, interstrand crosslink; MMR, mismatch repair; NER, 
nucleotide excision repair; NHEJ, non-homologous end joining; ROS, Reactive oxygen species; 8-oxoG, 
8-hydroxyguanine. Based on1
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Figure 2 Nucleotide excision repair
The global genome (GG-NER) repair pathway is initiated by XPC, in complex with RAD23 and Centrin 2, detects a lesion, 
either on its own, or with the help of UV-DDB complex. In transcription-coupled repair (TC-NER) RNA polymerase II 
stalls at a lesion and CSB, UVSSA and USP7 bind. It is postulated that with the help of CSA the polymerase backtracks, 
exposing the lesion. After damage recognition, the multi-subunit complex TFII-H binds to the lesion and unwinds the 
surrounding DNA with the help of XPB and XPD. RPA coats the exposed intact single-strand DNA. XPA helps to verify 
the presence of a lesion and recruits the nuclease XPF-ERCC1, which incises the DNA on the ‘5 end of the lesion. XPG 
cleaves on the 3’ side and a stretch of approximately 30 base pair is removed. The gap is filled by a polymerase and 
the nick ligated by DNA ligase. Figure based on9
substrate. To facilitate CPD detection, the 
UV-DDB1-DDB2 complex helps XPC to repair 
those lesions4,5. After binding of XPC, the 
transcription initiation and repair complex 
TFII-H is recruited. The subsequent steps are 
identical for TC-NER and GG-NER (explained 
below).
GG-NER is not fast  and efficient enough to 
repair all lesions and transcription stops when 
RNA polymerase II (RNA pol II) encounters a 
lesion. This stalling activates the transcription-
coupled repair pathway. Cockayne syndrome 
protein A and B (CSA and CSB) together with 
UV-stimulated scaffold protein A (UVSSA) 
12
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and ubiquitin-specific-processing protease 
7 (USP7) transiently bind to RNA pol II6–8. The 
CSA-CSB complex helps to remove the stalled 
polymerase to make the lesion accessible for 
repair and the TFII-H complex is recruited9.  
The TFII-H complex contains two 
helicases, XPB and XPD, which open the DNA 
around the lesion10,11 and, with the help of 
XPA, verify the presence of damaged DNA12. 
The ssDNA that becomes exposed in this step 
is bound by RPA. The damaged bases and 
approximately 30 base pairs of surrounding 
DNA are excised by XPG and XPF-ERCC113. The 
gap filling is performed via PCNA, replication 
factor C (RFC), DNA Pol δ, DNA Pol ε or DNA 
Pol κ, and DNA ligase I or XRCC1–DNA ligase 
III ligate the nick9.
Base excision repair
The bases in DNA can be damaged by 
oxidation, alkylation, deamination, and 
depurinatiation/depyrimidination. Damaged 
bases no longer form the canonical base pairs, 
leading to mis-incorporation of nucleotides 
during replication and thereby mutations. To 
prevent mutations, the damaged bases are 
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Figure 3 Base excision repair 
Base damage, such as a deaminated cytosine (uracil) can be repaired either by short or long patch repair. 
In both cases a DNA glycosylase cleaves off the damaged base and an AP-endonuclease or AP-lyase 
removes the DNA backbone. In short patch repair, polymerase β inserts a new base and removes the 
overhang and the nick is ligated by DNA ligase III. In long patch repair, polymerase β or δ inserts a stretch 
of nucleotides, displacing the intact DNA. The protruding DNA flap is removed by FEN1 and the nick 
ligated by DNA ligase I. Figure based on14
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removed by the base excision repair pathway 
(BER). BER can be divided into two sub 
pathways: long patch and short patch repair. 
In short patch repair only a single nucleotide 
is repaired, while in long patch repair a 
stretch of DNA containing the damaged base 
is removed14.
DNA glycosylases recognize damaged 
bases and cleave off the damaged base, 
leaving an apurinic or apyrmidinic site (AP 
site). The part of the DNA backbone without a 
base is then removed by an AP-endonuclease 
or an AP-lyase. A DNA polymerase, specifically 
DNA polymerase β, can fill the gap and a DNA 
ligase seals the nicks. In long patch repair the 
polymerase filling of the gap replaces more 
than one base, resulting in displacement of 
the DNA strand. This flap is then removed by 
FEN1 to create a ligatable nick14.
Mismatch repair
Mismatches arise due to the incorporation 
of the wrong nucleotide during replication 
and are corrected via the mismatch repair 
pathway (MMR). Although replicative 
polymerases have proofreading activities, 
some mismatches still occur. Inactivation of 
mismatch repair leads to increased numbers 
of mutations in the genome and predisposes 
for example to colon cancer15,16. Apart 
from correcting mismatches and insertion/
deletion loops, mismatch repair also plays 
a role in the repair of oxidative damage and 
meiotic and mitotic recombination17.
In mammalian cells mismatches are 
recognized by MSH2/MSH6 (MutSα) or 
MSH2/MSH3 (MutSβ) during replication. 
Subsequently, MutLα is recruited and this 
complex then slides along the DNA until it 
encounters a strand discontinuity and binds 
PCNA17. At the gap EXO1 is recruited and 
initiates degradation of the nicked strand 
past the mismatch. The newly formed single-
strand DNA is stabilized by RPA and filled in 
by polymerase δ. DNA ligase I seals the nick18. 
Single strand break repair
Single-strand breaks can be caused by 
ionizing radiation as well as reactive oxygen 
mismatch
Gap
Gap
MutSα
Gap
MutLα PCNA
Exo1
RPA
RPA
polymerase δ
DNA ligase
Figure 4 Mismatch repair 
MutSα recognizes single DNA mismatches, while 
MutSβ recognizes loops. Upon binding to a 
mismatch, MutSα undergoes a conformational 
chance and recruits MutLα. This complex scans 
the DNA for a gap and once it has found one, 
binds PCNA and a nuclease such as EXO1. At the 
gap, degradation of the nicked strand is initiated 
and the DNA is degraded past the mismatch. The 
exposed single-strand DNA is bound by RPA, the 
gap is filled in by polymerase δ and a ligase ligates 
the nick. Figure based on17
species (ROS) generated by the cellular 
metabolism. Single-strand breaks are rapidly 
recognized by poly (ADP-ribose) polymerase 
protein (PARP), which sequesters the scaffold 
protein XRCC1. Most single-strand breaks 
have damaged termini and end processing 
by polynucleotide kinases, polymerases and 
other enzymes can be required. Gap filling is 
usually performed by polymerase β and DNA 
ligase I or III ligates the nicks. 19 
14
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Intermezzo: Role of PARPs in 
DNA repair
Poly(ADP-ribose) polymerase (PARP) 
enzymes add negatively charged poly(ADP-
ribose) (PAR) chains to itself and/or other 
proteins as a posttranslational modification. 
The ADP-ribose monomers are derived 
from NAD+ and are attached to glutamine, 
asparagine, and lysine residues. In total there 
are 17 PARP enzymes, but only PARP1, PARP2 
and PARP3 have been linked to DNA damage 
and repair so far. PARP1 is responsible for 
about 85% of all PARylation in the cells, while 
the remaining 15% is catalyzed by PARP2. The 
activity of PARP3 seems to be very limited20. 
PARP1 and PARP2 seem to have 
overlapping roles, since the enzymes are 
partially redundant. Parp1-/- mice and Parp-
2-/- mice are viable, but the double knock-
out is lethal21. Parp1-/- and Parp2-/-- mice are 
hypersensitive to ionizing radiation and 
display signs of chromosomal instability such 
as increased sister chromatid exchange and 
micronuclei 21,22.
PARP1 is abundant in chromatin23 and 
has a high affinity for DNA single and double 
strand breaks24. At single-strand breaks, 
PARP1 (and PARP2 to a much lesser extent) 
rapidly synthesize PAR-chains, which are 
soon after removed by the (poly(ADP-ribose) 
glycohydrolase (PARG). In the absence of 
PARP1, the repair rate of single-strand breaks 
is decreased. However, for PARP2-depletion 
there is no effect, even in the absence of 
PARP125. It is important to note that in the 
absence of PARP1 the repair is only slower, 
but still functioning25. 
PARP1 also plays a role during the 
detection and repair of other types of 
damage. At stalled replication forks, PARP1 
stimulates HR by suppressing NHEJ.PARP1-/- 
chicken DT40 cells show decreased HR, but 
this phenotype is rescued by the deletion 
of Ku or DNA ligase IV, indicating that NHEJ 
needs to be prevented at stalled forks26. 
Additionally, PARylation might promote 
recruitment of HR factors such as MRE11 at 
stalled forks27. PARP1 is also recruited to UV 
damage by DDB2. Recruitment of PARP1 and 
subsequent PARylation of DDB2 result in 
decreased DDB2 auto-ubiquitination and this 
auto-ubiquitination increases the retention 
time of DDB2 at sites of damage20. 
PARP3 has been linked to NHEJ via 
the PAR binding protein Aprataxin-and-
PNK-like Factor (APLF). In the absence of 
PARP3, γH2AX foci disappear more slowly, 
indicating a decrease in NHEJ efficiency. This 
phenotype can be rescued by overexpression 
of APLF, which binds to PARP3-ribosylated 
substrates28. In the absence of APLF, the 
retention of XRCC4 at laser damage is 
decreased, so PARylation by PARP3 at sites of 
damage probably increases NHEJ by retention 
of XRCC4-DNA ligase IV via APLF28. PARP3 has 
also been linked to the stabilization of the 
mitotic spindle and in telomere integrity29. 
As described above, the enzyme PARG 
rapidly removes PAR chains from substrates. 
Deletion of PARG is embryonically lethal, 
but MEFs could be isolated by Min et al.30 
These cells show micronuclei, chromosomal 
aberrations and increased sister chromatid 
exchange, demonstrating that the removal 
of PAR-chains is also important for genomic 
stability and efficient DNA repair. 
DNA double strand break repair
One of the most detrimental types of DNA 
damage is the double strand break (DSB). 
Improper repair can lead to mutations and 
gross chromosomal rearrangements. DSBs 
are caused by ionizing radiation or can result 
from collapsed replication forks. Furthermore, 
DSBs are generated as an intermediate in the 
repair of interstrand crosslinks, during meiotic 
recombination and in antigen receptor gene 
rearrangements in T- and B-cells. There are 
two main pathways to repair a double strand 
break: HR and NHEJ.
The most accurate and reliable way to 
repair a DSB is via HR. This pathway relies on 
an intact sister chromatid, present during S 
and G2 phase of the cell cycle, as a template 
for accurate repair31,32. First, the DNA is 
resected by the MRE11, RAD50, NBS1 (MRN)-
complex33,34  together with CtIP35,36 and other 
15
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Figure 5 Homologous recombination and non-homologous end joining
NHEJ starts with recognition of the DNA ends by the Ku70/80 heterodimer, which recruits DNA-PKcs. If 
the ends are incompatible, nucleases such as Artemis can trim the ends. The XRCC4-DNA Ligase IV-XLF 
and PAXX ligation complex seals the break. For HR, the MRN-CtIP-complex starts resection on the breaks 
to generate single-stranded DNA (ssDNA). After resection the break can no longer be repaired by NHEJ. 
The ssDNA is first coated by RPA, which is subsequently replaced by RAD51 with the help of BRCA2. 
These RAD51 nucleo-protein filaments mediate strand invasion on the homologous template (the sister 
chromatid). Extension of the D-loop, capture of the second end and resolvation of the Holliday junctions 
leads to repair. Figure from31 (Chapter 2).
nucleases, generating a 3’-ssDNA overhang. 
This overhang is coated by replication 
protein A (RPA). RAD51 then replaces RPA 
with the help of BRCA2, forming nucleo-
protein filaments. During strand invasion, 
these filaments invade the homologous 
sequence on the sister chromatid and the 
DNA is extended using the intact DNA of the 
sister chromatid as a template. The second 
end of the broken DNA is captured and the 
junctions are resolved, resulting in two intact 
DNA strands. 
16
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NHEJ can take place throughout the cell 
cycle and does not require a template 31. In 
this pathway, the Ku70/80 heterodimer binds 
the end of the broken DNA and the catalytic 
subunit of the DNA dependent proteins kinase 
(DNA-PKcs) is recruited. Compatible ends 
can be created with the help of polymerases 
or nucleases such as Artemis37. The ligation 
complex, consisting of DNA ligase IV, X-ray 
cross-complementation group 4 (XRCC4) and 
XRCC4 like factor (XLF)/Cernunnos ligates 
the ends38,39. Recently a new component of 
the NHEJ machinery, PAralog of XRCC4 and 
XLF (PAXX), was identified40,41. PAXX interacts 
with Ku and is required for the formation of a 
stable NHEJ complex. Defects in NHEJ result 
in hypersensitivity to IR, immunodeficiency 
and genomic instability42–45. 
Chapter 2 discusses the regulation of 
pathway choice and the importance of the 
balance between NHEJ and HR, as well as 
assays to measure these pathways.
 
Trans Lesion Synthesis
Trans lesion synthesis (TLS) is a DNA 
damage tolerance mechanism. Many DNA 
lesions can block replication fork progression, 
eventually resulting in collapsed forks 
and DSBs. The TLS polymerases prevent 
prolonged fork stalling by bypassing 
Lagging strand
Leading strand
pol ε
pol δDamaged 
base
pol ε
pol δ
Ub
PCNA
pol ε
pol δ
Ub
PCNA
REV1
pol ε
pol δ
Ub
PCNA
REV1REV3
7
pol ε
pol δ
A
C
E
B
D
Figure 6 Trans Lesion Synthesis
When a replicative polymerase such as polymerase δ or ε encounters a damaged or modified base, 
replication stalls (A) and PCNA is ubiquitinated (B) by the Rad6-Rad18 complex (not shown). A Y-family 
translesion polymerase such as Rev1 can place a base opposite a damaged base (C) and polymerase ζ 
or other TLS polymerases can take over to bypass the lesion (D). After several bases, the TLS polymerase 
probably falls off and a replicative polymerase takes over (E). Figure based on 55–57
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damaged or missing bases, ensuring timely 
completion of replication46. To allow the 
incorporation of bases opposite damaged 
bases, TLS polymerases have a lower fidelity 
than normal replicative polymerases and 
their use increases the mutation frequency. 
However, TLS polymerases have a low 
processivity and detach from the DNA after 
synthesizing only a short stretch of DNA 
preventing excessive mutagenesis. In 
addition to bypassing replication blocks, TLS 
polymerases can repair ssDNA gaps left after 
completion of replication47,48. 
In mammals the main TLS polymerases 
can be subdivided into two groups: the Y 
family polymerases (REV1, Pol η, Pol ι and Pol 
κ) and the B-type polymerase ζ. Polymerase 
ζ consists of a polymerase subunit REV3 and 
three accessory subunits REV7, PolD2 and 
PolD349.
The recruitment of TLS polymerases is 
regulated by post-translational modifications 
on PCNA50. RAD6-RAD18 associates with 
RPA and mono-ubiquitinates PCNA at 
Lys164, the marker for the recruitment of 
TLS polymerases51–53. To bypass the lesion, it 
is generally thought that one of the Y-family 
polymerases inserts a nucleotide opposite a 
damaged base. These polymerases have an 
uncommonly large and flexible active site, 
which can accommodate such an altered 
template and lack proofreading activity48,54. 
After insertion of a nucleotide opposite the 
damage polymerase ζ or possibly other TLS 
polymerases can extend the sequence after 
which a normal replicative polymerase can 
take over 47. 
Interstrand crosslinks and the Fanconi 
Anemia pathway
Endogenous metabolites as well as 
chemotherapeutics such as cisplatin and 
Mitomycin C can form covalent bonds with 
proteins as well as DNA, causing crosslinks 
due to the presence of two reactive groups. 
Intrastrand crosslinks connect two adjacent 
bases on the same strand, while interstrand 
crosslinks are formed between two bases of 
complementary DNA strands, preventing 
opening of the DNA to allow transcription 
and replication. To remove the crosslink, both 
strands of the DNA must be incised. Proteins 
involved in the Fanconi Anemia pathway are 
required for this process58, as well as HR, TLS 
and NER.
When a replication fork encounters an 
interstrand crosslink, replication stalls and 
FANCM is recruited together with FAAP24 
and MHF1/2. This complex remodels the 
replication fork59, forming ssDNA. RPA 
localizes on the ssDNA, which activates ATR 
and thereby the DNA damage checkpoint60. 
ATR also phosphorylates FANCD2 and 
FANCI61,62 and the MRN-complex, which is 
necessary for resection58.
The FA-core complex consists of 
FANCA, B, C, E, F, G, L, M, FAAP20, FAAP24 
and MHF1/2. Assembly of this complex is 
required for monoubiquitination of FANCD2 
and FANCI by FANCL62, a critical and highly 
conserved step in ICL repair. The FANCM-
FAAP24-MHF1/2-complex recruits the FA 
core complex to the stalled replication fork59. 
Mono-ubiquitylation of FANCD2 precedes 
its translocation to chromatin63,64, where it 
promotes chromatin remodeling together 
with FANCI65. Ubiquitinated FANCD2 acts as 
a recruitment platform for nucleases involved 
in the excision of the ICL59. It is unclear exactly 
which nucleases perform the incision, but 
several nucleases such as XPF-ERCC1, MUS81-
EME1, SLX4-SLX1, FAN1, SNM1A and SNM1B 
have been implicated in ICL repair58.
Incision on both sides of the ICL results in 
unhooking of the lesion, which can then be 
bypassed by translesion synthesis forming 
an intact HR substrate. Numerous human 
TLS polymerases, including Pol η, Pol ι, Pol κ, 
Pol ν and REV1 have been shown to be able 
by bypass ICLs or to insert a base opposite 
and ICL58. Also Polζ plays an important role 
in ICL repair, since deficiency in REV3 or 
REV7 strongly sensitizes cells to crosslinking 
agents55. REV1 is thought to serve as a scaffold 
to coordinate the recruitment and activity of 
other TLS polymerases59. 
Once TLS is completed, the replication 
fork can be restarted using HR. Resection of 
18
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Figure 7 Interstrand crosslink repair
(A) Two forks converse at an interstrand crosslink. (B) The lesion is recognized by the FANCM-FAAP24-
MHF1/2 complex, which recruits the multi subunit FA-core complex. FANCM also activates ATR, which 
phosphorylates FANCD2, FANCI and components of the FA core complex. (C) The FA core complex 
ubiquitinates FANCD2 and FANCI and this complex is recruited to the lesion. (D) The ubiquitinated 
FANCD2-FANCI acts as a recruitment platform for nucleases that make incisions next to the lesion. It is 
unclear which nuclease makes which incision, but SLX4, ERCC1-XPF, MUS81-EME1 and Fan1 are probably 
involved. (E) After incision, the lesion is unhooked and can be bypassed by a translesion polymerase. The 
lesion with the crosslink attached is probably repaired via nucleotide excision repair. (F, G) Replication is 
restarted via homologous recombination. Figure based on 59
19
DNA repair – A general introduction
1
the break and RAD51 nucleoprotein filament 
formation appears to be independent of 
the FA core complex66,67. The remaining 
unhooked ICL is no longer an obstacle and is 
a likely substrate for NER. Finally, the FANCD2, 
FANCI complex is deubiquitinated by the 
DUB complex USP1-UAF168,69. 
BRCA1
BRCA1 function
In 1994 Miki et al. identified the tumour 
suppressor protein BRCA1 (Breast cancer 
type 1 susceptibility protein)70. Four years 
earlier, the location had already been linked 
to early-onset familial breast cancer71. BRCA1 
is an E3 ubiquitin-ligase that plays multiple 
roles in the repair of DNA damage, cell cycle 
regulation and transcription. 
BRCA1 contains an N-terminal RING 
domain and two C-terminal BRCT repeats. 
The RING domain, found in many E3 ubiquitin 
ligases, is likely to be required for BRCA1’s 
function as a tumour suppressor, since many 
pathogenic mutations are found in this 
domain. The RING domain of BRCA1 interacts 
with the RING domain of BARD172 and this 
interaction stimulates the ubiquitin ligase 
activity of the complex. The pathogenic C61G 
mutation in BRCA1 disrupts the interaction 
between BRCA1 and BARD1 and abolishes 
the ubiquitin ligase activity73 The BRCA1/
BARD1 complex forms K6-linked ubiquitin 
chains and auto-ubiquitylates BRCA174. 
Upon DNA damage, BRCA1 is hyper-
phosphorylated and relocates to sites 
of damage75,76, where it colocalizes with 
RAD5177. BRCA1-deficient cells are unable 
to form RAD51 foci78, indicating that BRCA1 
is essential for homologous recombination. 
Unlike BRCA2, BRCA1 does not play a role 
in one specific step of HR, but seems to 
be required for multiple processes such as 
checkpoint activation, damage signalling, 
and DNA repair, each linked to specific 
interaction partners. 
BRCA1 interacts with BRCA2 via PALB2 
(partner and localizer of BRCA2).  PALB2 was 
first identified as an essential component 
for BRCA2 and RAD51 loading at sites of 
damage79. BRCA1 localization at sites of 
damage does not require PALB280, but 
localization of PALB2 does require BRCA181. 
The interaction between BRCA1 and PALB2 
is important for homologous recombination, 
because expression of proteins with 
mutations that abrogate this interaction 
results in a reduction in homologous 
recombination80. 
BRCA1 also plays a role in resection, the 
generation of ssDNA at sites of damage, via 
its interaction with CtIP82.  CtIP is activated 
by a CDK-mediated phosphorylation on T847 
and this activation is essential for viability and 
maintenance of genomic stability83. However, 
the interaction between BRCA1 and CtIP 
might not be essential for resection84, as 
BRCA1 only seems to affects the speed of the 
process85. CtIP also interacts with the MRN 
complex36 and plays an important role in DSB 
repair pathway choice86.
BRCA1 deficiency and rescue of the 
phenotype 
To date, many BRCA1-deficient 
mouse models have been generated 87. 
Homozygous deletion of Brca1 is lethal in 
mice and nullizygous embryos die early in 
development. This phenotype is partially 
ameliorated by homozygous deletion of 
p53 and death of the embryo shifts to a later 
stage88.  Brca1Δ11/Δ11 mice also die before birth 
and this can be rescued by haploid loss of 
p53 as well89. However, these mice develop 
tumours later in life and display premature 
ageing90. Chk2 loss can also rescue the 
embryonic lethality of Brca1 loss and these 
mice live longer than Brca1Δ11/Δ11p53+/- mice90. 
Later in life the mice still develop tumours. This 
indicates that the ATM-CHK2-p53 pathway is 
important for inducing senescence, apoptosis 
and cell cycle arrest in BRCA1-deficient cells, 
preventing growth of these cells. 
Brca1Δ11/Δ11 fibroblasts rapidly undergo 
senescence in culture. This phenotype can 
be rescued by the loss of 53bp191. 53BP1 loss 
also rescued the lethality of Brca1Δ11/Δ11 mice 
and while Brca1Δ11/Δ11p53+/- mice showed 
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signs of accelerated ageing at the age of 
seven months, Brca1Δ11/Δ1153bp1-/- mice did 
not91. Furthermore, the cancer incidence was 
also much lower in Brca1Δ11/Δ1153bp1-/- mice 
compared to Brca1Δ11/Δ11p53+/- mice. 
In BRCA1-deficient cells, in the absence 
of functional homologous recombination, 
breaks are aberrantly joined via non-
homologous end joining. This is dependent 
on 53BP1 and DNA ligase IV92,93.  In the absence 
of 53BP1, ATM-dependent processing 
of DNA breaks is stimulated, resulting in 
restoration of homologous recombination92. 
Additionally, 53BP1 loss abrogates the ATM-
dependent G2 checkpoint that is activated 
upon DNA double strand break damage93. 
Deletion of DNA ligase IV does not rescue 
HR in BRCA1-deficient cells92 and although 
53BP1 loss rescues HR in BRCA1-deficient 
cells, this seems to be a specific effect. 53BP1 
loss does not rescue BRCA2-deficiency93, 
XRCC2-deficiency92 or CtIP-deficiency83. 
BRCA1 and PARP inhibitors 
Women carrying heterozygous germ line 
mutations in the tumour-suppressor genes 
BRCA1 and BRCA2 have a strongly increased 
lifetime risk of developing breast and ovarian 
cancer94. In the absence of functional HR 
the use of other error-prone DNA repair 
mechanisms can lead to chromosomal 
aberrations and can enhance tumorigenesis95.
Women with breast cancer are commonly 
treated with chemotherapy. These 
chemotherapeutics have severe side effects 
because they target all dividing cells in the 
patient’s body. Recently a new treatment 
strategy has been developed, targeting 
specifically the tumour cells with a defect in 
homologous recombination96,97 and thereby 
reducing side effects95. Cells deficient in 
homologous recombination are extremely 
sensitive to inhibition of the enzyme PARP1. 
The extreme sensitivity of HR-deficient 
cells to PARP inhibition is an excellent 
example of synthetic lethality. Synthetic 
lethality describes a situation where a defect 
or mutation in only one of two separate genes 
is compatible with life, but the combination 
of the defects results in lethality. This defect 
can be genetic, but it can also be induced by 
drugs, as is the case for PARP inhibitors.
Several mechanisms probably contribute 
to the synthetic lethality of PARP inhibitors in 
BRCA1- and BRCA2-deficient cells. Firstly, the 
inhibition of PARP1 leads to decreased repair 
of single-strand breaks. At these single-
strand breaks replication forks collapse and 
their repair requires functional homologous 
recombination. In the absence of HR, damage 
is thought to accumulate or to be repaired 
via error-prone repair mechanism, resulting 
in cell death. However, Patel et al. showed 
that the synthetic lethal interaction between 
PARP inhibitors and HR does not depend on 
the essential BER protein XRCC198. Therefore, 
plain inhibition of BER is not sufficient to kill 
HR-deficient cells and other mechanisms are 
probably at play as well.  
Secondly, it has been postulated that 
PARP inhibitors trap the PARP enzyme on 
DNA, blocking access of other DNA repair 
enzymes. PARP inhibitors such as Olaparib, 
Niraparib, Veliparib and BMN673 are generally 
small molecule inhibitors that mimic the 
PARP1 cofactor β-NAD+ and bind to the 
catalytic site in PARP195. PARP1 catalyses the 
PARylation of various substrates, including 
itself (auto-PARylation). This auto-PARylation 
increases the negative charge on the enzyme, 
eventually resulting in its release from DNA99. 
Upon inhibition of its enzymatic activity, 
PARP would no longer be able to release itself 
from DNA. This process could contribute to 
the cytotoxicity of PARP inhibitors in both HR-
proficient and deficient cells. 
NHEJ is probably also involved in PARP 
inhibitor mediated cell killing in HR-deficient 
cells. Collapsed replication forks result in one-
ended DNA double strand breaks that should 
not be repaired via NHEJ, since this leads to 
chromosomal rearrangements and is toxic. 
The combination of a DNA-PK inhibitor and 
a PARP inhibitor reduces the hypersensitivity 
of BRCA1- and BRCA2-deficient cells to PARP 
inhibitors and decreased the number of PARP 
inhibitor induced chromosomal aberrations98.
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Resistance to PARP inhibitors
The treatment of BRCA1- and BRCA2-
deficient tumours with PARP inhibitors is 
very promising, but unfortunately most 
tumours eventually become resistant95,100. 
Identification of these mechanisms of 
resistance is important for patient selection 
and the identification of biomarkers. 
Additionally, knowledge of the mechanisms 
will help to select treatment strategies for 
resistant tumours. 
A pharmacological cause of resistance is 
overexpression of the P-glycoprotein efflux 
pump101. The PgP-efflux pump is a multi-
drug transporter that simply pumps small 
molecules such as olaparib out of the cells, 
resulting in a lower toxicity. This mechanism 
of resistance was observed in a genetically 
engineered mouse model (GEMM) for BRCA1-
associated breast cancer. Tumours initially 
responded to treatment with the PARP 
inhibitor Olaparib (AZD2281), but eventually 
became resistant. The resistance could 
be overcome by using the P-glycoprotein 
inhibitor Tariquidar101 or using a PARP 
inhibitor that is a poor PgP substrate, such as 
AZD2461102. When the P-glycoprotein efflux 
pump is genetically inactivated, tumours 
respond to PARP inhibitors for a longer period, 
but still become resistant eventually102. This 
indicates that there are other mechanisms of 
resistance at play as well. 
Most pathogenic mutations in BRCA1 and 
BRCA2 result in a frame shift or a premature 
stop and expression of a truncated or non-
functional protein. One of the main genetic 
mechanisms of resistance is reversion of 
the BRCA mutation or an internal deletion. 
These new mutations result in restoration 
of the reading frame and expression of a 
functional protein. Since there is no longer a 
defect in HR, these tumours are resistant to 
PARP inhibitors. This mechanism of resistance 
has been shown to occur in BRCA2-deficient 
CAPAN-1 cells and can also occur in response 
to cisplatin in BRCA- mutated ovarian cancers 
in patients whose tumours have become 
resistant to cisplatin treatment103,104. Norquist 
et al. showed that these secondary mutations 
arise in hereditary ovarian carcinomas after 
cisplatin treatment and that they also confer 
resistance to PARP inhibitors105. In that study 
Figure 8 PARP inhibitors 
Single-strand breaks occur spontaneously and are repaired efficiently by single-strand break repair. If 
PARP enzymes are blocked by a PARP inhibitor, single-strand breaks are repaired less efficiently and may 
remain open when the DNA is replicated in S-phase. When a replication forks runs into a single-strand 
break, the fork collapses. Homologous recombination is required to restart the replication fork. In BRCA1-
deficient tumours, homologous recombination is impaired, resulting in accumulation of damage and 
eventually cell death. BRCA1-deficient cell and tumours can become resistant to PARP inhibitors via 
several mechanisms. 
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six patients were first treated with cisplatin 
and then with PARP inhibitors. So far, this is 
the only mechanism of resistance that has 
been demonstrated to occur in patients. 
Another genetic mechanism of resistance 
that does not depend on restoration of 
BRCA1 or BRCA2 protein expression but still 
leads to restoration of HR is the loss of 53BP1. 
Brca1Δ11/Δ1153bp1-/-cells are not hypersensitive 
to PARP inhibition while Brca1Δ11/Δ11 MEFs 
are hypersensitive to the drug92. Loss of 
53BP1 in BRCA1-deficient cells results in an 
almost complete restoration of homologous 
recombination. BRCA1-deficient cells are 
unable to form RAD51 foci after damage 
(described above), but after deletion of 
53BP1, cells can form RAD51 foci to a similar 
extent as wild-type cells92,93. Also gene-
targeting93, sister chromatid exchange and 
HR as measured via the DR-GFP assay92 were 
increased in BRCA1 and 53BP1-deficient  cells 
compared to BRCA1-deficient cells. Addition 
of an ATM inhibitor resensitized Brca1Δ11/
Δ1153bp1-/- cells to PARP inhibition, because 
53BP1 loss restores ATM-dependent RPA 
phosphorylation levels back to wild-type 
levels92. Jaspers et al. showed that in a fraction 
of cases (3 out of 11), 53BP1 loss occurs as a 
mechanism of resistance in mice bearing 
mammary tumours from K14cre;Brca1F/F;p53 
F/F;Mdr1a/b-/-mice, a model for breast cancer 
in which the P-glycoprotein efflux pump is 
genetically inactivated (Mdr1a/b−/−) 102. 
It thus seems that restoration or increase 
of resection is an important mechanism 
of resistance. This hypothesis is further 
supported by the finding that expression of 
a phospho-mimicking mutant of CtIP that is 
constitutively active (CtIP-T847E) is able to 
rescue the sensitivity to PARP inhibitors in 
BRCA1-deficient cells 83. 
In vitro loss of PARP1 has also been 
observed as a mechanism of resistance in 
haploid cells that were not HR-deficient106. 
This mechanism is less likely to occur in HR-
deficient cells, because PARP1 loss decreases 
survival97. However, after restoration of HR by 
another resistance mechanism, PARP1 loss 
may be beneficial.
BRCA2
Wooster et al. identified the locus of the 
second breast cancer susceptibility gene in 
199494 and few years later it was discovered 
that BRCA2 is required for HR and thereby 
maintenance of chromosomal stability107,108. 
BRCA2 also plays a role in the loading of 
RAD51109 during meiotic recombination and 
via the meiosis specific recombinase DMC1110.
BRCA2 consist of a largely unexplored 
N-terminal domain, a middle domain which 
contains BRC repeats that interact with 
RAD51111 and a large C-terminal domain. 
PALB2 interacts with BRCA2 at the N-terminal 
part, but the structure of this domain is still 
unknown. The C-terminal domain contains 
the DNA-binding domain (DBD), which 
consists of three OB-folds and a helical 
domain112. FANCD2 and HSF2BP interact with 
BRCA2 in the C-terminal region.
The main function of BRCA2 in 
homologous recombination is to load RAD51 
on the single-stranded DNA, replacing RPA. 
BRCA2 interacts with RAD51113 via its BRC 
repeats114. Loss of BRCA2 results in mis-
localization of RAD51 in the cytoplasm, 
indicating that BRCA2 is required to keep 
RAD51 in the nucleus114. Upon DNA damage 
such as ionizing radiation, RAD51 and BRCA2 
colocalize in nuclear foci115. 
PALB2 interacts with BRCA1 as well as 
BRCA2 and all three proteins colocalize in 
nuclear foci together with RAD5179,80. PALB2 
promotes stable nuclear localization and 
accumulation of BRCA2 and interacts with 
BRCA2 via its C-terminal WD40 domain116. In 
the absence of PALB2, BRCA2 foci formation is 
decreased79. The interaction between PALB2 
and BRCA2 is also important for tumour 
suppression, since several pathogenic 
mutations in BRCA2 disrupt the interaction 
with PALB279. Furthermore, mutations in 
PALB2 predispose to breast and pancreatic 
cancer117. Other functions of PALB2 in the 
DNA damage response are reviewed by Park 
et al. 116. 
BRCA2 also interacts with FANCD2, an 
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important player in the Fanconi Anemia 
pathway. BRCA2 and FANCD2 are in a complex 
that also contains FANCG and XRCC3118. In the 
BRCA2-mutated cell line CAPAN-1, FANCD2 
still forms nuclear foci upon damage, 
indicating that the interaction between 
BRCA2 and FANCD2 is not required for the 
recruitment of FANCD2 to sites of damage119. 
Reciprocally, the absence of FANCD2 has little 
effect on HR and RAD51 foci formation120.
 
Cell lines and phenotype
Cell lines expressing truncated BRCA2 
proteins show decreased proliferation that 
worsens over time. This proliferation defect is 
associated with cell cycle arrest in G1 and G2/M 
and increased p21 and p53 expression121. 
The most studied BRCA2-deficient cell line 
is CAPAN-1. In this pancreatic cancer derived 
cell line one wild-type copy of BRCA2 is lost, 
while the other has a 6174delT mutation, 
which results in a truncation at amino acid 
1982122,123. 
BRCA2-deficient cells are hypersensitive 
to DNA damaging agents such as UV, IR, 
MMS, MMC and PARP inhibitors96,97,113,121,124. 
Since BRCA2 is essential for recombination, 
BRCA2-mutated cells lines such as CAPAN-1 
display decreased homology directed repair 
as measured by the DR-GFP assay107 and a 
homologous plasmid-targeting frequency 
assay125.  Furthermore, BRCA2-deficient cells 
are unable to form RAD51 foci108.
Also for BRCA2, several different 
(conditional) mouse models have been 
created87. BRCA2 deficiency is embryonically 
lethal and development of the embryo arrests 
after 6.5 days of gestation113. As for BRCA1, 
the phenotype of BRCA2 nullizygous mice 
is less severe in a p53 null background 88. 
However, even in a p53 null background no 
mice are born. Additionally, BRCA2 deficiency 
can not be rescued by deletion of 53BP193.  
  
BRCA2 and the Fanconi Anemia pathway
Fanconi Anemia (FA) is a rare genetic 
disease characterized by congenital skeletal 
and renal anomalies, growth retardation, 
haematological abnormalities, bone marrow 
failure and predisposition to a variety of 
cancers58,126. The Fanconi Anemia pathway 
repairs interstrand crosslinks and cells from 
FA patients are hypersensitive to interstrand 
crosslinking agents such as MMC. Classically, 
FA was diagnosed by exposing patient cells 
to these agents, which results in increased 
levels of chromosomal aberrations compared 
to cells from a healthy control. Additionally, 
complementation studies were performed 
to distinguish between different FA sub-
types. To date, 16 FA complementation 
groups have been described (FANCA, FANCB, 
FANCC, FANCD1, FANCD2, FANCE, FANCF, 
FANCG, FANCI, FANCJ, FANCL, FANCM, 
FANCN, FANCO, FANCP and FANCQ)126,127. 
Different FA complementation groups differ 
in their causative mutations and severity of 
the disease. FANCA, FANCB, FANCC, FANCE, 
FANCF, FANCG, FANCL, and FANCM together 
form the FA core complex that ubiquitinates 
FANCD2 and FANCI and mutations in these 
genes account for approximately 90% of the 
patients128. 
To repair DNA interstrand crosslinks, both 
HR and the FA pathway are required and 
mutations in several HR proteins also give an 
FA-phenotype. For example FANCJ is BRIP1/
BACH1129,130 and FANCO is RAD51C131,132. 
Heterozygous mutations in BRCA2 
predispose to breast and ovarian cancer, 
but patients with certain homozygous 
mutations suffer from Fanconi Anemia 
(complementation group D1133). BRCA1-/- and 
BRCA2-/- tumour cells are hypersensitive to 
MMC, similar to FA patient cells. Howlett et al. 
sequenced BRCA1 and BRCA2 in FA-B and FA-
D1 patients cells and identified homozygous 
BRCA2 mutations in two FA-D1 patient cell 
lines and two unclassified lines133. 
Mutations in BRCA2 partner PALB2 also 
cause Fanconi Anemia. Xia et al.134 started 
from an unclassified FA line (EUFA1341) that 
showed normal FANCD2 ubiquitination and 
no mutations in the then known downstream 
proteins BRCA2 and FANCJ.  The individual 
was classified as a new FA complementation 
group FANCN. Western Blot analysis showed 
the absence of PALB2 and re-expression 
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of PALB2 in EUFA1341 rescued the MMC 
sensitivity134. Reid et al identified PALB2 
mutations in seven families affected with 
Fanconi Anemia135. 
Scope of this thesis
DNA repair pathways are essential for the 
maintenance of a healthy genome. Mutations 
in proteins involved in DNA repair can lead, 
on a cellular level, to increased numbers of 
mutations and chromosomal aberrations and 
eventually oncogenic transformation. On a 
the scale of a whole human, defective DNA 
repair proteins can cause syndromes such 
as Fanconi Anemia or predispose to certain 
types of cancer. 
Excessive amounts of DNA damage can 
be used to treat cancer. Tumours can be 
treated with ionizing radiation, which causes 
single and double strand breaks or with 
interstrand crosslinking chemotherapeutics 
such as Mitomycin C. There are also targeted 
treatments available that are very effective 
against cancer cells with for example 
defective homologous recombination. These 
targeted treatments are very promising, 
since the side effects are less severe than for 
conventional chemotherapy. Unfortunately 
cancer cells can become resistant to these 
drugs by rerouting DNA repair pathways, 
genetic reversion of mutations or other 
mechanisms. Understanding how DNA repair 
mechanisms works on a molecular level can 
help to prevent and treat cancer. To increase 
our knowledge on the details of DNA 
repair mechanisms, we set out to identify 
mechanism of resistance to PARP inhibitors in 
the first part of this thesis and and to identify 
new interactors of BRCA2 in the second part. 
Chapter 1 introduces the main DNA repair 
pathways and their function. This knowledge 
is important to understand the interplay 
between pathways. Damaged DNA can be 
a substrate for different pathways and then 
competition takes place, while in other cases 
several repair pathways are required to repair 
a lesion. For most pathways it is well known 
how they work, but the interaction between 
pathways is still a largely unexplored area. 
Many proteins are also involved in multiple 
DNA repair pathways or have numerous 
functions in one pathway. The introduction 
focuses on BRCA1 and BRCA2 because these 
are main players in the subsequent chapters.
The balance between repair pathways is 
important for genomic stability. In chapter 2 
we review what is known about the balance 
between the DNA double strand break repair 
pathways homologous recombination and 
non-homologous end joining. Additionally, 
several assays are described that can be used 
the measure the activity of these pathways. 
Therapeutic strategies to exploit a disturbed 
balance are discussed as well. 
Cells with mutations in the homologous 
recombination proteins BRCA1 are extremely 
sensitive to inhibition of the enzyme PARP1, 
which is required for the efficient repair of 
DNA single-strand breaks. In chapter 3 we 
investigate how BRCA1-deficient cells can 
become resistant to treatment with PARP 
inhibitors. We show that loss of Rev7 leads 
to restoration of homologous recombination 
and thereby PARP inhibitor resistance. In 
chapter 4 we continue this research to find 
out how this resistance mechanism works 
on a molecular level. REV7 plays a role in cell 
cycle progression, translesion synthesis and 
several other processes and we investigate 
which REV7 function is important in 
mediating PARP inhibitor resistance.
In chapter 5 we identify a new interaction 
partner of BRCA2: HSF2BP. Overexpression of 
this protein gives a phenotype that is similar 
to that of cells from patients suffering from 
Fanconi Anemia. Upon overexpression of 
HSF2BP the cells become very sensitive to the 
chemotherapeutic Mitomycin C and show 
increased chromosomal aberrations after 
exposure to this drug. Finally we map the 
domain of BRCA2 that interacts with HSF2BP. 
Chapter 6 discusses the findings 
described in this thesis as well as implications 
for the future of cancer research.
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Abstract
Proper repair of DNA double strand breaks 
(DSBs) is vital for the preservation of genomic 
integrity. There are two main pathways that 
repair DSBs, Homologous recombination (HR) 
and Non-homologous end-joining (NHEJ). 
HR is restricted to the S and G2 phases of 
the cell cycle due to the requirement for the 
sister chromatid as a template, while NHEJ 
is active throughout the cell cycle and does 
not rely on a template. The balance between 
both pathways is essential for genome 
stability and numerous assays have been 
developed to measure the efficiency of the 
two pathways. Several proteins are known 
to affect the balance between HR and NHEJ 
and the complexity of the break also plays a 
role. In this review we describe several repair 
assays to determine the efficiencies of both 
pathways. We discuss how disturbance of the 
balance between HR and NHEJ can lead to 
disease, but also how it can be exploited for 
cancer treatment.
Introduction
Genomic integrity and faithful replication 
are essential to prevent mutations and 
chromosomal rearrangements, which may 
otherwise lead to diseases and in some 
cases even death. DNA damage is generated 
by several different genotoxic agents such 
as reactive oxygen species, UV light from 
the sun and mutagenic chemicals1. These 
agents cause many types of DNA damage, 
ranging from base damage to double strand 
breaks (DSBs). To protect the genome from 
the deleterious effects of these lesions, 
several mechanisms have evolved that 
detect and repair DNA damage. Together 
with mechanisms that regulate cell cycle 
progression and cell death pathways this is 
known as the DNA damage response (DDR).
In this review we concentrate on DSBs, 
which are among the most cytotoxic types 
of DNA damage. The therapeutic effect of 
several commonly used cancer treatment 
modalities, such as ionizing radiation and 
the chemotherapeutic doxorubicin, are 
based on the cell killing effect of DSBs. 
However, DSBs are also the initiating lesion of 
disease-causing chromosomal translocations 
in cancer. Therefore, it is important to 
understand the intricate regulation of 
the DDR upon DSB formation. We mainly 
concentrate on the two main DSB repair 
pathways, Non-homologous end joining 
(NHEJ) and Homologous recombination 
(HR), with a special emphasis on the balance 
between both repair mechanisms in health 
and disease.
NHEJ
NHEJ is a relatively simple DSB repair 
pathway (Figure 1). Both ends of the break are 
first bound by the Ku70/Ku80 heterodimer, 
which then recruits the catalytic subunit of 
the DNA dependent protein kinase (DNA-
PKcs)2. If necessary, the ends can be trimmed 
by nucleases (such as Artemis) or filled in by 
DNA polymerases (such as Polμ or Polλ) to 
create compatible ends3. Finally, the ligation 
complex, consisting of DNA ligase IV, X-ray 
cross-complementation group 4 (XRCC4) and 
XRCC4 like factor (XLF)/Cernunnos ligates the 
ends4,5. NHEJ can take place throughout the 
cell cycle. For an extensive review on NHEJ 
see3.
HR
HR uses a sequence similar or identical to 
the broken DNA as a template for accurate 
repair. The sister chromatid is used as an 
identical template in the S and G2 phases 
of the cell cycle, when the DNA has been 
replicated. HR is restricted to these cell cycle 
phases in higher eukaryotes to prevent 
recombination between (repetitive) non-
identical sequences. Spurious HR can lead 
to loss of heterozygosity (when HR takes 
place between paternal and maternal 
chromosomes) or insertions/deletion (when 
repeats are not aligned properly). 
The HR pathway starts with resection 
of the broken DNA ends (Figure 1) by 
the MRN-complex6,7, together with CtBP-
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interacting protein (CtIP)8,9 and other 
exonucleases, generating 3’-single stranded 
DNA (ssDNA)9,10. The ssDNA tail is coated 
by Replication protein A (RPA) to remove 
secondary structure11. Subsequently, BRCA2 
mediates the replacement of RPA by RAD51, 
to form a nucleoprotein filament that 
searches for the homologous sequence on 
the sister chromatid. After strand invasion, 
catalyzed by RAD51 and many other proteins, 
the DNA end is extended using the intact 
sequence as a template. After restoration of 
any lost sequence information, the second 
end of the broken DNA is captured and the 
junctions are resolved to give a precisely 
repaired DSB12. This resolution step can be 
DNA-
PKcs
Ku
Artemis
NHEJ
MRN
CtIP
sister chromatid
DSB
HR
BRCA2
Resection
Ku
DNA-
PKcs
XLF
XRCC4 Lig4
RPA RPA
Rad51
Rad51D-loop
CtIP
MR
N
Strand invasion
Ligation
End recognition
Processing
Figure 1 HR and NHEJ. 
NHEJ) NHEJ starts with recognition of the DNA ends by the Ku70/80 heterodimer, which recruits DNA-
PKcs. If the ends are incompatible, nucleases such as Artemis can trim the ends. The XRCC4-DNA Ligase 
IV-XLF ligation complex seals the break. HR) The MRN CtIP- complex starts resection on the breaks to 
generate single stranded DNA (ssDNA). After resection the break can no longer be repaired by NHEJ. The 
ssDNA is first coated by RPA, which is subsequently replaced by Rad51 with the help of BRCA2. These 
Rad51 nucleoprotein filaments mediate strand invasion on the homologous template. Extension of the 
D-loop and capture of the second end lead to repair.
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accomplished via formation of two Holliday 
junctions, which are subsequently resolved 
to give crossover or non-crossover products 
(the double Holliday junction model). 
An alternative HR model, the synthesis 
dependent strand annealing (SDSA) model, 
does not involve Holliday junctions and 
results in non-crossover products only13.
Foci
Microscopically, DSBs can be visualized 
as local spots of repair protein accumulation 
(also called foci) in the nucleus. For example, 
histone H2AX is phosphorylated locally 
around the DSB and 53BP1, RPA and RAD51 
accumulate in foci after ionizing radiation. 
Changes in the number of foci per nucleus 
in time can be quantified to analyze the 
dynamics of DNA repair14. Not all repair 
proteins accumulate in sufficient numbers 
to form foci. For example Ku70/80 does not 
form foci, although it is recruited to DNA 
damage15,16.
Alternative DSB repair pathways
In addition to classical HR, several 
subpathways result in slightly different 
products. For example the single strand 
annealing (SSA) pathway uses directly 
repeated stretches of homology to repair 
DSBs. After resection of the break (as 
described above for HR) complementary 
stretches in the ssDNA anneal and the 
intervening sequence and one of the repeats 
is deleted17. Since HR and SSA use the same 
substrate, these pathways compete when 
repeats are present on both sides of the break 
and SSA should be suppressed to prevent its 
mutagenic effect.
Alternative end-joining pathways can 
also join DSBs in an error-prone manner, 
especially when classical NHEJ is impaired 
by deletion of essential components. The 
genetics of this pathway are not well defined 
and there may even be several alternative 
end-joining pathways. A dependence on DNA 
ligase III, Xrcc1 and PARP1 has been found in 
genetic assays18,19. However, in another assay 
the repair of I-SceI induced DSBs in XRCC4-
deficient pro-B cell lines did not require 
Xrcc120. Alternative pathways show increased 
DSB joining using microhomologies 
(stretches of 1–6 bp of direct repeat at the 
junction), possibly to stabilize the synapsed 
ends3.
Although these alternative DSB repair 
pathways can work in specific experimental 
settings, they probably do not play a major 
role in repair of most DSBs in wild type cells. 
Therefore this review will focus on the balance 
between the classical forms of HR and NHEJ.
Repair assays
To study the balance between HR and 
NHEJ, one would ideally measure both 
types of repair at the same time using a 
defined chromosomal site. Unfortunately 
such an assay is not yet available. There are, 
however, many assays to measure HR and 
NHEJ separately. A good understanding 
of these assays is indispensable for correct 
interpretation of the results obtained using 
these different approaches. We therefore 
review the major assay systems and discuss 
their merits and drawbacks.
Assays to measure NHEJ
NHEJ can be measured in many different 
ways. The simplest version is transfection of 
linearized DNA into wild type and mutant 
cells. Joining of the ends can be monitored 
by cloning out individual plasmids or PCR 
amplification followed by sequencing or 
digestion of the junction21 (Figure 2a). 
Recircularization can also be monitored by 
following the restoration of expression of a 
reporter gene, such as an antibiotic resistance 
gene or a fluorescent marker (Figure 2b). A 
major disadvantage of these assays is that 
the linear DNA is extrachromosomal and 
NHEJ cannot be measured in the normal 
context of chromatin. However, it is a simple 
assay that can monitor decreased activity of 
the core NHEJ machinery as a shift towards 
microhomology use at the newly formed 
junctions.
Another type of NHEJ assays uses two 
I-SceI restriction sites. These sites can 
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CCA ATCAGC ATCAGC TGG 
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GGT  TAGTCG ACC
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GGT TAGTCG             TAGTCG ACC
GFP GFP
Coding 
joint
Signal 
joint
Figure 2 NHEJ repair assays. 
a) Linear plasmid DNA with 6 bp repeats at the ends is joined after transfection. The joints are amplified 
by PCR and digested using BstXI to distinguish between direct repair and microhomology mediated 
repair21. b) Repair of linearized plasmid DNA results in restoration of GFP expression. c) Cleavage by I-SceI 
and subsequent repair lead to loss of the middle splice donor and acceptor sites (SD and SA) and the 
adenoviral exon (AD), resulting in the expression of active GFP22. d) H2Kd fused to CD8 is expressed from 
the intact substrate. Repair of the oppositely oriented I-SceI breaks results in loss of H2Kd-CD8 and allows 
expression of CD4 23. e) Similar to d), the intact substrate expresses GFP, while the repaired substrate allows 
expression of RFP and loses GFP expression24. f ) Between the opposite I-SceI sites, a translation start site 
is located, preventing translation of the XHATM resistance gene. Repair of the I-SceI breaks and loss of 
the intervening ATG results in XHATM resistance. The sequence around the breaks can be sequenced to 
monitor loss of nucleotides25. g) V(D)J recombination assay. Cleavage by the Rag1/2 endonuclease at the 
recombination signal sequences induces inversion of the intervening sequence. Small arrows indicate 
location of PCR primers to amplify joints21.
be in the same or opposite orientation, 
generating compatible or incompatible ends, 
respectively. These constructs are generally 
integrated into the genome. The general 
theme of all these assays is restoration of 
expression of a marker gene, in some cases 
accompanied by inactivation of another 
gene. Mao et al. interrupted the GFP gene 
with an intron containing an adenoviral exon 
(AD) flanked by two I-SceI sites (Figure 2c). 
Repair of the two I-SceI induced DSBs leads to 
loss of the intervening exon and expression 
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of functional GFP22. Guirouilh-Barbat et al. 
developed a similar assay (Figure 2d) with 
compatible or incompatible I-SceI sites, but 
they used surface antigens as a read-out for 
repair23. Coleman and Greenberg also used 
a comparable assay (Figure 2e) with GFP 
between the I-SceI sites and RFP downstream, 
resulting in loss of GFP and expression of 
RFP after repair of the I-SceI induced DSBs24. 
In these assays with a double I-SceI site it is 
also possible to sequence the joints and to 
determine the loss of nucleotides around the 
breaks25 (Figure 2f ).
A disadvantage of these assays using 
I-SceI restriction sites is that the individual 
I-SceI break has compatible ends and can 
recreate an I-SceI site if it is repaired precisely 
by NHEJ. Therefore, several cycles of cleavage 
and repair can happen before the site is 
lost due to inaccurate repair and these 
assays cannot measure the NHEJ efficiency 
accurately. However, sequencing of the 
junctions can provide interesting information 
about imprecise end-joining events. To avoid 
the cut-and-paste cycle problem of the I-SceI 
sites, some assays use transposon excision 
to create a break. Repair of transposon 
induced DSBs can reveal details of efficiency 
as well as precision of NHEJ26,27. In principle, 
transposons would also be useful to study 
HR, although their DSB formation efficiency is 
generally lower than endonucleases.
The immune system depends on 
end-joining for V(D)J and class switch 
recombination (CSR). Pan-Hammarstrom and 
colleagues studied CSR by PCR amplification 
and sequencing of the junctions in normal 
individuals and patients. They found that 
patients with mutations in NHEJ components, 
such as DNA ligase IV, showed an increased 
dependence on longer microhomology 
stretches at the junctions28. An advantage 
of this assay is that repair is measured on 
endogenous substrates. However, it is not 
clear whether these loci are representative 
for other types of DSBs.
V(D)J recombination also depends on 
NHEJ factors to repair the breaks induced 
by the RAG1 and RAG2 proteins. This type of 
repair can be assayed using a specific repair 
substrate containing Recombination Signal 
Sequences, the recognition sites for Rag1 and 
Rag221 (Figure 2g). The V(D)J recombination 
assay gives a clear phenotype for defects in 
proteins involved in DNA end-processing, 
such as the Artemis nuclease29. The major 
disadvantage of these types of assays is the 
special nature of the DSBs formed by the 
RAG-proteins, which may shuttle the breaks 
towards NHEJ30.
Assays to measure HR
The most commonly used assay to 
measure HR is the DR-GFP assay developed 
by Pierce and Jasin31 (Figure 3). The reporter 
construct can be inserted by gene targeting 
or random integration. It contains two GFP 
sequences separated by a selection marker. 
The 5’ GFP sequence is inactivated by an I-SceI 
site and internal stop codons, preventing GFP 
expression. The 3’ truncated GFP serves as a 
template for repair after DSB induction by 
I-SceI. Repair of the break by gene conversion 
using the downstream GFP sequence leads 
to restoration of the GFP gene and the 
percentage of GFP expressing cells can be 
determined by FACS analysis.
This HR assay has been used successfully 
to characterize defects in various (repair) 
mutant genetic backgrounds. An important 
advantage of this HR assay is that it measures 
repair using a chromatinized reporter 
construct in the chromosome. However, 
the template for repair is downstream of 
the break, whereas the normal template for 
HR is the equivalent position on the sister 
chromatid. Furthermore, the I-SceI site can 
be subject to several cycles of cleavage and 
repair by precise NHEJ or restoration of the 
sequence using the sister chromatid as a 
repair template, which leaves a high degree 
of uncertainty about the relative levels of HR 
and NHEJ.
Expression of I-SceI is usually induced by 
transfection of an expression plasmid into 
an asynchronously growing cell population. 
This creates DSBs in the reporter substrate 
throughout the cell cycle, whereas HR 
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only takes place in the S and G2 phases. To 
overcome this problem, Hartlerode et al. 
developed an I-SceI fusion protein that is 
drugactivatable. Enriching cells in a certain 
phase of the cell cycle then allows restricted 
activation of I-SceI32.
HR can also be estimated by scoring 
sister chromatid exchanges (SCEs). In this 
assays a nucleotide analog is added in the 
first cell cycle to allow incorporation into the 
newly synthesized strand in S phase. After 
a second replication round, only one of the 
sister chromatids is labeled, which allows 
visualization of recombination between the 
sister chromatids in metaphase spreads by 
staining for the incorporated nucleotide 
analog. SCEs can be formed in S phase during 
the repair of collapsed replication forks as 
well as in G2 phase at two-ended DSBs33.
A completely different method to assess 
the efficiency of DSB repair is monitoring the 
disappearance of γH2AX foci. These foci form 
within a few minutes after DSB formation 
and disappear slowly as repair takes place. 
By comparing the kinetics of several known 
HR and NHEJ mutants, the efficiency and 
likely repair pathway can be determined. For 
a review on the advantages and potential 
pitfalls of this assay, see34.
As a more sophisticated approach, the 
formation and disappearance of 53BP1-YFP 
and Rad52-Cherry foci has been followed to 
estimate the use of HR and NHEJ in single 
cells throughout the cell cycle35. Karanam et 
al. found that there is a gradual increase in HR 
at the beginning of S phase. The number of 
Rad52 foci increases till mid S phase and then 
decreases towards the end of S phase. In G2, 
very few Rad52 foci were observed, showing 
that HR is not the predominant pathway in 
G2. This is consistent with data from Beucher 
et al., who demonstrated that NHEJ repairs 
approximately 85% of all IR-induced DSBs in 
G2, as measured by γH2AX foci kinetics36.
Balancing HR and NHEJ
The presence of large numbers of highly 
repetitive sequences in the DNA of higher 
eukaryotes makes HR between sequences 
other than sister chromatids prone to 
misalignment of the homologous sequences. 
Therefore, HR generally dominates in 
organisms with a small genome (with low 
abundance of repetitive sequences), whereas 
mammals mainly rely on NHEJ for DSB 
repair35,37. However, even in highly complex 
genomes, HR is used as the preferred DSB 
repair mechanism to deal with DSBs that are 
formed during replication. This necessitates 
intricate control mechanisms to prevent 
access of the wrong repair pathway to the 
DSB.
Resection & cell cycle
HR can only safely be used to repair breaks 
in the S and G2 phases of the cell cycle. The first 
mechanism to regulate this depends on S/
G2 specific cyclin dependent kinases (CDKs). 
DNA end resection requires phosphorylation 
of CtIP on a CDK consensus sequence9,38,39.
Proteasome-mediated degradation of the 
CtIP protein in G140 adds an additional layer 
of regulation at the resection step.
CDK1/CyclinB also phosphorylates the 
NBS1 component of the MRN complex on 
Serine 432 during the S, G2 and M phases, 
which is required for resection and efficient 
HR. However, IR sensitivity was not affected in 
DR-GFP
GFP iGFP
I-SceI
Stop
GFP iGFP
puro resistance
Before break After repair
puro resistance
Figure 3 HR Assay. 
The 5’ GFP is inactivated by several in frame stop codons and contains an I-SceI site. A downstream 
truncated GFP, lacking the I-SceI sites and stops, serves as a template. Accurate repair via HR results in 
GFP expression.
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the Ser432Ala NBS1 mutant, consistent with 
the notion that NHEJ is the major DSB repair 
pathway in mammals41.
Although activation of HR proteins in a 
cell cycle dependent manner helps to restrict 
their activity, it is insufficient to ensure safe 
use of HR. While replication is ongoing in 
the S phase, parts of the genome have not 
yet been replicated and recombination of 
these parts should be avoided to prevent 
loss of heterozygosity and non-allelic 
recombination. Therefore, another layer 
of regulation is provided by the structural 
maintenance of chromosomes (SMC) 
proteins such as Cohesin, Condensin and 
SMC5/6: they are able to confine repair to the 
sister chromatid and prevent HR between 
other sequences42,43.
Complexity of the break
Whether HR or NHEJ is used also depends 
on DSB complexity. This phenomenon has 
been studied in detail in the G2 phase of 
the cell cycle, when both HR and NHEJ 
contribute to DSB repair. Treatment of cells 
with the topoisomerase II inhibitor Etoposide 
results in breaks with a 4 bp 5’-overhang 
with covalently attached protein44. The large 
majority of these breaks are repaired rapidly 
by NHEJ. The remaining 10% of the Etoposide 
induced breaks is repaired with slow kinetics 
via HR45. High linear energy transfer (LET) 
carbon ions, on the other hand, induce highly 
complex clusters of DSBs and other types of 
DNA damage46, because this type of radiation 
causes a high number of ionizations in a small 
volume. These breaks are frequently resected 
and their repair takes place via HR with slow 
kinetics45. From the breaks induced by low 
LET ionizing irradiation (IR), which causes less 
complex DSBs, only 20-30% is resected and 
their repair is much less dependent on HR36,45.
The chromatin structure around 
the DSB affects repair as well. Breaks in 
heterochromatin are repaired more slowly 
than breaks in euchromatin47 probably 
because euchromatin is more easily accessible 
for repair and requires less or no remodeling. 
Repair of breaks in heterochromatin requires 
ATM47. ATM phosphorylates transcriptional 
corepressor Krüppel-associated box (KRAB)-
associated protein (KAP)-148, which disrupts 
the interaction between KAP-1 and CHD349. 
CHD3 is an ATP-dependent nucleosome 
remodeling enzyme and its dispersion 
allows chromatin relaxation, facilitating DSB 
repair in heterochromatin. Furthermore, 
the ATPdependent chromatin remodeler 
SMARCAD1 can also be recruited to sites of 
DNA damage where it facilitates resection50.
Genetic factors influencing pathway 
choice
The core HR and NHEJ machineries have 
been conserved from yeast to mammals51. 
However, several genes have been added to 
optimize or regulate both pathways in higher 
eukaryotes. For example, NHEJ has acquired 
DNA-PKcs and HR added several RAD51 
paralogs. Furthermore, several additional 
genes in higher eukaryotes regulate DSB 
repair pathway choice without direct 
participation in the catalytic steps of the 
repair reaction.
53BP1
The p53 binding protein 1 (53BP1) is 
recruited to DSBs, where it has functions 
in cell cycle checkpoint maintenance and 
double strand break repair52. The fast phase in 
DSB repair is normal in the absence of 53BP1, 
but repair of breaks in heterochromatin is 
severely impaired, probably as a result of 
impaired KAP1 phosphorylation49,53.
A deeper understanding of the 53BP1 
function has been gained from studies in 
the immune system. During class switch 
recombination, highly repetitive DNA 
segments are recombined to generate the 
different classes of antibodies. DSBs generated 
during this recombination reaction can be 
repaired via NHEJ or alternative end joining. 
In the absence of 53BP1, resection increases 
and microhomology mediated alternative 
end-joining takes over from classical NHEJ54. 
In V(D)J recombination, Variable (V), Diversity 
(D) and Joining (J) segments are recombined 
to create a large variety of functional coding 
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sequences for immunoglobulins and T-cell 
receptors. DSBs created by RAG1/2 are 
repaired via NHEJ. 53BP1 prevents extensive 
degradation and it promotes synapsis of DNA 
ends and stabilizes long-range interactions, 
not only between breaks created during 
V(D)J recombination55, but also between 
deprotected telomeres56.
BRCA1 and associated proteins
In contrast to the NHEJ promoting effect 
of 53BP1, the tumor suppressor BRCA1 is 
required for efficient HR57 and formation of 
RAD51 foci after DSB induction58. BRCA1 is 
an E3-ubiquitin ligase that forms a complex 
with the E2 enzyme BARD1 via its RING 
domain. This interaction is required for the 
ligase activity, as well as protein stability 
and nuclear localization59. Although several 
RING-domain mutations have been found 
in patients, it is currently unknown how 
the HR defect is related to the E3-ligase 
function and BARD1 interaction. Drost et 
al. recently showed that the RING-domain 
is necessary for tumor suppression, but not 
required for the development of resistance 
to chemotherapeutics. Tumors with a 
C61G mutation in the RING-domain rapidly 
develop resistance to platinum drugs and the 
PARP inhibitor Olaparib, while retaining this 
mutation60.
In addition to its function as a ubiquitin 
ligase, BRCA1 may also function as a scaffold 
protein that associates with many interaction 
partners, such as Abraxas, BACH1 and BRCA2/
PALB259. For efficient resection of DNA 
ends, its interaction with CtIP and the MRN 
complex is probably important39,61. BRCA1 
also interacts with RAP80 and the BRCA1/
RAP80 complex is recruited to ubiquitylated 
chromatin around DSBs62-64. In contrast to 
the BRCA1 interactions described above, 
the RAP80-BRCA1 interaction decreased HR: 
depletion  of Rap80 stimulated recruitment 
of CtIP and Mre11 and thereby resection24. 
The BRCA1 interactions with CtIP and 
RAP80 are mutually exclusive, indicating 
that competition for this BRCA1 binding 
site affects resection and thereby pathway 
choice. For replication-associated breaks, 
BRCA1 clearly tips the balance towards HR.
Genetic interactions of BRCA1 and 53BP1
Recently, some unexpected genetic 
interactions between BRCA1 and 53BP1 shed 
new light on their function in balancing DSB 
repair pathways. Deletion of BRCA1 causes 
embryonic lethality, but this can be rescued 
by deletion of 53BP165. Unexpectedly, 
deletion of 53BP1 also restored HR and RAD51 
foci formation in BRCA1 deficient cells66,67, 
implying that both factors influence HR in 
opposite directions and that inactivation 
of both genes largely restores the balance. 
Inactivation of 53BP1 in BRCA1−/− ES cells 
led to an increase in both nucleolytic DNA 
end processing and RPA phosphorylation67. 
ATM inhibition in BRCA1−/− 53BP1−/− cells 
reduced RPA phosphorylation and Rad51 foci 
formation, indicating that ATM-dependent 
resection allows partial restoration of HR67.
Figure 4 presents a plausible model to 
accommodate these findings. One-ended 
DSBs that are formed during replication 
require BRCA1 to stimulate resection. In 
BRCA1 deficient cells, 53BP1 prevents 
resection of DNA ends, leading to aberrant 
diversion of breaks to NHEJ. This creates dead-
end products (if only one DNA end is present) 
or inappropriate joining to distant sequences 
causing chromosomal translocations (if a 
DNA end combines with an unrelated other 
DNA end). Two-ended DSBs, on the other 
hand, require 53BP1 to limit resection and 
allow efficient NHEJ. Overactive resection 
in 53BP1−/− cells may result in aberrant HR 
reactions (such as single-strand annealing) 
or alternative end-joining pathways, creating 
microhomology-mediated translocations 
and/or junctions with excessive deletions68,69 .
Further insight into the role of BRCA1 and 
53BP1 in repair pathway choice was recently 
obtained using super resolution microscopy 
of IR induced foci (IRIF). The core of the focus 
contained mainly 53BP1 molecules in the G1 
phase of the cell cycle, probably representing 
repair via NHEJ. In S phase, however, the core 
of the IRIF was filled with BRCA1 and 53BP1 
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Figure 4 BRCA1 and 53BP1 in DSB repair. 
a) Repair of replication associated breaks requires HR. 53BP1 blocks resection of the one-ended break in 
BRCA1 deficient cells, preventing repair via HR. The breaks are either left unrepaired or repaired via NHEJ 
using other random DNA ends, which leads to chromosomal rearrangements and genomic instability. 
In the absence of 53BP1, resection of the DNA ends can take place, allowing faithful repair via HR. b) IR 
induced two ended DSBs are mainly repaired via NHEJ, however part of the breaks is repaired via HR 
or alternative end-joining (alt-EJ). Repair via HR or alt-EJ increases when classical NHEJ is impaired by a 
mutation in one of the core NHEJ genes or 53BP1.
formed a ring around this core, suggesting 
that BRCA1 physically excludes 53BP1 from 
the break to allow repair via HR70.
BRCA1 deficient cells are exquisitely 
sensitive to PARP inhibitors, which inhibit 
single strand break repair71,72. The rationale 
for this observation is that replication of DNA 
with single strand breaks results in formation 
of single DNA ends, which require HR for their 
repair (Figure 4). As described above, deletion 
of 53BP1 in BRCA1-deficient cells rescues 
embryonic lethality. However, loss of 53BP1 
also leads to resistance to PARP inhibition66,73. 
In the BRCA1- deficient cells that have also 
lost 53BP1, the number of chromosome and 
chromatid breaks is decreased and checkpoint 
activation is diminished compared to cells 
that are only BRCA1 deficient66, suggesting 
that the regained HR capacity in these cells is 
largely sufficient to restore genomic stability. 
A subset BRCA1 and BRCA2 mutant tumors 
shows loss of 53BP1, indicating that therapy 
resistance via loss of 53BP1 may be clinically 
relevant66 .
Ubiquitylation and sumoylation
Ubiquitin and the small ubiquitin-like 
modifier (SUMO) are small polypeptides 
that can be attached to proteins as a 
posttranslational modification. After 
activation of ubiquitin or SUMO by an 
E1 enzyme, they are transferred to an 
E2 conjugating enzyme. With the help 
of a ubiquitin (or SUMO) ligase (E3) the 
modification is attached to the substrate. 
Deubiquitylating enzymes (DUBs) can reverse 
the ubiquitin modification.
Many proteins involved in the DDR can 
be ubiquitylated or sumoylated2,74-76. For 
the sake of simplicity, we will focus on one 
part of the DDR signaling cascade as an 
example. Upon DSB formation, histone H2AX 
is phosphorylated by ATM or DNA-PK. MDC1 
is recruited to this phosphorylated histone 
39
Pathway choice in DNA double strand break repair: observations of a balancing act 
2
(γH2AX) and is in turn phosphorylated by 
ATM. This attracts the E3 ligase RNF8 which 
ubiquitylates H2A and H2AX. Subsequent 
action of the E3 ligase RNF168 leads to more 
extensive ubiquitylation of the chromatin 
around the break, creating a recruitment 
platform for many other repair proteins, 
including 53BP1 and BRCA177 . These 
ubiquitylation events are also required for 
phospho-KAP-1 foci formation and thereby 
chromatin relaxation at sites of damage53.
In addition to an effect on recruitment 
of repair proteins, ubiquitylation can also 
affect release of proteins from the lesion. The 
transient binding of Ku at DNA ends affects 
pathway choice. Ku binds in all phases of 
the cell cycle and must be removed to allow 
resection78,79. This removal can be facilitated 
via ubiquitlyation of Ku by the E3 ligase RNF8 
and an unknown E2 conjugating enzyme, 
leading to proteasome-dependent Ku 
degradation80. Since ubiquitylation is a very 
abundant modification on DDR proteins, it 
is likely that more modifications affecting 
pathway choice will be discovered in the 
future.
Concluding remarks
A unifying model for DSB repair pathway 
choice should take into account that NHEJ 
is relatively fast, while resection is a slow 
process that probably creates a point of no 
return. Therefore, it is to be expected that 
NHEJ initially tries to repair all DSBs and 
only if this repair pathway fails to repair the 
lesion, the chance that resection takes place 
increases over time, necessitating repair via 
HR. This is consistent with the observation 
that the binding of the Ku heterodimer 
to DNA ends is a very fast process, but 
the assembly of end-joining complexes is 
dynamic and may in the long run give way 
to proteins mediating resection if they are 
active16. This means that initiation of HR will 
mainly be restricted to the S and G2 phases 
of the cell cycle, when CtIP is active. Indeed, 
a subfraction of DSBs in G2 requires BRCA2 
for their repair, but knock-down of both CtIP 
and BRCA2 alleviates this repair defect45, 
suggesting that avoiding resection prevents 
HR and allows repair of these DSBs by NHEJ. 
Replication associated breaks, on the other 
hand, should be channeled to HR, which is 
the only pathway that can restart a replication 
fork from a single broken DNA end.
The study of the balance between HR 
and NHEJ is important for the prediction of 
treatment responses upon inhibition of these 
pathways in various genetic backgrounds. 
Combined treatments might backfire when 
the balance is tipped the wrong way. For 
example, the treatment of BRCA1 and BRCA2 
deficient cells is most effective when NHEJ is 
functional, whereas impaired NHEJ prevents 
lethal genomic instability and cytotoxicity, 
which counteracts the effect of PARP 
inhibitors in HR deficient cells73,81.
The balance between HR and NHEJ 
is heavily regulated, but the wiring and 
hierarchy of this regulatory network is still 
incompletely understood. Development 
of targeted therapies using DNA damage 
response defects requires a much more 
detailed knowledge of the precise network 
of the cellular responses to DNA damaging 
treatments. It is to be expected that new 
assay systems will be developed and that 
a flurry of novel combinations of chemical 
inhibitors and genetic defects will increase 
our understanding of these processes in 
the near future. This knowledge will then 
be an invaluable source for developing new 
targeted therapies for tumors with DNA 
damage response defects, which should 
yield more specific and effective therapeutic 
approaches to combat cancer. Novel tools 
to characterize tumor-specific (DNA repair 
gene) mutations, such as whole genome 
sequencing approaches, should then bring 
truly personalized medicine for cancer 
treatment within reach.
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Abstract
Error-free repair of DNA double-strand 
breaks (DSBs) is achieved by homologous 
recombination (HR), and BRCA1 is an 
important factor for this repair pathway1. 
In the absence of BRCA1-mediated HR, 
the administration of PARP inhibitors 
induces synthetic lethality of tumour 
cells of patients with breast or ovarian 
cancers2,3. Despite the benefit of this 
tailored therapy, drug resistance can occur 
by HR restoration4. Genetic reversion of 
BRCA1-inactivating mutations can be the 
underlying mechanism of drug resistance, 
but this does not explain resistance in 
all cases5. In particular, little is known 
about BRCA1-independent restoration of 
HR. Here we show that loss of REV7 (also 
known as MAD2L2) in mouse and human 
cell lines re-establishes CTIP-dependent 
end resection of DSBs in BRCA1-deficient 
cells, leading to HR restoration and PARP 
inhibitor resistance, which is reversed by 
ATM kinase inhibition. REV7 is recruited 
to DSBs in a manner dependent on the 
H 2 AX– M D C 1 – R N F 8 – R N F 1 6 8 – 5 3 B P 1 
chromatin pathway, and seems to block HR 
and promote end joining in addition to its 
regulatory role in DNA damage tolerance6. 
Finally, we establish that REV7 blocks DSB 
resection to promote non-homologous 
end-joining during immunoglobulin class 
switch recombination. Our results reveal 
an unexpected crucial function of REV7 
downstream of 53BP1 in coordinating 
pathological DSB repair pathway choices 
in BRCA1-deficient cells.
To identify mechanisms of BRCA1-
independent restoration of the HR pathway, 
we carried out a loss-of-function short hairpin 
RNA (shRNA) screen using the KB1P-B11 and 
KB1P-G3 cell lines that we previously derived 
from Brca1-/-p53-/- (p53 is also known as Trp53) 
mouse mammary tumours7 (Fig. 1a and 
Supplementary Table 1). Resistant cells were 
selected with a high concentration of olaparib 
(500nM, about 100-fold the half-maximal 
inhibitory concentration(IC50)), which killed 
cells of the empty vector control. Sequencing 
of the olaparib-surviving colonies revealed 
a reproducible enrichment of various 
individual hairpins targeting Rev7 or 53bp1 
(also knownas Trp53bp1). To validate the Rev7 
hit, we introduced two different hairpins into 
the KB1P-B11 and KB1P-G3 cell lines; these 
substantially inhibited Rev7 expression (Fig. 
1b, c and Extended Data Fig. 1a). Despite 
the role of REV7 in metaphase-to-anaphase 
transition8, the level of Rev7 inhibition 
in these cells did not affect proliferation 
(Extended Data Fig. 1b, c), allowing long-term 
clonogenic survival assays. We confirmed that 
loss of Rev7 resulted in increased resistance 
to the PARP inhibitors (PARPi) olaparib and 
AZD2461 (ref. 7) in both cell lines (Fig. 1d and 
Extended Data Fig. 1d–g). Resistant cells that 
survived olaparib treatment (Rev7 sh1/2-ola) 
yielded even lower REV7 expression levels 
and increased numbers of colonies after 
PARPi treatment (Fig. 1b–d and ExtendedData 
Fig. 1h). When we reconstituted the Rev7-
depleted cells with shRNA-resistant Rev7 
complementary DNA resulting in similar 
REV7 protein levels (Extended Data Fig. 1i), 
we successfully re-sensitized the tumour cells 
to PARPi (Fig. 1e, f ).
Tumours derived from the Brca1-/-p53-/- 
cells with stable Rev7 inhibition also showed 
olaparib resistance in vivo, in contrast to the 
empty vector controls (Fig. 1g and Extended 
Data Fig. 1j–l). In addition, we found that Rev7 
loss explains some cases of in vivo acquired 
PARPi resistance in BRCA1-deficient mouse 
mammary tumours (data not shown). REV7 
depletion also resulted in PARPi resistance 
of the human BRCA1-deficient cell line 
SUM149PT (Extended Data Fig. 2). Together, 
these data strongly indicate that inhibition 
of Rev7 confers PARPi resistance in BRCA1-
deficient tumour cells.
Together with the catalytic subunit 
REV3, REV7 forms the translesion synthesis 
polymerase z (Pol z), and it interacts with 
REV1 (ref. 9). We therefore investigated 
whether loss of REV1 or REV3 also confers 
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Figure 1 Identification of loss of Rev7 in PARPi-resistant Brca1-/-p53-/- mammary tumour cells. 
a, Design of the functional shRNA screen. gDNA, genomic DNA. b, c, Quantification of Rev7 transcript (b) 
or protein (c) levels in KB1P-G3 cells transduced with Rev7-targeting shRNAs or the vector control. Hprt 
was used as a control for transcript expression, and b-tubulin was used as a control for protein expression. 
The data represent the mean±s.d. d, e, Long-term clonogenic assay using KB1P-G3 cells transduced
with the indicated constructs (wt Rev7 stands for pLenti6-wt Rev7) and treatments. f, Quantification of 
the clonogenic assay in e by determining the absorbance of crystal violet at 590 nm. All the groups were 
normalized to the absorbance of the vector control. The data represent the mean±s.d. g, Overall survival 
of mice with KB1P-G3-derived Rev7-depleted or control tumours treated with one regimen of 50 mg 
olaparib per kilogram daily for 28 days or left untreated. The P value was calculated using the log-rank 
test.
PARPi resistance in Brca1-/-p53-/- cells. A 60% 
inhibition of Rev1 or Rev3 transcripts did not 
cause olaparib resistance (Extended Data 
Fig. 3a–d). Moreover, we studied various 
shRNA-resistant REV7 mutants that lack 
REV1 (Leu186Ala/Gln200Ala/Tyr202Ala and 
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a 1–183-amino-acids truncated protein) 
or REV3 (Cys70Arg) binding sites10,11. In 
contrast to the truncated 1–140-amino-acid 
REV7 protein, these mutants are recruited 
to DNA damage sites (Extended Data Fig. 
3e–g), and their expression in Rev7 shRNA 
KB1P-B11 and KB1P-G3 cells significantly 
restored the sensitivity to PARPi to a degree 
Figure 2 | Dissection of REV7 function and its dependent factors.
a, b, Long-term clonogenic assay (a) and quantification (b) using KB1P-G3 cells transduced with the 
indicated constructs (wt Rev7 stands for pMSCVGFP- wt Rev7) and treatments. All groups were normalized 
to the absorbance of the shRev7-GFP control. The data represent the mean6s.d. c, GFP–REV7 recruitment 
to sites of DNA damage (visualized by 53BP1–mCherry) was observed 5 min after 405nm laser exposure 
(0.99mW, 60% laser power, 50 s) in KB1P-B11 cells. pEGFP denotes a mammalian expression vector 
containing enhanced GFP. Scale bar, 5 mm. d, REV7 foci formation in H2ax-/- (also known as H2afx-/-),Atm-/-, 
Mdc1-/- and Rnf8-/- mouse embryonic fibroblast (MEF) cells and their corresponding controls before 
and 4 h after 10 Gy ionizing radiation (IR). DAPI, 49,6-diamidino-2-phenylindole. Scale bar, 10 mm. e, 
Quantification of REV7 foci formation (>8 foci per cell) in Atm-/- and Atm+/+ MEF cells. The quantification of 
foci-positive cells was performed by counting a total of 100 cells per sample. Data are presented as
mean±s.d. from three different experiments. P value calculated using the t-test.
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approaching that of wild-type REV7 (Fig. 2a, 
b; P=0.001, t-test). The remaining differences 
of the Leu186Ala/Gln200Ala/Tyr202Ala or 
Cys70Arg mutants with wild- type REV7 may 
be explained by unequal expression levels 
(Extended Data Fig. 3f ). These data suggest 
that the REV1 or REV3 interaction is not 
absolutely required for the REV7-mediated 
function in this context. We observed that 
green fluorescent protein (GFP)-tagged REV7 
colocalizes with 53BP1 shortly after DNA 
damage induction, suggesting that REV7 acts 
directly at the site of DNA damage (Fig. 2c). 
REV7 recruitment depends on H2AX, MDC1, 
RNF8, RNF168 and partly ATM, in both mouse 
and human cells (Fig. 2d, e and Extended 
Data Fig. 4a–d). To examine whether PARPi 
resistance in Rev7-depleted Brca1-/-p53-/- 
tumour cells is due to HR restoration, we 
investigated RAD51 focus formation after 10 
Gy ionizing radiation. As shown in Fig. 3a, b 
and Extended Data Fig. 4e, f,  Rev7 loss resulted 
in the restoration of RAD51 foci formed after 
DNA damage. To exclude potential off-target 
effects of the hairpins, we reconstituted 
Rev7 shRNA1 and shRNA2 cells with shRNA-
resistant mouse or human REV7–GFP fusion 
proteins (Extended Data Fig. 4g). REV7 re-
expression abolished RAD51 focus formation 
after DNA damage in GFP-positive cells (Fig. 
3b). We confirmed the re-appearance of 
RAD51 foci after tumour irradiation in vivo 
using computed tomography (CT)-guided 
high precision cone beam irradiation of 
animals carrying PARPi-resistant KB1P(M) 
tumours with low Rev7 gene expression (Fig. 
3c). 
We then tested whether the processing 
of broken DNA ends requires ATM in Rev7-
depleted cells, and found that inhibition of 
ATM using KU55933 efficiently suppresses 
DNA damage-induced RAD51 foci and 
increases olaparib sensitivity (Extended Data 
Fig. 4h, i). Hence, the partial restoration of 
RAD51 focus formation in Brca1-deficient 
mammary tumour cells after DNA damage by 
inhibition of Rev7 is ATM dependent.
In contrast to the results with BRCA1-
deficient cells, Rev7 depletion in BRCA2-
deficient cells did not result in PARPi 
resistance (Extended Data Fig. 5a–f ). 
Furthermore, we did not observe increased 
PARPi resistance after Rev7 inhibition in 
the BRCA1/2-proficient p53-/- tumour cell 
line KP3.33 (Extended Data Fig. 5g–i). This 
indicates that REV7 works upstream of BRCA2 
and is antagonized by BRCA1. We therefore 
tested whether DNA end resection is altered 
in the absence of Rev7 in BRCA1-deficient 
cells. Accumulation of the single-strand 
binding protein, RPA, was used as a marker 
for the generation of singlestranded DNA 
(ssDNA). Cells were exposed to a-particles12, 
and BRCA1-deficiency resulted in a marked 
decrease in RPA-positive a-tracks compared 
to BRCA1-proficient cells (Fig. 3d, e). REV7 
depletion in the Brca1-/-p53-/- cells largely 
suppressed this defect in both KB1P-G3 and 
KB1P-B11 cells (Fig. 3e and Extended Data 
Fig. 6a). In addition to coating resected DNA 
ends, RPA also interacts with ssDNA gaps (for 
example, during replication)13. To exclude 
that the observed RPA accumulation reflected 
interaction with internal ssDNA gaps, we 
prevented DNA end resection (without 
influencing replication) by knocking down 
CTIP (ref. 14). This eliminated the increase 
in RPA-positive tracks induced by Rev7 
knockdown in Brca1-/-p53- cell lines (Fig. 3f 
and Extended Data Fig. 6b), without affecting 
cell cycle distribution (Extended Data Fig. 
6c). We therefore conclude that increased 
resection and not binding to ssDNA gaps is 
responsible for RPA accumulation.
As Rev7 loss could restore end resection in 
BRCA1-deficient cells, we analysed whether 
its depletion could restore full HR proficiency 
in this context. Using mouse embryonic stem 
(mES) cells with a Brca1 selectable conditional 
knockout allele15, we observed that Rev7 loss 
indeed prevented cell death of mES cells after 
BRCA1 deletion, and restored RAD51 focus 
formation upon DNA damage (Extended 
Data Fig. 6d–h). Moreover, we reproducibly 
observed a partial restoration of HR function 
in the DR–GFP reporter assay for homologous 
recombination16 when Rev7 was depleted in 
BRCA1-deficient mES cells (Fig. 3g).
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Figure 3 The effect of REV7 inhibition on RAD51 and RPA focus formation of Brca1-/-p53-/- cells. 
a, RAD51 focus (red) formation in KB1P-G3 cells before and 5 h after 10 Gy ionizing radiation. Scale bar, 
10 mm. b, Quantification of RAD51 foci in KB1P-G3 cells (with or without REV7 depletion) transfected with 
an empty vector (GFP) or vectors containing mouse or human Rev7 or REV7, respectively. At least 150 
GFP-positive cells were analysed per group in three independent experiments each. The data represent
the mean±s.d. IR denotes 5 h after 10 Gy ionizing radiation. c, In situ analysis of RAD51 foci in PARPi-
resistant KB1P(M) tumours with low Rev7 gene expression. KP (KP3.33) denotes mouse mammary 
tumour cell line (p53-/-); IR denotes 2 h after 15 Gy ionizing radiation; NIR denotes no ionizing radiation. 
****P=0.0001, Mann–Whitney U test. Legend continues on next page.
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Figure 3 continued 
d, e, Representative images of 53BP1-labelled a tracks in cells positive or negative for RPA (d) and 
quantification of RPA-positive tracks 2 h after ionizing radiation (e). KP (p53-/-) or KB1P-G3 cells with or 
without Rev7-targeting shRNAs were tested. Scale bar, 5 mm. f, Quantification of RPA- and 53BP1-positive a 
tracks in KB1P-G3 cells transfected with non-targeting control (ctrl) short interfering RNAs (siRNAs) or siRNAs 
against mouse Ctip. CTIP protein expression of the indicated groups was checked by western blotting, with 
b-actin (ACTB) as a loading control. g, Quantification of HR using the DR-GFP reporter assay. GFP-positive 
cells normalized to the vector-transduced Brca1-/- p53 shRNA cells are shown. The data represent mean±s.d. 
**P=0.01, two-tailed t-test.
Figure 4 REV7 is a downstream effector of 53BP1 on inhibiting end resection and promoting CSR. 
a, REV7 foci formation in 53bp1-/- and 53bp1+/+ MEF cells before and 4 h after 10 Gy ionizing radiation. Scale 
bar, 10 mm. b, Quantification of CSR to IgA of shRNA-transduced CH12 cells 40 h after stimulation (CIT 
denotes CD40 antibody, IL-4 and TGF-b1). Data represent mean±s.d. from two independent experiments 
performed in triplicate. c, Schematic of IgH locus shows relative positions of quantitative PCR amplicons 
used in ChIP experiments. A control non-IgH locus (Rpp30) was also examined. Indicated CH12 cell lines 
stimulated for 30 h with CIT were subjected to ChIP with IgG (control), histone H2AX and RPA32 monoclonal 
antisera. After background subtraction, values were normalized to the DNA input signals, followed by the 
maximum value in each data set. Mean signals, two replicates ±s.e.m.
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Our data for REV7 are reminiscent of 
previous findings that 53BP1 loss occurs in 
subsets of human breast carcinomas15 and can 
also restore HR to BRCA1-deficient cells7,15,17. 
As with 53BP1, we found a frequent aberrant 
reduction or loss of the REV7 protein in human 
triple-negative breast carcinomas (Extended 
Data Fig. 7). Addressing the relationship 
between REV7, 53BP1 and the 53BP1 non-
homologous end-joining (NHEJ) effector 
protein, RIF1 (ref. 18), we found that Rev7 
deficiency did not compromise the formation 
of endogenous 53BP1 or RIF1 foci (Extended 
Data Fig. 8a–d). By contrast, endogenous 
REV7 foci or laser induced stripes were absent 
in 53BP1-depleted mouse and human cells 
(Fig. 4a and Extended Data Fig. 4c, d), strongly 
suggesting that REV7 acts downstream of 
53BP1. This is also consistent with our results 
that PARPi resistance is not increased when 
both Rev7 and 53bp1 are depleted (data not 
shown). Despite such strong evidence for a 
cooperative role for REV7 and 53BP1, we did 
not detect REV7 in 53BP1 immunocomplexes 
isolated from untreated cell lysates, or ATM-
phosphorylated 53BP1 immunocomplexes 
containing RIF1 that were induced by DNA 
damage19 (Extended Data Fig. 8e and data 
not shown). Although the intricacies of the 
interactions remain to be determined, REV7 
recruitment to DNA damage sites by 53BP1 
may result from indirect interactions or an 
activity elicited by 53BP1 protein complexes 
in chromatin at DSB sites.
To examine whether REV7, like 53BP1 (ref. 
18), also promotes NHEJ of DSBs during class 
switch recombination (CSR), we depleted 
Rev7 transcripts in the mouse CH12 B-cell 
line, which after stimulation undergoes CSR 
from IgM to IgA at a high rate20. Efficient 
Rev7 knockdown was achieved using several 
shRNAs, reducing CSR to levels comparable 
with 53BP1-depleted cells when compared to 
control-depleted cells (Fig. 4b and Extended 
Data Fig. 9a, b). Moreover, these defects 
were not accompanied by defects in cell 
proliferation, Aid (also known as Aicda), or 
germ-line transcript (mGLT/aGLT) expression 
(Extended Data Fig. 9c–e). Conditional REV3-
ablation has been reported to reduce CSR 
efficiency in B lymphocytes21, suggesting that 
distinct from 53BP1, REV7 might participate in 
CSR through Polz  function. This considered, 
we reasoned that we might separate the 
function of REV7 from that of Polz during 
CSR, at the level of DSB resection inhibition. 
To this end, RPA enrichment was measured 
by chromatin immunoprecipitation (ChIP) 
at control and several IgH loci in control, 
53BP1-, REV3- or REV7-depleted CH12 lines 
stimulated to undergo CSR. Consistent with 
the role of 53BP1 in resection inhibition, 
53BP1-depletion was accompanied by a 3–5-
fold enrichment of RPA ChIP signal specifically 
in donor (Sm) and acceptor (Sa) IgH switch (S) 
regions where DSBs occur during IgM to IgA 
CSR, but not at an IgH Sc1 locus or a control 
non-IgH Rpp30 locus (Fig. 4c). Notably, these 
defects were closely mimicked after REV7 
depletion, whereas shRNA-mediated REV3 
depletion yielded no detectable increase 
in RPA IgH S-region enrichment, despite 
diminishing CSR efficiency (Extended Data 
Fig. 9f ) as expected21. Importantly, at each 
locus equivalent ChIP signals for total histone 
were obtained between cell lines. Thus, our 
data support a Polz-independent function of 
REV7 in inhibiting the nucleolytic processing 
of DSBs generated during CSR.
Our data uncover a crucial role for REV7 in 
regulating DSB repair. REV7 depletion restores 
homology-directed DNA repair of BRCA1-
deficient cells resulting in PARPi resistance. 
We attribute this result to the inhibitory effect 
of REV7 on DNA end resection. Like 53BP1 
together with RIF1 and PTIP (ref. 18), REV7 
may function as a NHEJ factor that performs 
a regulatory role in DSB repair pathway 
choice. This provides new insight into the 
versatile functions of REV7 in addition to its 
role in translesion synthesis9,22, and helps to 
explain how HR can be partially restored in 
the absence of BRCA1.
Received 17 February 2014; 
Accepted 13 February 2015.
Published online 23 March 2015.
53
REV7 counteracts DNA double-strand break  resection and affects PARP inhibition
3
References
1. Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: dif-
ferent roles in a common pathway of genome pro-
tection. Nature Rev. Cancer 12, 68–78 (2012).
2. Lee, J.-M., Ledermann, J. A. & Kohn, E. C. PARP Inhib-
itors for BRCA1/2 mutationassociated and BRCA-like 
malignancies. Ann. Oncol. 25, 32–40 (2013).
3. Farmer, H. et al. Targeting the DNA repair defect in 
BRCA mutant cells as a therapeutic strategy. Nature 
434, 917–921 (2005).
4. Lord, C. J. & Ashworth, A. Mechanisms of resistance 
to therapies targeting BRCAmutant cancers. Nature 
Med. 19, 1381–1388 (2013).
5. Ang, J. E. et al. Efficacy of chemotherapy in BRCA1/2 
mutation carrier ovarian cancer in the setting of 
PARP inhibitor resistance: a multi-institutional study. 
Clin. Cancer Res. 19, 5485–5493 (2013).
6. Chun, A. C.-S., Kok, K.-H. & Jin, D.-Y. REV7 is required 
for anaphase-promoting complex-dependent ubiq-
uitination and degradation of translesion DNA poly-
merase REV1. Cell Cycle 12, 365–378 (2013).
7. Jaspers, J. E. et al. Loss of 53BP1 causes PARP inhib-
itor resistance in Brca1- mutated mouse mammary 
tumors. Cancer Discov 3, 68–81 (2013).
8. Listovsky, T. & Sale, J. E. Sequestration of CDH1 by 
MAD2L2 prevents premature APC/C activation prior 
to anaphase onset. J. Cell Biol. 203, 87–100 (2013).
9. Gan, G. N., Wittschieben, J. P., Wittschieben, B. Ø. & 
Wood, R. D. DNA polymerase zeta (pol zeta) in higher 
eukaryotes. Cell Res. 18, 174–183 (2008).
10. Hara, K. et al. Crystal structure of human REV7 in 
complex with a human REV3 fragment and structur-
al implication of the interaction between DNA poly-
merase zeta and REV1. J. Biol. Chem. 285, 12299–
12307 (2010).
11. Khalaj,M. et al. A missense mutation in Rev7 disrupts 
formation of Polζ, impairing mouse development 
and repair of genotoxic agent-induced DNA lesions. 
J. Biol. Chem. 289, 3811–3824 (2014).
12. Stap, J. et al. Induction of linear tracks of DNA dou-
ble-strand breaks by alphaparticle irradiation of 
cells. Nature Methods 5, 261–266 (2008).
13. Fanning, E., Klimovich, V. & Nager, A. R. A dynamic 
model for replication protein A (RPA) function in 
DNA processing pathways. Nucleic Acids Res. 34, 
4126–4137 (2006).
14. Sartori, A. A. et al. Human CtIP promotes DNA end 
resection. Nature 450, 509–514 (2007).
15. Bouwman, P. et al. 53BP1 loss rescues BRCA1 defi-
ciency and is associated with triple-negative and 
BRCA-mutated breast cancers. Nature Struct. Mol. 
Biol. 17, 688–695 (2010).
16. Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, 
M. XRCC3 promotes homology-directed repair of 
DNA damage in mammalian cells. Genes Dev. 13, 
2633–2638 (1999).
17. Bunting, S. F. et al. 53BP1 inhibits homologous re-
combination in Brca1-deficient cells by blocking re-
section of DNA breaks. Cell 141, 243–254 (2010).
18. Zimmermann, M. & de Lange, T. 53BP1: pro choice in 
DNA repair. Trends Cell Biol.24, 108–117 (2014).
19. Chapman, J. R. et al. RIF1 is essential for 53BP1-de-
pendent nonhomologous end joining and suppres-
sion of DNA double-strand break resection. Mol. Cell 
49, 858–871 (2013).
20. Muramatsu, M. et al. Class switch recombination and 
hypermutation require activation-induced cytidine 
deaminase (AID), a potential RNA editing enzyme. 
Cell 102, 553–563 (2000).
21. Schenten, D. et al. Pol ζ ablation in B cells impairs the 
germinal center reaction, class switch recombina-
tion, DNA break repair, and genome stability. J. Exp. 
Med. 206, 477–490 (2009).
22. Kikuchi, S., Hara, K., Shimizu, T., Sato, M. & Hashimoto, 
H. Structural basis of recruitment ofDNApolymerase 
ζ by interaction betweenREV1andREV7proteins. J. 
Biol. Chem. 287, 33847–33852 (2012).
23. Evers, B. et al. Selective inhibition of BRCA2-deficient 
mammary tumor cell growth by AZD2281 and cis-
platin. Clin. Cancer Res. 14, 3916–3925 (2008).
24. Fradet-Turcotte, A. et al. 53BP1 is a reader of the 
DNA-damage-induced H2A Lys15 ubiquitin mark. 
Nature 499, 50–54 (2013).
25. Watanabe, S. et al. JMJD1C demethylates MDC1 to 
regulate the RNF8 and BRCA1-mediated chromatin 
response toDNA breaks.Nature Struct.Mol. Biol.20, 
1425–1433 (2013).
26. Doil, C. et al. RNF168 binds and amplifies ubiquitin 
conjugates on damaged chromosomes to allow 
accumulation of repair proteins. Cell 136, 435–446 
(2009).
27. Stewart, G. S. et al. The RIDDLE syndrome protein 
mediates a ubiquitindependent signaling cascade at 
sites of DNA damage. Cell 136, 420–434 (2009).
28. Stap, J. et al. Induction of linear tracks of DNAdou-
ble-strand breaks by a-particle irradiation of cells. 
Nature Methods 5, 261–266 (2008).
29. de Jager, M. et al. DNA-binding and strand-anneal-
ing activities of human Mre11: implications for its 
roles in DNA double-strand break repair pathways. 
Nucleic Acids Res. 29, 1317–1325 (2001).
30. Bouwman, P. et al. A high-throughput functional 
complementation assay for classification of BRCA1 
missense variants. Cancer Discov. 3, 1142–1155 
(2013).
31. Bartkova, J. et al. DNA damage response as a candi-
date anti-cancer barrier in early human tumorigene-
sis. Nature 434, 864–870 (2005).
Acknowledgements 
We thank B. Gerritsen, P. Halonen, B. Morris, T. Hala-
zonetis and O. Kallioniemi for advice on the DDR shRNA 
library, A. Gasparini and G. Borst for their assistance with 
the cone beam micro-irradiator, R. Kanaar for his RAD51 
antibody, J. Jacobs for the pMSCV-GFP vector, and M. 
O’Connor for olaparib and AZD2461. This work was sup-
ported by the Netherlands Organization for Scientific 
Research (NWO-Toptalent to J.E.J. and NWO-VIDI to S.R.), 
the Dutch Cancer Society, CTMM Breast Care, the Swiss 
National Science Foundation, and the European Union 
(EU) FP6 Integrated Project CHEMORES and FP7 Project 
54
3
Chapter 3
METHODS
Cell culture and reagents. KB1P-B11 (B11) and KB1P-G3 
(G3) cell lines were derived from a Brca1-/- p53-/- mouse 
mammary tumour as described7. KB2P-1.21 and KB2P-3.4 
cell lines originate from a Brca1-/- p53-/- mouse mammary 
tumour, and KP3.33 cell line from a p53-/- mouse mam-
mary23. These cell lines were cultured in DMEM/F-12 
(Life Technologies) supplemented with 10% FCS, 
50Uml-1 penicillin, 50 ng ml-1 streptomycin, 5 mg ml-1 
insulin (Sigma), 5 ngml-1 epidermal growth factor (Life 
Technologies) and 5 ng ml-1 cholera toxin (Gentaur)
under low oxygen conditions (3%O2, 
5%CO2, 37°C). SUM149PT cells were grown
in RPMI1640 (Life Technologies) supplemented with 
10%FCS, under normal oxygen conditions (21%O2, 
5%CO2, 37°C). U2OS, phoenix, 293T cells were cultured
in DMEM (Life Technologies) supplemented with 10% 
FCS, under normal oxygen conditions (21%O2, 5%CO2, 
37°C). mES cells with a selectable conditional BRCA1
deletion (R26CreERT2/wt;Brca1SCo/D)15 were cultured on gel-
atin-coated plates in 60% buffalo red liver cell-con-
ditioned medium supplied with 10% FCS, 0.1mM 
b-mercaptoethanol (Merck) and 1x103 Uml-1 ESGROLIF 
(Millipore) under normal oxygen conditions (21% O2, 
5% CO2, 37 °C). CH12 cells (CH12F3-2) were cultured in 
RPMI-1640 medium (Sigma) supplemented with 10% 
FBS, 5% NCTC 109medium(Sigma), 50 mM b-mercap-
toethanol, 50Uml-1 penicillin and 50 ng ml-1 strepto-
mycin under normal oxygen conditions. Olaparib and 
AZD2461 were provided by AstraZeneca;KU-55933 
(KuDOS) was bought from Selleckchem(S1092).
Lentivirus-based transduction of cells with shRNA. 
Glycerol stocks of shRNA hairpins were obtained from 
the Sigma Mission library (TRC 1.0) and isolation of 
plasmids was carried out with the high pure plasmid 
Mini Kit or Genopure maxi kit (Roche). 293T cells were 
seeded 16 h before transfection. For each 10-cm dish,
0.5 ml 2xHBS (8.18 g NaCl, 0.2 g Na2HPO4-7H2O, 5.95 
g HEPES in 500ml MilliQ water at pH7.01) was added 
into a sterile falcon tube. In another sterile falcon tube, 
6 mg plasmid DNA of interest, 2 mg pHCMV-G enve-
lope vector (pMD.G), 2 mg pRSV-Rev, 2 mg packaging 
vector pMDLg/pRRE, 250 ml 0.5MCaCl2 and distilled 
water were added to bring up to 0.5 ml. The CaCl2/
plasmid DNA mix was added to the 2xHBS and incu-
bated for 20 min and then added to the cells. Medium 
was refreshed after 6 h and another 18 h, respectively.
The supernatant of 293T cells containing lentivirus was 
collected after 24 h to infect cells with polybrene (6 mg 
ml-1) for 12 h. The medium was refreshed after lentivirus 
infection and the cells were selected with puromycin. 
Individual shRNA vectors used were collected from 
the TRC library. Mouse Rev7: sh1: TRCN0000012844_
CCAGTGGAGAAGTTTGTCTTT; sh2: TRCN 0000012846_
CATCTTCCAGAAGCGCAAGAA; sh3: TRCN0000012847_
GAT ACAGGTCATCAAGGACTT; human REV7: sh1: 
TRCN0000006569_CCCTGA TTCCAAGTGCTCTTA; sh2: 
TRCN0000006570_CCCGGAGCTGAATCAGTATAT; sh3: 
TRCN0000006571_CCCAGTGGAGAAATTCGTCTT; sh4: 
TRCN00 00006573_CATCTTCCAGAAACGCAAGAA; 
mouse 53bp1: (puromycin) sh:TRCN0000081778_
GCTATTGTGGAGATTGTGTTT; (neomycin) sh: 
same sequences as above; human 53BP1: sh1: 
TRCN0000018866_CCAGTGTGATTAGT ATTGATT; sh2: 
TRCN0000018865_GATACTTGGTCTTACTGGTTT; mouse
p53: (neomycin) TRCN0000054551_AGAGTATTTCACCCT-
CAAGAT; mouse Rev1: sh1: TRCN0000120298_GC-
CGAGATCAACTATGGAATA; sh2: TRCN 0000120297_
CAGCAGTGCTTGTGAGGTATT; mouse Rev3: sh1: 
TRCN0000119969_CCGTCACATTAGTGAGACTAT; sh2: 
TRCN0000119970_GCCCAC ATACACTTTCTTCTT.
Loss-of-functionscreen. In total, 1,976 lentiviral hair-
pins (pLKO.1) from the Sigma Mission library (TRC Mm 
1.0) that target 391 mouse genes involved in the DNA
damage response were selected (see Supplementary 
Table 1). This library was used to generate pools of len-
tiviral shRNA in 293T cells to infect target cells. After 
infection, the cells stably expressing integrated shRNA 
were selected with puromycin. Cells with HR restora-
tion were selected with a high concentration of olaparib
(500 nM, about 100-fold the IC50), which killed cells of 
the empty vector group. Surviving cells were pooled 
and genomic DNA was extracted using the Gentra
Puregene kit according to the manufacturer’s proto-
col (Qiagen). shRNA inserts were retrieved from 50 ng 
genomic DNA by PCR amplification (PCR1 and PCR2)
using the following conditions: (1) 95 °C, 5 min; (2) 95 °C, 
30 s; (3) 60 °C, 30 s; (4) 72 °C, 1 min; (5) go to step (2), 20 
cycles; (6) 72 °C, 5 min; (7) 4 °C. The PCR reaction system 
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were as follows: 0.6 μl DMSO, 4.0 μl phusion HF buffer 
5x, 0.4 μl dNTPs, 1.0 μl primer f (10mM), 1.0 μl primer r 
(10mM), 11.8 μl mQ, 0.2 μl phusion,1.0 μl gDNA for PCR1 
or 1 μl PCR1 products for PCR2. Adaptors and indexes
for deep sequencing (Illumina HiSeq 2000) were 
incorporated into PCR primers as follows: PCR1 
forward: PCR1_01_PLKO1_f_Integration deter-
mination_1, 5’-AC ACTCTTTCCCTACACGACGCTCTTC-
CGATCTCGTGATCTTGTGGAAAGGACGAAACACCGG-3’; 
PCR1_02_PLKO1_f_Integration determination_2, 5’-
A C A C T C T T T C C C TA C A C G A C G C T C T T C C G AT C T-
G TA G C C C T TG TG G A A A G G A C G A A A C A C C G G - 3 ’ ; 
PCR1_03_PLKO1_f_untreated_1, 5’-ACACTCTTTCCCT-
ACACGACGCTCTTCCGATCTCACTGTCTTGTGGAAAG-
GACGAAACACCGG-3’; PCR1_04_PLKO1_f_untreated_2, 
5’-ACACTCTTTCCCTACACACTCTTTCCCTACACGACGCTCT-
TCCGATC TGTAGCCC T TGTGGAAAGGACGAAACAC-
CGG-3’; PCR1_03_PLKO1_f_untreated_1, 5’-ACACTCTT 
ACGACGC TC T TCCGATC TAT TGGCC T TGTGGAAAG-
GACGAAACACCGG-3’; PCR1_05_PLKO1_f_olapar-
ib_1, 5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-
GATCTGCTTGTGGAAAGGACGAAACACCGG-3’; PCR1_06_
PLKO1_f_olaparib_2, 5’-ACACTCTTTCCCTA-
CACGACGC TC T TCCGATC T TCAAGTC T TGTGGAAA-
GGACGAAACACCGG-3’; PCR1_07_PLKO1_f_
olaparib_3, 5’-ACACTCTTTCCCTACACGACGCTCT-
T C C G AT C T C T G AT C C T T G T G G A A A G G A C G A A A -
CACCGG-3’; PCR1_08_PLKO1_f_olaparib_4, 5’-
ACACTCTTTCCCTACACGACGCTCTTCCGATCTAAGC-
TACTTGTGGAAAGGACGAAACACCGG-3’; PCR1 re-
verse: P7_pLKO1_r, 5’-CAAGCAGAAGACGGCATAC-
GAGATTTCTTTCCCCTGCACTGTACCC-3’; PCR2 forward:
P5_IlluSeq, 59-AATGATACGGCGACCACCGAGATCTA-
CACTCTTTCCCTACACGACGCTCTTCCGATCT-3’; PCR2 
reverse: P7, 5’-CAAGCAGAAGACGGCATACGAGAT-3’.
PCR2 products were purified using the PCR purification 
kit from Qiagen. The shRNA stem sequence was segre-
gated and aligned to the TRClibrary. The reads of dif-
ferent hairpins were counted and the following criteria 
were used to select the top hits for further validation: 
(1) hairpins targeting the same gene in survival clones
should have at least 13104 reads (total 6x106 reads); 
(2) at least two different hairpins targeting the 
same gene should be present; (3) hairpins in re-
sistant clones should be highly enriched (0.8-fold) 
in cells after olaparib selection; and (4) hairpins 
should be present in 4 out of 4 independent screens. 
PARPi treatment study. Long-term clonogenic as-
say: on day 0, 1,5x104 (B11) or 1x104 (G3, KB2P_1.21 
or KB2P_3.4) or 6x103 (KP3.33) cells were seeded per
well with PARPi (or untreated control) into six-well 
plates. The medium of the PARPi treatment groups was 
refreshed with PARPi every 4 days. On day 5, the un-
treated control group was stopped and the PARPi treat-
ment groups were stopped after another 2–3 weeks and 
stained with 0.1% crystal violet. Using the SUM149PT
cells, 4x104 cells were seeded per well with olaparib (or 
untreated control) into 12-well plates. The medium of 
the PARPi treatment groups was refreshed with olapar-
ib every 4 days. On day 6, the untreated control group 
was stopped and the olaparib treatment groups were 
stopped on day 8 and stained with 0.1% crystal violet.
Quantification of the clonogenic assay was done by de-
termining the absorbance of crystal violet at 590 nm.
 Short-term clonogenic assay: on day 0, 43102 
(G3) cells were seeded per well with olaparib (or untreat-
ed control) into 6-well plates. On day 4, the medium was 
refreshed with olaparib or untreated control. On day 
8, all the groups were stained with Leishman dye and 
quantification was done by the relative colony numbers.
ATM and PARP inhibitor combination study. On 
day 0, 1x104 (G3) cells were seeded per well into 6-well 
plates and then ATM inhibitor or olaparib or their com-
bination was added.The medium was refreshed every 3 
dayswith the different drugs. For the combination ther-
apy groups, ATM inhibitor was applied for 6 days. On
day 5, ATM inhibitor alone and untreated control 
groups were stopped and the other groups were 
stopped on day 12 and stained with 0.1% crystal violet.
Constructs. Human REV7 was amplified by PCR using 
Platinum Taq polymerase (Invitrogen) from U2OS cDNA 
using the following primers 5’-ATAGAATTCAATGAC-
CACGCTCACACGACAAGAC -3’ and 5’-ATATGGTACCAT-
CAGC TGCCTTTATGAGCGCGC-3’. Mouse Rev7 was am-
plified from mouse lung cDNA in two parts to introduce 
silent mutations, making it resistant to Rev7 shRNA2
(mRev7R). The following primers were used for part A: 
[IB11m] 5’-ATATGAATTCGATGACCACCCTCACGCGC-3’ 
[IB14m] 5’-TACTTCTTCCGTTTCTGAAAGATGCCCACCGG-
GTA-3’ and part B: [IB12m] 5’-ATATGGTACCATGCTGTTCT-
TATGCGCTCGCT-3’ [IB13m] 5’-GGGCATCTTTCAGAAACGG
AAGAAGTACAACGTGC-3’. Equal parts of both PCR reac-
tions were mixed and used for aPCR using IB11m and 
IB12m to create the complete mouse Rev7 sequence
including the silent mutations. The PCR product and 
pEGFP-C1 vector were digested using EcoRI and KpnI
and ligated using the T4 DNA Ligase (Roche) to gen-
erate pEGFP-hREV7 and pEGFP-mREV7R. Using pEG-
FP-mREV7R as a template, pEGFP-C1-based REV7 
truncated constructs was amplified by PCR using the 
following primers: forward: 5’-ATATGAATTCGATGAC-
CACCCTCACGCGC-3’, reverse: mREV7R (1–55aa): 5’-ATAT
GGTACCGGACATCTGAACCGGCAC-3’; mREV7R (1–81aa): 
5 ’-ATATGGTACCC TCCACATCGT TC T TC TCCAGG-3’ ; 
mREV7R (1–110aa): 5’-ATATGGTACCGATGGACAG-
CAAGGGAGGC-3’; mREV7R (1–140aa): 5’-ATATGGT
ACCGTTGTGATCCAGGACAGC-3’; mREV7R (1–183aa): 
5’-ATATGGTACCGTCGTGCATGTGGACATCCTG-3’. pEG-
FP-REV7 mutants (shRNA-resistant)  were ordered as 
gBlocks (IDT) and cloned into the pEGFP-C1 vector us-
ing EcoRI and KpnI restriction enzymes and quick ligase 
(NEB). The DNA sequences that were ordered as gBlocks 
are: mREV7_shRNAresistant (mREV7R): CGCCGCG
AATTCCGCCACCATGACCACCCTCACGCGCCAAGACCT-
CAACTTTGGCCAAGTGGTGGCTGACGTGCTCTCCGAGT-
TCCTGGAGGTGGCCGTGCACCTGATTCTCTATGTGCGC-
GAGGTCTACCCGGTGGGCATCTTTCAGAAACGGAAGAA-
GTACAACGTGCCGGTTCAGATGTCCTGTCACCCGGAGCTG 
A A C C A G TA C AT C C A G G A C A C A C T C C A C T G C G T-
CAAACCTCTCCTGGAGAAGAACGATGTGGAGAAGGT-
GGTGGTGGTGATTTTGGATAAGGAACACCGCCCAGTG-
GAGAAGTTTGTCTTTGAGATCACTCAGCCTCCCTTGCT-
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G TCC ATC A AT TC A G A C TCCC TCC TG TC TC ATG TG -
G A G C A G C TG C T TC G A G C C T TC ATC C T TA A G AT T-
A G T G T G T G T G A T G C T G T C C T G G A T C A C A A C C
CTCCAGGCTGCACATTTACAGTCCTCGTGCACACAA-
GAGAAGCTGCTACTCGAAACATGGAGAAGATACAG-
GTCATCAAGGACTTCCCATGGATCCTGGCAGATGAA-
CAGGATGTCCACATGCACGACCCCCGC T TGATACCC
C TA A A A A C C ATG A C G TC G G A C AT T T TA A A G ATG -
CAGCTCTACGTTGAAGAGCGAGCGCATAAGAACAGCT-
GAGGTACCCCGGG; mREV7_shRNA resistant_L186A/
Q200A/Y202A: CGCCGCGAATTCCGCCACCATGAC-
CACCCTCACGCGCCAAGACCTCAACTTTGGCCAAGT-
GGTGGCTGACGTGCTCTCCGAGTTCCTGGAGGTGGC-
CGTGCACCTGATTCTCTATGTGCGCGAGGTCTACCCG-
GTGGGCATCTTTCAGAAACGGAAGAAGTACAACGTGCC
G G T T C A G AT G T C C T G T C A C C C G G A G C T G A A C -
C A G T A C A T C C A G G A C A C A C T C C A C T G C G T -
CAAACC TC TCC TGGAGAAGAACGATGTGGAGAAGG
TGGTGGTGGTGATTTTGGATAAGGAACACCGCCCAGTG-
GAGAAGTTTGTCTTTGAGATCACTCAGCCTCCCTTGCT-
GTCCATCAATTCAGACTCCCTCCTGTCTCATGTGGAG-
CAGCTGCTTCGAGCCTTCATCCTTAAGATTAGTGTGTGT-
GATGCTGTCCTGGATCACAACCCTCCAGGCTGCACATTTAC
AGTCCTCGTGCACACAAGAGAAGCTGCTACTCGAAA-
CATGGAGAAGATACAGGTCATCAAGGAC T TCCCAT-
G G AT C C T G G C A G AT G A A C A G G AT G T C C A C AT G -
CACGACCCCCGCGCTATACCCCTAAAAACCATGACGTCG-
GACATTTTAAAGATGGCTCTCGCTGTTGAAGAGCGAG-
CGCATAAGAACAGCTGAGGTACCCCGGG; mREV7_ 
shRNAresistant _C70R: CGCCGCGAATTCCGCCACCAT-
GACCACCCTCACGCGCCAAGACCTCAACT T TGGCCA
A G T G G T G G C T G A C G T G C T C T C C G A G T -
T C C T G G A G G T G G C C G T G C A C C T
GATTCTCTATGTGCGCGAGGTCTACCCGGTGGGCATCT-
TTCAGAAACGGAAGAAGTACAACGTGCCGGTTCAGAT-
GTCCTGTCACCCGGAGCTGAACCAGTACATCCAGGA-
CACACTCCACCGCGTCAAACCTCTCCTGGAGAAGAAC-
GATGTGGAGAAGGTGGTGGTGGTGATTTTGGATAAG-
GAACACCGCCCAGTGGAGAAGTTTGTCTTTGAGATCACT-
CAGCCTCCCTTGCTGTCCATCAATTCAGACTCCCTCCT-
GTCTCATGTGGAGCAGCTGCTTCGAGCCTTCATCCTTAA-
GATTAGTGTGTGTGATGCTGTCCTGGATCACAACCCTC-
C A G G C TG C A C AT T TA C A G TCC TCG TG C A C A C A A -
GAGAAGCTGCTACTCGAAACATGGAGAAGATACAGGCAT-
CAAGGACTTCCCATGGATCCTGGCAGATGAACAGGAT-
GTCCACATGCACGACCCCCGCTTGATACCCCTAAAAAC-
CATGACGTCGGACATTTTAAAGATGCAGCTCTACGTTGAA
GAGCGAGCGCATAAGAACAGCTGAGGTACCCCGGG.Using 
pEGFPmREV7R, C70R and L186A/Q200A/Y202A mu-
tants as templates, Gateway compatible pMSCV-GFP or 
pLenti6-UBC(Invitrogen)-based REV7 truncated orREV7
mutated constructs were amplified by PCR using the 
following primers: forward: 5’-GGGGACAACTTTGTA-
CAAAAAAGTTGGCATGACCACCCTCACGCGCCAA-3’; 
reverse: mREV7R (full-length for wt REV7, C70R REV7, 
L186A/Q200A/Y202A REV7): 5’-GGGGACAACT-
T TGTACAAGAAAGT TGGGTAT TCAGC TGT TC T TATG-
CGCTCGCTC-3’; mREV7R(1–140aa): 5’-GGGGACAACTTT
GTACAAGAAAGTTGGGTATTCAGTTGTGATCCAGGA-
CAGC-3’; mREV7R (1–183aa): 5’-GGGGACAACTTTG-
TACAAGAAAGT TGGGTAT TCAGTCGTGCATGTGGA-
CATCCTG-3’. PCR productswere purified using PCR 
purification kit (Roche) and then subjected to BP (BP-
clonase II, Invitrogen) and LR (LRclonaseII, Invitrogen) re-
action according to manufacturer’s instructions. Wildtype 
53BP1 and 53BP120AQ constructs were previously de-
scribed19. All the constructs were verified by sequencing.
siRNA, cDNAtransfection and cDNA transduction. 
SMARTpool siRNAs targetingmouse Ctip (siGENOME: 
M-055713-02,Thermo Scientific) and non-targeting-
control were transfected into cells using Dharmacon1 
transfection reagent (Thermo Scientific). After 48 h, 
cells were subjected to western blot anda track assay. 
siRNAs against 53bp1, Rnf8 or Rnf168 were transfect-
ed into cells using Lipofectamine RNAiMax according 
to the manufacturer’s instruction. The sequences of 
53bp1 siRNA: 5’-GAGAGCAGAUGAUCCUUUA-3’ (ref. 
24); Rnf8 siRNA: 5’-GGACAAUUAUGGACAACAATT-3’ 
(ref. 25); Rnf168 siRNA: 5’-GGCGAAGAGCGAUGGAG-
GAtt-3’ (ref. 26); GFP siRNA: 5’-GGCUACGUCCAGGAG-
CGCACCTT-3’. Immunofluorescence and western 
blotting analysis was done 64 h aftertransfection.
 For pEGFP-based constructs, transient 
transfection was done using X-treme GENE HP 
DNA transfection reagent (Roche) according to the 
manufacturer’s manual. GFP-positive cells were 
sorted by flow cytometry and subjected to west-
ern blotting and immunofluorescence staining.
 For pMSCV-GFP (retrovirus)-based constructs, 
transient transfection was done using X-treme GENE 
HP DNA transfection reagent in phoenix cells and the 
medium was refreshed after 24 h. Retroviruses were 
collected 48 h after transfection, and then target cells 
were infected for two consecutive periods of 12 h using 
fresh virus. The medium was refreshed after retrovirus 
infection and the cells were selected with blasticidin.
 For pLenti6-UBC(lentivirus) based constructs, 
together with the packaging plasmids p59, p60 and p61, 
transient transfection was done using X-treme GENE HP
DNA transfection reagent in 293T cells and the medium 
was refreshed after 24 h. Lentiviruses were collected 48 
h after transfection and then target cells were infected
for two consecutive periods of 12 h using fresh vi-
rus. The medium was refreshed after lentivirus in-
fection and the cells were selected with blasticidin.
Mice, generation of PARPi-resistant mouse mam-
mary tumours. All mouse experiments were ap-
proved by the Animal Experiments Review Board 
of the Netherlands Cancer Institute (Amsterdam), 
complying with Dutch legislation. Olaparib resistant 
KB1P(M)- and AZD2461-resistant KB1P mouse mam-
mary tumours were generated as described7. In this 
study we analysed a total of 55 PARPi-resistant and 
52 PARPi-sensitive tumours derived from 13 individ-
ual KB1P(M) and 10 individual KB1P donor tumours. 
 To generate mouse mammary tumours 
from cell lines, 5x105 cells were orthotopically trans-
planted into 6-week-old female wild-type FVB/N_
Ola129 mice as reported previously7. Mice were ran-
domized to the PARPi or untreated control groups.
RT-qPCR. Total RNA was isolated from cells using the 
high pure RNA isolation kit (Roche). cDNA was made 
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from 1 μg RNA with the GoScript Reverse Transcription
system (Promega). For the quantitative PCR cDNA, Prim-
er Fw&Rv (400nM) and Lightcycler 480 SYBRGreenIMas-
ter (Roche) were applied in a Lightcycler 480 96-well 
plate (Roche). The SYBR green signals were measured 
with Lightcycler 480 II (Roche). The Cp value of the 
gene of interest was subtracted from the housekeep-
ing gene.This value was put in the power of 2 and this 
was also done for the s.d. The primer sequences used in 
this study are as follows: Mouse Hprt forward: 5’-CTGGT-
GAAAAGGACCTCTCG-3’; mouse Hprt reverse: 5’-TGAA-
GTACTCATTATAGTCAAGGGCA-3’; mouse Rev7 forward: 
5’-ACACTCCACTGCGTCAAACC-3’; mouse Rev7 reverse: 
5’-AAAGACAAACTTCTCCACTGGGC-3’; mouse Rev1 for-
ward: 5’-ACAGGATTGCTTGGTGCCTGTG-3’; mouse Rev1 
reverse: 5’-TGAAGTCCGCGTTGCTCTTCTC-3’; mouse Rev3 
forward: 5’-AAGAGATGTCACAGACAGGCCC-3’; mouse 
Rev3 reverse: 5’-AGTTAGACAGCCGCTGTTGTGC-3’; 
mouse αGLT forward: 5’-GACATGATCACAGGCACAGG-3’;
mouse αGLT reverse: 5’-TTCCCCAGGTCACATTCATCGT-3’; 
mouse μGLT forward: 5’-TAGTAAGCGAGGCTCTAAAAAG-
CAT-3’; mouse μGLT reverse: 5’-AGAACAGTCCAGT-
GTAGGCAGTAGA-3’; mouse Aid forward: 5’-GAAA
GTCACGCTGGAGACCG-3’; mouse Aid reverse: 5’-TCT-
CATGCCGTCCCTTGG-3’. Human HPRT-P1 (primers 
pair 1) forward: 5’-GCAGACTTTGCTTTCCTTGG-3’; 
human HPRT-P reverse: 5’-ACACTTCGTGGGGTCCT-
TTT-3’; human HPRT-P2 forward: 5’-TGCTCGAGAT-
GTGATGAAGG-3’; human HPRT-P2 reverse: 5’-AATC-
CAGCAGGTCAGCAAAG-3’; human REV7-P1 forward: 
5’-TGCTGTCCATCAGCTCAGAC-3’; human REV7-P1 re-
verse: 5’-TCTTCTCCATGTTGCGAGTG-3’; human REV7-P2 
forward: 5’-GCTCACACGACAAGACCTCA-3’; human 
REV7-P2 reverse: 5’-GACCGGCACGTTGTACTTCT-3’; mouse 
53bp1 forward: 5’-TCAGCCAAACAGGACAAGCA-3’; mouse
53bp1 reverse: 5’-GCAGAATCTTCAGCAGCAAGG-3’.
Western blotting. Cells were washed with ice-cold PBS 
and lysed on ice for 30 min with RIPA lysis buffer supple-
mented with three protease inhibitors (P8340, P5726,
P0044; Sigma-Aldrich). Protein concentration was deter-
mined by the Bradford Protein Assay Kit (Bio-Rad) and 
a calibration standard curve created from the BSA. The 
samples were prepared for loading by adding 4x sam-
ple buffer (Invitrogen) and heating the samples at 70 °C 
for 10 min. Total proteins were separated bySDS–PAGE 
on 3–8% Tris-acetate (for 53BP, RIF1) or 4–12% Bis-Tris 
gradient gels (all others). Next, proteins in the gel were 
electrophoretically transferred to PVDF membrane
(Millipore) (for REV7, ACTB, α-tubulin) or to NC mem-
branes (Invitrogen) (all others) and then the membrane 
was blocked in 5% milk with Tris-buffered saline Triton 
X-100 buffer (100mMTris, pH7.4, 500mM NaCl, 0.1% Tri-
tonX-100) (TBS-T0.1%). Membranes were incubated with 
primary antibodies in 5% milk in TBS-T0.1% overnight 
at 4 °C. Horseradish peroxidase (HRP)-conjugated sec-
ondary antibody incubation was performed for 1 h at 
room temperature in 5% milk in TBS-T0.1% and signals 
were visualized by ECL. Primary antibodies used in this
study were as follows: mouse anti-REV7 (612266, 
BD Biosciences), 1:5,000 dilution; rabbit anti-53BP1 
(NB100-304, Novus), 1:1,000 dilution; rabbit anti-53BP1 
(A300-272A, Bethyl), 1:5,000 dilution; rabbit anti-CTIP 
(ab70163, Abcam), 1:1,000 dilution;mouse anti-α-tu-
bulin (T6074, Sigma), 1:5,000 dilution;mouse anti-ACTB
(MAB1501R,Millipore), 1:5,000 dilution; rabbit an-
ti-mouse RIF1 (SK1316) (ref. 19), 1:2,000 dilution; mouse 
anti-RNF8 (B-2, Santa Cruz), 1:1,000 dilution; rabbit anti-
RNF168 (ref. 27), 1:5,000 dilution; mouse anti-GAPDH 
(1D4, GeneTex) 1:1,000 dilution. Secondary antibod-
ies used in this study were as follows: polyclonal rabbit
anti-mouse immunoglobulins/HRP (P0161, Dako), 
1:10,000 dilution; polyclonal swine anti-rabbit immu-
noglobulins/HRP (P0217, Dako), 1:10,000 dilution.
Immunofluorescence. Cells were grown on glass cov-
erslips (12mm) in 24-well plates.To induce ionizing ra-
diation-induced foci, cells were γ-irradiated (10Gy) and
compared to non-irradiated controls 5 h after ionizing 
radiation. For this purpose the cells were pre-extract-
ed using cold CSK buffer (10mM HEPES-KOH, pH7.9, 
100mM NaCl, 300mM sucrose, 3mM MgCl2, 1mM EGTA 
and 0.5% (v/v) Triton X-100) on ice for 5 min and then 
cold CSS buffer (10mM Tris, pH7.4, 10mM NaCl, 3mM 
MgCl2, 1% (v/v) Tween and 0.5% (w/v) sodium deoxy-
cholate) on ice for 5 min. Cells were washed with PBS++ 
(PBS with 1mM CaCl2 and 0.5mM MgCl2) and fixed using 
2% PFA/PBS++ for 20 min at room temperature. Fixed
cells were washed three times with PBS++ and stored 
at 4 °C. The cells were incubated 20 min in 0.2% Triton 
X-100/PBS++ to be permeabilized. Then the cells were 
washed three times in staining buffer (PBS++: 1% BSA, 
0.15% glycine, 0.1% Triton X-100), incubated for 30 
min in staining buffer at room temperature, incubated
with the first antibody for 2 h at room temperature in 
staining buffer, washed three times in staining buffer, 
incubated with the second antibody for 1 h at room
temperature in staining buffer and washed three times 
in staining buffer. Next, the cells were counter-stained 
with DAPI for 5 min, washed in staining buffer, washed
in PBS++, mounted in Vectashield and sealed with 
nail polish. Primary antibodies used in this study were 
as follows: rabbit anti-RAD51 (70-001, BioAcademia),
1:20,000 dilution; rabbit anti-53BP1 (A300-272A, 
Bethyl), 1:4,000 dilution. Secondary antibodies 
used in this study were as follows: Alexa Fluor 568 
F(ab’)2 Fragment goat anti-rabbit (A21069, Invitro-
gen), 1:1,000 dilution; Alexa Fluor 488 anti-mouse 
antibody (A11001, Invitrogen), 1:1,000 dilution.
 For REV7 staining in MEF cells, cells cultured 
on coverslips were treated with 10 Gy IR and allowed to 
recover for 4 h. Cells were then washed with PBS, pre-
extracted with 0.5% Triton X-100 solution for 3 min and 
fixed with 3% paraformaldehyde for 12 min. Coverslips 
were washed with PBS and then immunostained with 
REV7 antibody (612266, BD Biosciences, 1:200 dilu-
tion) and anti-cH2AX or anti-53BP1 in 5% goat serum 
for 1 h at room temperature. Coverslips were washed 
and incubated with secondary antibodies conjugated 
with rhodemine or FITC for 30min at roomtemperature.
Cellswere then stained with DAPI to visualize nuclear
DNA. The coverslips were mounted onto glass slides with 
anti-fade solution. For RIF1 staining in MEF cells,wild-type-
MEFs stably transduced with indicated shRNAexpressing 
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lentiviruses were examined for RIF1 foci following neocar-
zinostatin treatment. Automated quantification of RIF1 
foci following mock and neocarzinostatin treatment was 
performed using Cell-Profiler software (Broad Institute).
Laser irradiation of human cells and immunofluo-
rescence staining. Cells were grown on plastic disks 
(17mm diameter) that were cut using CNC cutter from 
the bottom of standard 10-cm cultivation dish (TPP) 
ultraviolet-sterilized and placed inside the wells of a 
12-well plate. BrDU(0.5 mM)was added into siRNA-trans-
fected cells 40 h after the transfection to pre-sensitize 
cells towards UV-A wavelength. Twenty-four hours after 
BrdU addition, the plastic disks with cells were removed
and covered by a coverslip and immediately placed 
inside Zeiss AxioObserver Z.1 inverted microscope 
combined with LSM 780 confocal module. Cells were 
irradiated at 20 °C via 40x water immersion objective 
(ZeissC-Apo 403/1.2WDICIII), using 355nm 65mW la-
ser set on 100% power. The total laser dose that can be
further manipulated by the amount of irradiation cycles 
was empirically set to six irradiation cycles. Laser track 
was pre-defined to cover all the cells within the acqui-
sition area with at least one stripe across the nucleus. 
After the irradiation process the coverslip was gently 
removed and plastic disk was quickly placed back into
the same well of the 12-well plate and incubated for 
another 45 min at standard cultivation conditions. The 
plastic disks with laser-irradiated cells were first pro-
cessed by pre-extraction at 4 °C. It involves washing 
by PBS (4 °C), equilibration for 2 min in sucrose buff-
er 1 (10mM PIPES, pH6.8, 100mM NaCl, 1.5mM MgCl2
and 300mM sucrose) on ice and then pre-ex-
traction for 15 min on ice, on slowmoving
shaker using sucrose buffer 2 (10mM PIPES, pH6.8, 
100mMNaCl, 1.5mM MgCl2, 300mM sucrose, 0.5% Tri-
ton X-100, 5 mg ml-1 leupeptin, 2 mg ml-1 aprotinin,
0.1mM phenylmethanesulfonylfluoride (PMSF), 1mM 
dithiothreitol (DTT)). After the pre-extraction cells were 
washed by PBS (4 °C) and fixed by 4% paraformalde-
hyde (PFA) for 15 min at room temperature. PFA was 
washed out three times by PBS. The disks were further 
processed as standard coverslips (that is, blocking in 
blocking solution (DMEM plus 20% FCS) for 1 h followed 
by incubation with primary antibodies involving REV7 
(BDBioscience,mouse, 1:200), pS139-H2AX (Cell Signa-
ling, 20E3, rabbit, 1:300) and 53BP1 (Santa Cruz, H-300, 
rabbit 1:400) for 2 h, and with appropriate secondary 
antibodies coupled to Alexa Fluor 488 and Alexa Flour 
568 fluorophores (dilution 1:1,000) (Life Technologies). 
Both primary and secondary antibodies were dissolved 
in the blocking solution. After washes in PBS, the disks 
were incubated in 1 mg ml-1 DAPI in dH2O at room
temperature for 5 min and air dried. Dried disks were 
placed on a standard microscopy glass (cell layer face 
up) and anchored by two rubber bands laced over the
glass. Stained cells were mounted using VectaShield 
(Vector Labs) mounting medium and covered by a cov-
erslip. The samples were examined using Zeiss Axio-
Observer Z.1 inverted microscope combined with LSM 
780 confocal module using x40 oil objective (Zeiss 
EC PlnN 403/1.3 Oil DICII). It means that after the first
acquisition the plastic disk and themicroscopy glass-
wasmarked by diamond cutter (to ensure same po-
sitioning of the disk in the future), the coverslip was 
gently removed and disk was washed three times in 
PBS, 0.5% Tween to remove the mounting medium. 
Next, the disk was incubated in the 1xRe-Blot solution 
(Re-Blot Plus Mild, Millipore) for 30 min on a slow mov-
ing shaker. The solution was washed out three times in 
PBS. Such sample was ready for new staining procedure 
involving new set of primary and secondary antibod-
ies following the same protocol as described above.
In situ analysis of RAD51 foci formation. Five matched 
PARPi-resistant and -sensitive KB1P(M)tumours were 
orthotopically transplanted into wild-type FVB/N re-
cipient mice. When tumours reached 500mm3 in vol-
ume, the mice were randomized to be either irradiated 
(dose: 15 Gy) using a CT-guided high precision cone 
beam micro-irradiator (X-RAD 225Cx) or left untreat-
ed. As a positive control a BRCA1-proficient KP tumour 
was taken along. Two hours after irradiation the tu-
mours were taken out and fixed in 4% formalin. Immu-
nofluorescence staining was performed on FFPE slides.
RAD51foci were detected using a non-commercial
antibody provided by R. Kanaar in a dilution of 1:5,000. 
53BP1 foci were detected using rabbit anti-53BP1 (A330-
272A, Bethyl), diluted 1:500. As a secondary antibody 
goat-anti rabbit-Alexa Fluor568 (Invitrogen) was used 
at a dilution of 1:1,000 (2 mg ml-1). Images were taken 
by a ‘blinded’ investigator using a confocal microscope 
(Leica SP5, LeicaMicrosystemsGmbH), equipped with 
a3100 objective. For each tumour five random are-
as (246x246 μm) were imaged. Image stacks (~four
slices) were analysed in ImageJ, using an in-house de-
veloped macro to automatically and objectively evalu-
ate the RAD51 foci. In brief, nuclei were segmented by
thresholding the (median-filtered)DAPI signal, followed 
by a watershed operation to separate touching nuclei. 
For every z-stack the maximum-intensity projection of
the foci signal was background-subtracted using a dif-
ference of gaussians method. Next, for each nucleus, 
foci candidates were identified as locations where the 
resulting pixel values exceeded the background by a 
factor (typically tenfold) times the median standard de-
viation of all nuclei in the image. In combination with 
additional filters discriminating for foci size and abso-
lute brightness this procedure yielded a robust and re-
liable foci count for all nuclei. Results were validated by
visual inspection. 
REV7 recruitment to local laser-induced DNA dam-
age sites. pEGFP-REV7 or pEGFP and 53BP1–mCherry 
were co-transfected into Brca1-/-p53-/- cells using X-treme 
GENE HP DNA Transfection Reagent according to the 
manufacturer’s manual. GFP and mCherry double-pos-
itive cells were sorted by flowcytometry and seeded 
onto coverslips. Cells were sensitized by pre-incuba-
tionwith Hoechst33342 and were subsequently irradiat-
ed using a 405-nm diode laser (363 objective, 0.99mW,
60% laser power, 50 s) on a Leica SP5 confocal 
microscope equipped for live-cell imaging. EG-
FP-REV7 and 53BP1–mCherry recruitment in liv-
ing cells was monitored by time-lapse imaging.
59
REV7 counteracts DNA double-strand break  resection and affects PARP inhibition
3
Alpha track assay. Cells were seeded in dishes with a 
mylar surface as previously described28, allowing α-par-
ticle irradiation through the bottom of the dish. One or
two hours after irradiation three times for 30 s with a 
241americiumsource, cells were washed once in ice-cold 
PBS. Subsequently, cells were extracted with cold CSK 
buffer (10mM HEPES-KOH, pH 7.9, 100mM NaCl, 300mM 
sucrose, 3mM MgCl2, 1mM EGTA, 0.5% (v/v) Triton X-100) 
and cold CSS buffer (10mMTris, pH 7.4, 10mM NaCl, 3mM 
MgCl2, 1% (v/v) Tween 20, 0.5% (w/v) sodium deoxycho-
late) for 5 min each before fixation in 4% PFA in PBS for 
20 min at room temperature. Fixed cells were washed 
five times in PBS plus 0.1% Triton X-100 and washed 
once in blocking solution (0.5% BSA plus 0.15% glycine 
in PBS). Primary antibodies were diluted in blocking 
solution and cells were incubated overnight at 4 °C. Af-
ter incubation, cells were washed five times with PBS 
plus 0.1% Triton X-100 and washed once in blocking 
solution. Secondary antibodies were diluted in blocking
solution and cells were incubated at room tempera-
ture for at least 1 h. Afterwards, cells were washed five 
times in PBS plus 0.1% Triton X-100 and once in PBS. 
Finally, mylar films were glued on glass slides and cells 
were mounted using Vectashield with DAPI. For quan-
tification, at least 100 53BP1 or MRE11-positive tracks 
were scored for the presence of RPA. Primary antibod-
ies used in this study were as follows: rabbit anti-53BP1 
(NB100-304, Novus), 1:1,000 dilution; mouse anti-RPA2 
(Ab2175, Abcam), 1:500 dilution; MRE11 antibody29, 
1:200 dilution. Secondary antibodies used in this 
study were as follows: Alexa Fluor 594 goat anti rabbit
IgG (A 31631, Invitrogen), Alexa Fluor 488 
goat anti-mouse IgG (A11001,Invitrogen). 
BrdU propidium iodide cell cycle assay. Cells were 
seeded in 6-cm dishes and attached overnight. The next 
day, cells were incubated for 15 min with 5 mM BrdU
in growth medium, trypsinized, washed in PBS and fixed 
in 70% ethanol overnight. Fixed cells were washed in 
PBS, resuspended in pepsin solution (5 mg pepsin in
10 ml 0.1N HCl) and incubated for 20 min at room 
temperature. Subsequently blocking solution (0.5% 
Tween, 0.1% BSA in PBS) was added to wash. Next, cells 
were resuspended in 2N HCl and incubated 12min at 
37°C. To neutralize, 100mM borate buffer (pH8.5) was 
added and cells were pelleted. Anti-BrdU-FITC anti-
body (347583, BD Bioscience) was diluted in block-
ing solution, added to cells and incubated for 2 h on 
ice. Stained cells were washed once with blocking 
solution and resuspended in 500 ml PBS plus 12.5 ml 
RNaseA and 1 ml propidium iodide (P3566, Invitro-
gen). Cell cycle analysis was performed the next day. 
Survival assay of mES cells. R26CreERT2/wt; Brca1SCo/D 
mES cells15 were infected with hairpins targeting 
Rev7 or the vector control and selected with puro-
mycin. Expression of mouse Brca1 was switched off 
by overnight incubation with 0.5 mM 4-hydroxyta-
moxifen. Four days after switching, 5,000 cells of the 
indicated groups were seeded per well into 6-well 
plates and assayed for growth. Surviving colonies 
were fixed in formalin and stained with crystal violet.
DR-GFP for HR assay. R26CreERT2/wt; Brca1SCo/D  mES cells 
were targeted with a modified version of the p59X DR-
GFP construct as described30. To allow experiments on 
a p53-deficient background, cells were infected with a 
lentiviral p53 shRNA (5'-AGAGTATTTCACCCTCAAGAT-3') 
using a pLKO1vector provided with a neomycinre-
sistancemarker. A G418-selected p53-deficient clone 
was subsequently infected with hairpins targeting Rev7 
or the vector control and selected with puromycin.
Expression of mouse Brca1 was switched off by over-
night incubation with 0.5mM 4-hydroxytamoxifen 
to measure the effect of Rev7 loss on HR. HRreporter
assays were performed by Lipofectamine 2000 (Invitro-
gen) transfection of the I-SceI-mCherry plasmid, which 
was generated by providing the cBasI-SceI expression
plasmid with CMV-mCherry (Clontech). Forty-eight 
hours after transfection, mCherry/GFP double-positive 
cells were monitored by flow cytometry as described15.
53BP1 pull-down. 53BP1 pull-downs were performed 
as described19. Flag pulldowns were performed from 2 
mg lysate prepared from MEFs following mock or ne-
ocarzinostatin treatment (2 h at 250 ng μl-1). Control, 
53BP1 and 53BP120AQ immuneprecipitates were then 
treated with sequential low-salt (150mM) and high salt
(500mM) RIPA buffer washes, before re-equilibra-
tion in nuclear extract buffer (20mMHEPES, pH7.9, 
100mMKCl, 0.2mMEDTA, 20% glycerol, 0.5mM PMSF, 
0.5mM DTT and protease inhibitors (Roche,Com-
plete)). After incubation in Hela Nuclear Extract 
(2mg), control, 53BP1 and 53BP120AQ complex-
es were washed four times in nuclear extract buff-
er, then eluted with triple-Flag peptide (Sigma).
Immunoglobulin CSR. CH12 cells were either 
mock-treated or stimulated with agonist anti-CD40 an-
tibody (0.5 mg ml-1; eBioscience; HM40-3),mouse IL-4 (5 
ng ml-1; R&DSystems) and TGF-β1 (1.25 ng ml-1;R&DSys-
tems). Cell-surface IgA expression was determined by 
flow cytometry, immunostaining with biotinylated 
anti mouse IgA antibody (eBioscience; 13-5994), and 
Alexa488-streptavidin conjugate (Life Technologies).
Carboxyfluorescein succinimidyl ester assay. Cell pro-
liferation was assessed in stimulated CH12 cells using 
carboxyfluorescein succinimidyl ester (CFSE) according 
to manufacturer’s instructions (CellTrace; Life Technolo-
gies).
Chromatin immunoprecipitation. Each ChIP was per-
formed from chromatin prepared from ,1x107 CH12 cells 
stimulated for 30 h with agonist CD40 antibody, IL-4 and 
TGF-β1 essentially as described19. For each individual 
ChIP, 4 μg of RPA34- 20 (Ab-3, Calbiochem), 2 μg H2AX 
(3522-1, Epitomics), or 4 μg control mouse anti-IgG (sc-
2025; Santa Cruz) coupled to 25 μl Protein-GDynabeads 
(Life Technologies, 10003D) was used. Quantities of im-
munoprecipitated chromatin were calculated relative to 
total input chromatin by quantitative PCR in duplicate
on an CFX96 Real-Time Analyzer (Biorad) with the use of 
iQ SYBR Green (Biorad) for each primer pair (see below). 
Rpp30: forward, 5'-TCCAGTGTGCAAGAAAGCTAAATG-3', 
reverse, 5'-GGCAGTGCGTGGAGACTCA-3'; A (target
IgH Sm): forward, 5'-CAATGTGGTTTAATGAATTT-
GAAGTTGCCA-3', reverse, 5'-TCTCACACTCACCTTG-
GATCTAAGCACTGT-3'; B (target IgH Sm): forward,
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5'-GCTAAACTGAGGTGATTACTCTGAGGTAAG-3', reverse, 
5'-GTTTAGCTTAGCGGCCCAGCTCATTCCAGT-3'; C (target 
IgH Sc1): forward, 5'-AGTGTGGGAACCCAGTCAAA-3', re-
verse, 5'-GTACTCTCACCGGGATCAGC-3'; D (target IgH Sa): 
forward, 5'-TGAAAAGACTTTGGATGAAATGTGAACCAA-3', 
reverse, 5'- GATACTAGGTTGCATGGCTCCATTCACACA-3'.
Immunohistochemistry on paraffin sections. The 
panel of formalin-fixed, paraffin-embedded archival 
specimens from a series of 50 human primary breast car-
cinomas was examined, surgically resected before any 
chemotherapy or radiotherapy. In parallel, sections from 
ten specimens of formalin-fixed, paraffin-embedded his-
tologically normal human breast tissues were used as 
normal tissue controls, for immunohistochemical anal-
ysis of REV7 expression patterns. The breast carcinomas
were all of the triple-negative type, defined in this cohort 
as having fewer than 1% tumour cells positive in stand-
ard immunohistochemical staining for oestrogen and 
progesterone receptor proteins, and lacking amplifica-
tion of the HER2 (also known as ERBB2) gene. For the im-
munohistochemical analysis, 4-μm-thick sections were 
cut from representative blocks of the tumour tissues, the 
sections were deparaffinized and processed for sensitive 
immunoperoxidase staining with the primary mouse 
monoclonal antibody to REV7 (BD Biosciences, 612266, 
diluted 1:100). The staining procedure was essentially as 
described15, with antigen unmasking in citrate buffer, pH 
6.0, for 15–20 min in a microwave oven, and overnight 
incubation with the primary antibody, followed by the 
Vectastain Elite kit (Vector Laboratories) and nickel sul-
fate enhancement without nuclear counterstaining31. 
Mouse normal serum and antibody to γH2AX served as 
negative and positive controls, respectively. Evaluation 
of the staining patterns was performed by two inde-
pendent observers (with very similar outcomes), includ-
ing a senior oncopathologist with more than 20 years 
of experience with breast cancer pathology. The results 
were scored in the following categories, based on com-
parison of cancer cells with the series of normal breast 
tissue controls, and also the normal of cells present with-
in each of the tumour sections. As normal breast epithe-
lium showed reproducible positivity for REV7 protein in 
over 90% of cells, we considered as aberrantly decreased 
expression in a tumour when fewer than 70% of can-
cer cells were positive. In addition to the percentage of 
stained tumour cells, staining intensity was classified as 
either normal (comparable with the intensity of normal 
cells present on each section) or aberrantly low (clearly 
below the intensity seen in adjacent normal cells, and up 
to undetectable in some cases). Overall, while 6 out of 47
informative cases showed concomitantly aberrant 
fraction of REV7-stained cells and reduced intensity of 
staining, 12 additional cases showed less pronounced 
defects limited to either staining intensity or reduced 
percentage of cancer cells, respectively. As the primary 
goal of these analyses was to establish a detection assay 
for REV7 on archival tissue specimens and to assess the 
frequency of potentially REV7-deficient breast tumours, 
correlation analyses with clinical parameters including 
treatment outcome remain to be performed on larger 
cohorts of patients in the future.
Statistics. Statistical tests used were log-rank test, t-test 
and Mann–Whitney U test, with P, 0.05 as the significance 
level. No statistical methods were used to predetermine 
sample size.
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Extended Data Figure 1 Loss of Rev7 causes PARPi resistance in vitro and in vivo. 
a, Quantification of Rev7 transcript levels in KB1P-B11 cells transduced with Rev7-targeting shRNAs or the 
vector control. Hprt was used as a control for transcript expression. The data represent mean± s.d. b, c, Cell
proliferation rates in KB1P-G3 (b) or KB1P-B11 (c) cells analysed using the MTT assay. d–g, Long-term 
clonogenic survival assays and quantification of KB1P-G3 (d, f ) or KB1P-B11 (e, g) cells transduced with 
the indicated constructs and treatments. All the groups were normalized by the absorbance of the vector 
control. The data represent mean±s.d. h, Quantification of the real colony numbers from the short-term 
clonogenic survival assay of KB1P-G3 cells with or without Rev7 loss exposed to olaparib. i, REV7 protein 
levels were determined by western blotting of lysates derived from KB1P-G3 cells transduced with the 
indicated constructs. j, Overall survival of mice with KB1P-B11-derived Rev7-depleted or control tumours 
treated with one regimen of 50 mg kg-1 olaparib daily for 28 days or left untreated. The P value was 
calculated using the log-rank test. k, l, Relative tumour growth of individual KB1P-G3- (k) and KB1P-B11- 
(l) derived Rev7-depleted or control tumours treated with one regimen of 50 mg kg-1 olaparib daily for 28 
days or left untreated.
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Extended Data Figure 2 Loss of REV7 causes olaparib resistance in BRCA1-deficient SUM149PT 
cells. 
a, Western blotting analysis of REV7 or 53BP1 expression in SUM149PT cells transduced with REV7- or 
53BP1-targeting hairpins or the vector control. b, Example of a long-term clonogenic survival assay using 
the indicated hairpins and olaparib concentrations. c, Quantification of the clonogenic assays using 
absorbance of crystal violet at 590 nm. The data represent mean±s.d. All the groups were normalized 
by the absorbance of the vector control and showed significant differences to the control (P,0.01, t-test).
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Extended Data Figure 3 Rev1 or Rev3 inhibition and PARPi sensitivity of Brca1-/-p53-/- mammary 
tumour cells. 
a, b, Quantification of Rev1 (a) or Rev3 (b) transcript levels in KB1P-G3 cells transduced with Rev1- or Rev3-
targeting shRNAs or the vector control. Hprt was used as a control for transcript expression. The data 
represent the mean±s.d. c, Long-term clonogenic survival assays of KB1P-G3 cells exposed to the indicated 
PARP inhibitors. d, Quantification of the clonogenic assay by determining the absorbance of crystal violet 
at 590nm. All the groups were normalized by the absorbance of the vector control. The data represent 
the mean±s.d. e, f, Quantification of Rev7 transcript (e) or protein (f ) levels in KB1P-G3 cells transduced 
with Rev7-targeting shRNAs or the vector control. Hprt was used as a control for transcript expression; 
α-tubulin as a control for protein expression. The data represent mean±s.d. g, GFP-tagged REV7 mutants 
recruitment to sites of DNA damage was observed 5 min after 405nm laser exposure (0.99mW, 60% laser 
power, 50 s) in KB1P-B11 cells. Scale bar, 10 mm.
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Extended Data Figure 4 REV7 recruitment to the DNA damage sites in human cells. 
a–c, Human REV7 recruitment to sites of laser-induced DNA damage was analysed in U2OS cells 
transfected with siRNAs targeting RNF8 (siRNF8), RNF168 (siRNF168) (a), 53BP1 (si53BP1) (c) and GFP 
(siGFP). RNF8 and RNF168 protein levels were determined by western blotting (b) using lysates derived 
from U2OS cells transfecting with the indicated siRNAs. d, For the quantification of the REV7 signal 
within laser-induced DNA damage stripes, a minimum of 100 striped (that is, γH2AX-positive) cells were 
analysed for the presence of the REV7 signal in two independent experiments. Scale bars, 50 μm. e, 
RAD51 focus (red) formation in KB1P-B11 cells before and 5 h after 10 Gy ionizing radiation. Scale bar, 
10 μm. f, Quantification ofRAD51 foci in KB1P-B11 cells in the presence or absence of REV7 depletion. At 
least 150 cells were analysed per group in three independent experiments each. Error bars indicate s.d.; 
IR denotes 5 h after 10 Gy ionizing radiation. g, Western blotting analysis of REV7-depleted KB1P-G3 cells 
transfected with human REV7–GFP or Rev7-shRNA-resistant mouse REV7–GFP fusion proteins. h, Same 
as in e and f using the ATM inhibitor KU55933 with or without IR (5 h after 10 Gy ionizing radiation).i, 
Long-term clonogenic survival assay of KB1P-G3 cells exposed to olaparib in the presence or absence of 
KU55933 pre-treatment.
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Extended Data Figure 5 Loss of Rev7 does not cause PARPi resistance in Brca2-/-p53-/- or p53-/- 
mammary tumour cells in vitro.
a, b, Quantification of Rev7 transcript levels in Brca2-/- p53-/- (KB2P-1.21 or KB2P-3.4) cells transduced with 
Rev7-targeting shRNAs or the vector control. Hprt was used as a control for transcript expression. The 
data represent the mean±s.d. c–f, Long-term clonogenic survival assays and quantification of KB2P-1.21 
or KB2P-3.4 cells with or without Rev7 depletion exposed to the indicated treatments. All the groups were 
normalized by the absorbance of the vector control. The data represent mean±s.d. g, Quantification of 
Rev7 transcript levels in p53-/- (KP3.33) cells transduced with the indicated constructs. Hprt was used as a 
control for transcript expression and the data represent the mean±s.d. h, i, Long-term clonogenic survival 
assays and quantification of KP3.33 cells exposed to the indicated treatments. The data represent the 
mean±s.d.
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Extended Data Figure 6 Rev7 loss promotes end resection at DSBs in BRCA1-deficient cells after 
ionizing radiation. 
a, Quantification of RPA positive α tracks in KB1P-B11 cells 1 or 2 h after irradiation with a particles.
b, Quantification of RPA- and 53BP1-positive a tracks in KB1P-B11 cells transfected with non-targeting 
control siRNAs or siRNAs against Ctip. c, Cell cycle analysis (BrdU incorporation and propidium iodine 
labelling) of KB1P-B11 cells transduced with the indicated constructs and siRNAs. d, e, Quantification 
of Rev7 transcript (d) or protein (e) levels in BRCA1-deficient mES cells transduced with Rev7-targeting 
shRNAs or the vector control. Hprt was used as a control for transcript expression, α-tubulin as a control 
for protein expression. The data represent mean±s.d. f, Representative images of surviving colonies of 
Brca1-/- mES cells transduced with an empty vector control or Rev7-targeting shRNAs. g, Quantification 
of colony formation normalized to the vector control. h, Quantification of RAD51 foci in Brca1-/- mES cells 
that were transduced with the indicated constructs.
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Extended Data Figure 7 REV7 loss frequently occurs in triple-negative breast cancer. 
a, b, Quantification of human REV7 transcript levels (a) and protein levels (b) in U2OS cells transduced with 
indicated constructs. Two different pairs of primers for REV7 or HPRT were used for the quantification of
REV7 transcript levels. c–e, Examples of aberrantly reduced REV7 protein expression in triple-negative 
human breast carcinomas. Immunohistochemical detection of REV7 in human breast carcinomas shows 
moderate to high nuclear expression in normal human breast tissue (data not shown), and most invasive 
breast tumours (c). Aberrant reduction of REV7 with less than 70% of cancer cells that show nuclear 
positivity (d, e) was observed in 18 out of 50 cases.
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Extended Data Figure 8 REV7 is a downstream effector of 53BP1.
a, Quantification of 53BP1 foci in KB1P-G3 cells in the presence or absence of REV7 depletion. At least 100 
cells were analysed per group in three independent experiments each. Error bars indicate s.d.; IR denotes 
5 h after 10 Gy ionizing radiation. b, REV7 or 53BP1 protein levels were determined by western blotting of 
lysates derived from MEF cells transduced with the indicated control (CNTL) or Rev7- and 53bp1-targeting 
shRNA constructs. c, d, RIF1 foci formation (c) after neocarzinostatin (NCS) treatment and quantification 
of RIF1 foci (d) in MEF cells in the presence or absence of REV7 or 53BP1 depletion. e, Flag pull-downs 
were performed from 2 mg lysate prepared from 53bp1-/-, 53bp1-/-plus 53BP1 and 53bp1-/- plus 53BP120AQ
MEFs after mock or neocarzinostatin treatment. Control, 53BP1 and 53BP120AQ immunoprecipitates 
were incubated in HeLa nuclear extract (HNE, 2 mg) and then eluted with triple-Flag peptide. HA, 
haemagglutinin.
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Extended Data Figure 9 The effect of REV7 inhibition on CSR after antigenic stimulation of CH12 
cells. 
a, Rev7 messenger RNA levels determined by qRT–PCR were normalized against β-actin (Actb) transcripts 
in the indicated shRNA-transduced CH12 cell lines. The data represent the mean±s.e.m. from two primer 
sets specific for Rev7 transcript.CNTL, control. b, 53BP1 protein of each group normalized to vector-
transduced cells (CH12) was analysed by western blotting. c, IgH μ and α germ-line transcripts (GLT) and 
Aid mRNA were estimated by semi-quantitative RT–PCR using twofold serial dilutions of cDNA made from 
indicated CH12 cell lines 40 h after stimulation. Hprt was used as a control for transcript expression. d, 
Representative flow cytometric profiles of shRNA-transduced CH12 B cells stained with anti-IgA antibody 
40 h after stimulation with the indicated cytokines. e, Cells (CH12) were labelled with CFSE immediately 
before cytokine stimulation as in Fig. 4d, and cell proliferation was assessed by flow cytometry at indicated 
time points. f, Quantification of CSR to IgA of shRNA-transduced CH12 cells 40 h after stimulation with 
CD40 antibody, IL-4 and TGF-β1 (CIT). Data represent the mean±s.d. from two independent experiments 
performed in triplicate.
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Abstract
Cells and tumours deficient in homologous 
recombination are exquisitely sensitive to 
PARP inhibitors. Unfortunately, a fraction of 
the tumours treated with PARP inhibitors 
eventually becomes resistant. In BRCA1-
deficient cells resistance can be caused by 
restoration of homologous recombination 
due to loss of REV7 expression. REV7 (MAD2B 
or MAD2L2) plays a role in translesion 
synthesis together with REV3, is involved in 
regulation of cell cycle progression via the 
anaphase-promoting complex and has been 
linked to several other processes via other 
interaction partners. Here we investigate 
which roles and interaction partners of REV7 
are important for PARP inhibitor resistance in 
BRCA1-deficient cells. The role of REV7 in cell 
cycle progression seems to be dispensable for 
restoration of homologous recombination, 
but the interaction between REV3 and REV7 
is possibly involved. 
Introduction
Breast cancer is one of the most common 
types of cancer in women1. Carriers of 
mutations in the tumour-suppressor genes 
BRCA1 and BRCA2 have a strongly increased 
lifetime risk of developing breast cancer. The 
BRCA1 and BRCA2 proteins play a role in 
homologous recombination (HR), a pathway 
to repair DNA double strand breaks in an 
error-free manner. Double strand breaks can 
be caused by ionizing radiation or they are 
formed during the repair of DNA crosslinks. 
To repair a double strand break, the broken 
DNA is first resected, generating single-
stranded DNA overhangs, which are bound 
by replication protein A (RPA). RPA is then 
replaced by RAD51 forming nucleo-protein 
filaments. RAD51 helps to pair the damaged 
DNA with the homologous sequence on 
the sister chromatid. The intact DNA on the 
sister chromatid is then used as a template 
for accurate repair of the broken DNA. Failure 
to repair DNA breaks in this reliable manner 
can cause mutations, translocations and 
chromosomal aberrations, which eventually 
can lead to cancer. 
Women with breast cancer are commonly 
treated with chemotherapy, which has severe 
side effects because the chemotherapeutics 
target all dividing cells in the patient’s body. 
Recently a new treatment strategy has been 
developed that reduces side effects by 
targeting specifically the tumour cells with 
a defect in homologous recombination2,3. 
Cells deficient in homologous recombination 
are extremely sensitive to inhibition of Poly 
[ADP-ribose] polymerase 1 (PARP1), which 
is required for the efficient repair of single-
strand breaks in the DNA. When these 
breaks are repaired inefficiently due to PARP 
inhibition, replication forks collapse at these 
sites of damage, resulting in DNA double 
strand breaks. To repair these breaks, BRCA1 
and BRCA2 are needed. In tumours where 
these proteins are not functioning properly, 
DNA damage accumulates, eventually 
leading to cell death. 
Unfortunately, although the treatment 
of BRCA1- and BRCA2-deficient tumours 
with PARP inhibitors such as Olaparib is 
very promising, tumours often eventually 
become resistant4. Resistance has various 
causes such as overexpression of a drug-
efflux pump5, loss of 53BP16 or reversion of 
the mutation in BRCA1 or BRCA27,8. However, 
these mechanisms do not explain all cases of 
resistance.
Recently, Xu et al. described loss of REV7 
as a resistance mechanism in BRCA1-deficient 
cells and tumours9. In BRCA1-deficient 
cells, loss of REV7 restored CtIP-dependent 
resection and thereby homologous 
recombination, causing PARP inhibitor 
resistance. REV7 (also known as MAD2B or 
MAD2L2) and REV3 form the translesion 
polymerase Zeta (Polζ), a low-fidelity 
polymerase that plays a role in the bypass 
of replication-blocking lesions such as DNA 
crosslinks or damaged bases. REV3 contains 
the polymerase domain of Polymerase ζ 
and REV7 is an accessory subunit. Apart 
from functioning in trans lesion synthesis 
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(TLS), REV7 has been linked to end-joining 
as well. Boersma et al. showed that when 
TRF2 is inactivated and telomeres become 
uncapped, telomeres no longer fuse when 
REV7 is absent10. 
REV7 has also been shown to be 
involved in cell-cycle progression through 
the anaphase-promoting complex. The 
anaphase-promoting complex/cyclosome 
(APC/C) is an E3-ubiquitin ligase that controls 
progression through mitosis by targeting key 
mitotic factors for degradation at specific 
points during the cell cycle. During mitosis, 
APC/C is activated by CDC20 and from 
late mitosis to the G1/S transition, APC/C 
is activated by CDH111. REV7 (MAD2B) and 
MAD2 are both inhibitors of the APC/C, 
but REV7 targets APC/C-CDH1 while MAD2 
inhibits APC/C-CDC2012,13.  
As described above, REV7 loss results in 
Olaparib resistance in BRCA1-deficient cells 
due to restoration of resection and thereby 
homologous recombination. To be able 
to prevent resistance or to treat resistant 
tumours, it is important to understand how 
this resistance mechanism works. As it is 
still unclear whether the Olaparib resistance 
observed in BRCA1-deficient cells after 
REV7 loss is due to the role of REV7 in TLS 
(i.e. dependent on REV3), we generated 
several point mutants in REV7 that disturb 
the interaction with REV3. Additionally we 
used mass spectrometry to identify the main 
interacting partners of wild-type REV7 and 
the C70R mutant. We found that mutations 
in REV7 also lead to the loss of interaction 
with POGZ and CHAMP1 and investigated 
whether loss of those proteins had any effect 
in HR in BRCA1-deficient cells. 
Results
REV7 and the APC/C
Xu et al.9 found loss of REV7 as a resistance 
mechanism in a loss-of-function PARP-
inhibitor screen in BRCA1-deficient cells. 
Another hit from the screen was 53BP1, 
for which it was already known that its loss 
causes Olaparib resistance. REV7 has been 
linked to cell cycle progression and is known 
to be an inhibitor of the APC/C. Another 
example of an inhibitor of the APC/C is 
EMI1. REV7 only inhibits APC/C-CDH1, while 
EMI1 inhibits APC/C-CDH1 and APC/C in 
complex with CDC2014,15. To test whether 
the APC/C regulatory function of REV7 and 
EMI1 is important for restoring RAD51 focus 
formation, we depleted REV7 and EMI1 in 
BRCA1-deficient mouse mammary tumour 
cells (G3 cells). Unfortunately, EMI1 could not 
be knocked down using shRNA for more than 
60% (data not shown) as measured on mRNA 
level. EMI1 is essential for precise mitotic 
progression and EMI1 knockout embryos are 
not viable16. EMI1 depletion might therefore 
be very poorly tolerated, hampering our 
analysis of the connection of REV7 and APC/C 
with PARP inhibitor resistance. 
The APC/C complex can also be inhibited 
pharmacologically with the proTAME 
inhibitor17. G3 cells transfected with a 
scrambled shRNA or shRNA targeting REV7 
or 53BP1 were treated with proTAME for 5 
hours, irradiated with 5Gy one hour after the 
inhibitor was added and stained for RAD51 
foci (Fig 1A). 53BP1-depleted cells were taken 
along as a control, since the APC/C complex 
is not expected to play a role in restoration 
of homologous recombination in those cells. 
Treatment with proTAME had no effect on the 
formation of RAD51 foci in BRCA1-deficient 
G3+ shREV7 cells. 4 hours after 5 Gy, these cells 
were still able to form RAD51 foci in S-phase 
cells to a similar extent as DMSO treated cells 
(Fig1B). In G3 cells or G3 cells + sh53BP1 the 
addition of proTAME before irradiation did 
not affect the RAD51 focus formation either. 
As expected, BRCA1-deficient cells (G3 Scr) 
were still unable to form RAD51 foci after 
irradiation in the presence of proTAME.
To verify that the inhibitor was active, cells 
were stained for mitosis marker phospho-
histone H3 (pH3) after incubation with 
proTAME for three, five, eight or 24 hours. As 
expected, cells accumulated in mitosis after 
proTAME treatment, resulting in increased 
numbers of pH3-positive cells compared to 
DMSO-treated cells (Fig1C,D). After 24 hours 
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the effect of the proTAME inhibitor was no 
longer visible, probably because cells that 
were arrested in mitosis for a prolonged 
period died. 
Inhibition of the APC/C does not reverse 
the restoration of RAD51 focus formation 
in BRCA1-deficient cells with a depletion 
of REV7. This indicates that the APC/C has 
no effect on the restoration of RAD51 focus 
formation in REV7-depleted BRCA1-deficient 
cells. 
Disturbing the interaction between REV7 
and REV3
REV3 and REV7 form the DNA Polymerase 
ζ complex, which can bypass DNA lesions 
during translesion synthesis. Currently it is still 
unclear whether the REV3-REV7 interaction 
is required for restoration of HR in BRCA1-
deficient cells. REV3 deletion or knock-down 
is poorly tolerated in mammalian cells18, so 
as an alternative point mutants in REV7 that 
disturb the interaction with REV3 were used. 
Khalaj et al. recently found that the C70R 
point mutation caused infertility in mice19. 
Based on the crystal structure of REV7 in 
complex with a REV1 or REV3 peptide Hara 
et al. designed several other REV1 and REV3 
interaction mutants20. The C70R (Cys70Arg) 
and 2A (Y63A / W171A) mutants were chosen 
to disturb the interaction between REV3 and 
REV7 and the 3A (Leu186Ala / Gln200Ala / 
Tyr202Ala) mutant to disturb the interaction 
between REV1 and REV7.
An immunoprecipitation of GFP-REV7 
(wild-type or point-mutants) with MBP-REV3 
was used to verify that the REV7 mutants are 
defective in their interaction with REV3. All 
mutants and wild-type REV7 were cloned into 
a GFP-vector and transiently overexpressed in 
HEK293T cells co-transfected with MBP-REV3. 
All GFP-REV7 constructs were expressed at 
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Figure 1 Inhibition of the APC/C does not affect RAD51 foci formation in BRCA1-deficient G3 cells
(A) Incubation with proTAME does not affect RAD51 focus formation in EdU positive (S-phase) cells after 
irradiation. Indicated cell lines were incubated with proTAME or vehicle (DMSO), irradiated with 5 Gy and 
stained for RAD51. (B) Quantification of RAD51 focus formation in BRCA1-deficient G3 cells + indicated 
shRNAs treated with proTAME or vehicle (DMSO). The number of S-phase cells with more than 10 RAD51 
focus was quantified. Bars represent average ± SEM. At least 100 nuclei were counted per sample. (C,D) 
Incubation with proTAME results in an increase in mitotic cells. (C) Examples of phospho histone H3 
(pH3) positive cells after incubation with proTAME or DMSO. (D) Quantification of the percentage of pH3 
positive cells. At least 150 nuclei were counted per sample. Bars represent average ± SEM.
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similar levels, but MBP-REV3 expression was 
not detectable in the input, probably due to 
low levels, as has been observed previously21. 
After immunoprecipitation of the GFP-
constructs using GFP-beads, wild-type REV7 
and the 3A mutant pulled down MBP-REV3, 
while the 2A and C70R showed a decreased 
interaction with REV3 (Fig 2A).
REV7 mutants partially restore 
homologous recombination
REV7 depletion causes restoration of 
resection and thereby HR in BRCA1-deficient 
cells9. Re-expression of wild-type REV7 
abrogates this restoration. To investigate 
whether the interaction between REV7 
and REV1 or REV7 and REV3 is required for 
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Figure 2 REV7 point mutants affect RAD51 foci formation and resection.
(A) REV7 point mutants C70R and 2A show a decreased interaction with REV3. Immunoblot of input 
and bound fractions using MBP and GFP antibodies. MBP-REV3 was co-immunoprecipitated using wild-
type GFP-REV7 or the point mutants. Both MBP-REV3 and the GFP-REV7 constructs were transiently 
overexpressed in HEK293T cells and immunoprecipitated using GFP-beads. MBP-REV3 is not detectable 
in the input. (B) Examples of RAD51 foci (green) in G3 cells expressing GFP or GFP-REV7 constructs. 
S-phase cells were labeled using EdU incorporation (Red). (C) Quantification of the number of S-phase 
cells with more than 10 RAD51 foci. At least 300 nuclei in 3 experiments were counted per sample. Bars 
represent average ± SEM. (D) G3 cells expressing REV7 point mutants were damaged using alpha particles 
and stained for RPA and 53BP1 tracks. 300 tracks were counted over 3 experiments and bars represent 
average ± SEM. 
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the restoration of HR, G3 cells expressing 
shRNA-resistant GFP-tagged wild-type 
REV7 or the point mutants were generated. 
Endogenous REV7 was depleted with the 
stable expression of a shRNA. As the 2A 
mutant was not expressed in G3 cells, it 
was left out of the analysis (Fig S1A). These 
cells were irradiated and stained for RAD51 
foci 4 hours later, as a surrogate marker for 
homologous recombination (Fig 2B). EdU 
incorporation was used to label S-phase cells 
and the number of S-phase cells with more 
than 10 RAD51 foci was quantified (Fig 2C). 
As expected, re-expression of GFP-REV7 
results in a reduction of RAD51 foci after 
damage in BRCA1-deficient cells. Expression 
of the two REV7 mutants still allowed RAD51 
focus formation and their phenotype is more 
similar to GFP-expressing G3 cells than to 
REV7-expressing cells. This suggests that the 
mutants are not able to function as wild-type 
REV7. 
Loss of REV7 also increases DNA end 
resection in BRCA1-deficient cells9. As a 
measure for resection, cells were damaged 
with alpha particles, the tracks of DNA 
damage were stained for RPA and 53BP1 
and the number of RPA-positive tracks 
was quantified. Re-expression of wild-type 
shRNA-resistant REV7 in G3 cells+shREV7 
results in a decrease in the number of RPA-
positive tracks compared to G3+shREV7 
cells expressing GFP. Expression of the REV7 
interaction mutants on the other hand, only 
resulted in a minor decrease in resection 
compared to the expression of GFP (Fig 2D). 
This intermediate phenotype suggests that 
the interactions between REV7 and REV1 
and REV3 play a role in the prevention of end 
resection. However, in survival experiments 
with Olaparib treatment, expression of the 
REV7 point mutants does not result in a 
strong resistance phenotype9. The BRCA1-
deficient cell lines expressing mutant REV7 
are only slightly more resistant than cell lines 
expressing wild-type REV7. 
Dynamic behaviour of the REV7 mutants
REV7 is known to be recruited to sites 
of IR induced DNA damage9. To study 
how the recruitment to sites of damage 
affects the dynamic behavior of stably 
overexpressed GFP-REV7, FRAP experiments 
were performed after UV and IR damage. 
After DNA damage caused by  UV (10 J/m2) 
or IR (5Gy), wild-type REV7 does not become 
immobilized compared to untreated cells (Fig 
3A). The reduction in fluorescence compared 
to the pre-bleach intensity is partly due to 
the bleached volume. However, wild-type 
REV7 also seems to be more immobilized 
compared to the point mutants. This suggests 
that only a small fraction of REV7 is bound at 
sites of damage and that the bulk continues 
to diffuse freely through the nucleus.
FRAP experiments were also performed 
with the GFP-REV7 mutants to study whether 
they behave differently from wild-type 
GFP-REV7 in vivo. Wild type and GFP-REV7 
mutants were expressed in U2OS cells in 
which endogenous REV7 was depleted by 
shRNA targeting the 3’-UTR (Fig 3B, S1B). 
In undamaged cells, the recovery after 
photobleaching is faster for the mutants 
than for wild-type REV7 (Fig 3C), indicating 
decreased binding to sites of damage or faster 
diffusion of the mutants because the proteins 
are no longer part of a larger complex. 
The FRAP data for the mutants and wild-
type REV7 were further analyzed by fitting 
the curves using a Monte Carlo simulation22 
to determine the long and short bound 
fractions as well as the residence time, 
which are related to the rate constants for 
the interactions. Both short and long bound 
fractions were included in the modeling, since 
the behavior of many DNA-binding proteins 
and transcription factors can be characterized 
by initial short binding to random targets and 
subsequent stable binding to specific targets. 
Since it is unknown what fraction of REV7 
is in complex with REV3 (forming a larger 
complex with slower diffusion) the data was 
fitted using three different diffusion constants 
(dc=0.25 µm2/s, dc=1.0 µm2/s, dc=2.5 µm2/s). 
A dc of 0.25 corresponds to a very large 
complex in the range of megadaltons, while 
the diffusion constant of GFP is 7-9 µm2/s. 
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The best fitting curve for wild type REV7 
had a diffusion constant of 1 µm2/s, a long 
immobile fraction of approximately 21% 
percent (82 seconds immobilized) and a short 
immobile fraction of 29% (Table 1 and Fig S2). 
The residence time of the short immobilized 
fraction was set to 1 second for all mutants. 
All REV7 mutants showed a decreased long 
and short immobilized fraction compared 
to wild type REV7. Furthermore, for the 
point mutants, the fits are even better with 
a diffusion constant of 2.5 µm2/s, indicating 
that the diffusion of these proteins is faster 
than of wild-type GFP-REV7 (Table 1). 
REV7 contains a HORMA domain23 that 
could directly or indirectly bind to chromatin. 
REV7 was found in the cytoplasmic, nuclear 
and chromatin fractions (Fig S3). The 
interaction with chromatin could be via REV1 
and REV3, but it might also be via another 
interaction partner. The differences in the 
dynamic behavior between the wild-type 
and mutant REV7 might be due to their 
inability to form a complex with REV3, but 
since the REV1 interaction mutant (the 3A 
mutant) shows a similar increase in recovery 
after photobleaching as the other point 
mutants (Fig 3C), it is also possible that other 
interaction partners are disturbed as well. 
Also, the intermediate phenotypes in the 
RAD51 and alpha track assay for different 
mutants suggest that another common 
interaction partner might be disturbed. 
We therefore sought to identify the main 
interaction partners of wild type REV7 and 
the C70R mutant. 
A B
C
GFP-Rev7 wt GFP-Rev7 C70R
GFP-Rev7 2A GFP-Rev7 3A
Dapi GFP-Rev7 Dapi GFP-Rev7
Dapi GFP-Rev7 Dapi GFP-Rev7
Time (s)
Re
la
tiv
e 
u
or
es
ce
nc
e 
le
ve
l
10 μm
Figure 3 Dynamics of wild-type and mutant REV7 
(A) FRAP analysis of U2OS cells stably expressing an shRNA against the REV7 3’-UTR and GFP-REV7 
wild type in undamaged cells or cells treated with UV (10 J/m2) or IR (5Gy). FRAP measurement were 
performed directly after UV damage and 3-4 hours after IR damage. Graphs represent the average of 
20 cells and were normalized to the pre-bleach intensity. (B) Examples of GFP-REV7 wild type or mutant 
expressing cells used for FRAP analysis. Wild type and GFP-REV7 mutants were expressed in U2OS cells 
in which endogenous REV7 was depleted by shRNA targeting the 3’-UTR. Scale bar represents 10 µm. (C) 
FRAP analysis of U2OS cells stably expressing an shRNA against the REV7 3’-UTR and GFP-REV7 wild type 
or mutants. Cells were not damaged and the recovery was normalized to the average pre-bleach value. 
Graphs represent average of 20 cells. 
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REV7 interaction partners CHAMP1 and 
POGZ
A SILAC-based mass spectrometry analysis 
of immunoprecipitated GFP-REV7 wild type 
and mutants was used to investigate whether 
the interaction partners of the 3A and C70R 
mutants are different from wild-type REV7 
(Fig 4A). As expected, the interaction between 
REV3 and REV7 C70R is decreased compared 
to REV3 and wild-type REV7 (SILAC Ratio:1.3, 
Log2 converted ratio 0.45). However, the 
interaction partners that change most when 
comparing wild-type REV7 to the C70R 
mutant are CHAMP1 (C13orf8, ZNF828) and 
POGZ (Suppl table 1). The same is true when 
comparing wild-type REV7 to the 3A mutant 
(table not shown). 
A complex between REV7, CHAMP1 and 
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Figure 4 REV7 interacts with POGZ and CHAMP1
(A) Scatterplot showing the SILAC ratios of the proteins in the bound fractions after GFP 
immunoprecipitation of U2OS cells expressing GFP-REV7 wild type (Heavy), C70R (Medium) and 3A (Light). 
See also supplementary table 1; MAD2L2 is REV7. (B) Point mutations in REV7 disturb the interaction 
between GFP-REV7 and endogenous CHAMP1 and POGZ. Immunoprecipitation of GFP or GFP-REV7 wild 
type or mutants transiently overexpressed in U2OS cells.  
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POGZ has previously been identified in a 
screen for readers of epigenetic histone 
marks24. The complex might also contain the 
HP1 isoforms CBX1, CBX3 and CBX5, which 
bind to the repressive histone modification 
H3K9me3. POGZ (Pogo transposable element 
with ZNF domain) contains a transposase-
derived DDE domain and interacts with 
LEDGF/p75, a transcriptional co-activator 
that is the main interaction partner of 
HIV-1 integrase, via this DDE-domain25. 
Additionally, POGZ has been shown to 
play a role in modulating the dissociation 
of HP1α (Heterochromatin protein 1α) 
from mitotic chromosome arms through 
Aurora B activation26. CHAMP1 (CAMP) also 
contains a zinc finger motif and is involved in 
kinetochore–microtubule attachment27. 
Immunoprecipitations on wild-type GFP 
REV7 or the C70R, 2A or 3A mutant in U2OS 
cells showed that only wild-type GFP-REV7 
interacts with POGZ and CHAMP1 (Fig 4B) and 
all point mutants have lost the interaction. In 
fractionated cells, endogenous REV7 and GFP-
REV7 are present in the cytoplasm, nucleus 
and chromatin fraction. POGZ is mostly 
chromatin bound, while CHAMP1 is mainly 
nuclear but also found in the cytoplasm and 
on chromatin. Depletion of endogenous REV7 
or overexpression of GFP-REV7 did not affect 
the localization of CHAMP1. Depletion of 
REV7 seems to decrease the nuclear fraction 
of POGZ (Fig S3). 
To establish whether these interaction 
partners of REV7 play a role in mediating 
PARP inhibitor resistance in BRCA1-deficient 
cells, shRNAs were used to deplete POGZ in 
G3 cells (Fig 5B). Unfortunately, depletion of 
POGZ was inefficient in most clones, even 
after isolation of single clones. Selected 
clones with the most efficient depletion of 
POGZ were used to measure PARP inhibitor 
sensitivity in clonogenic survivals and RAD51 
focus formation after IR. REV7 and 53BP1-
depleted G3 cells were used as controls. Loss 
of REV7 or 53BP1 results in restoration of 
RAD51 focus formation after irradiation and 
PARP inhibitor resistance9,28,29. Although the 
depletion of POGZ was poor, one clone (81-5) 
showed PARP inhibitor resistance comparable 
to G3 cells with REV7 or 53BP1 depletion (Fig 
5A). Since it was found only in one clone, it 
could be an off target effect. Depletion of 
POGZ did not lead to restoration of RAD51 
focus formation in G3 cells with stable knock-
down of POGZ, even in the clone that was 
Olaparib resistant (Fig S4 A,B). 
As an alternative siRNAs were used to 
transiently deplete POGZ and CHAMP1 in G3 
cells. The transfection with siRNA targeting 
Figure 5 Stable POGZ depletion BRCA1-deficient cells
(A) Depletion of POGZ results in Olaparib resistance in one clone with POGZ depletion (81-5). KP (BRCA1-
proficient), G3 shScrambled (Scr, BRCA1-deficient) or G3 cells induced with indicated shRNAs were used 
for a clonogenic survival assay in the presence of increasing doses of Olaparib. Data represent average 
±SD. (B) Immunoblot of cell lines used in panel (A) with indicated antibodies. Ku70 was used as a loading 
control. 
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POGZ had little effect on POGZ expression 
(Fig 6A) and there was no restoration of 
RAD51 focus formation in G3 cells transfected 
with this siRNA (Fig 6B). CHAMP1 could be 
knocked down partially with siRNA. However, 
also in G3 cells transfected with CHAMP1 
siRNA, there was no increase in the formation 
of RAD51 foci after irradiation compared to 
G3 cells transfected with siRNA targeting 
Luciferase. This suggests that at least 
CHAMP1 does not have an effect on RAD51 
focus formation in BRCA1-deficient cells. For 
POGZ a better depletion would be required 
to draw any conclusions. 
Discussion
REV7 is a multifunctional protein that 
has been linked to trans lesion synthesis, 
cell cycle progression and transcriptional 
activation. Each of these functions could 
theoretically be important in mediating PARP 
inhibitor resistance in BRCA1-deficient cells. 
The role of REV7 in cell cycle progression does 
not seem to be important for the restoration 
of homologous recombination, but the 
interaction between REV3 and REV7 is likely 
to play a role. 
In the absence of REV7, mitotic aberrations 
such as lagging chromosomes and anaphase 
bridges occur more frequently30. Loss of REV7 
could lead to pre-mature or over-activation 
of the APC/C, disturbing the tight regulation 
of mitotic progression. To try to reverse 
the effect of REV7 loss, we inhibited the 
APC/C pharmacologically with the inhibitor 
proTAME17. Inhibition of the APC/C in BRCA1-
deficient cells, with or without REV7 depletion, 
had no effect on RAD51 focus formation. 
Therefore, the role of REV7 as inhibitor of the 
APC/C does not appear to be important for 
restoring HR in BRCA1-deficient cells. APC/C 
activation is tightly controlled, not only by 
REV7, but also by MAD2, EMI1 and several 
other proteins11, so loss of only REV7 might 
not result in over-activation of the complex. 
Also mechanistically, it is difficult to explain 
why proteins involved in mitosis would 
restore HR in BRCA1-deficient cells. 
The role of REV7 in TLS is more likely to be 
important. REV7 has been linked to HR31 and 
a flexible polymerase such as Polymerase ζ 
could be involved in taking care of resected 
DNA ends that cannot be used for HR, by 
refilling the resected DNA for example. If the 
TLS role of REV7 (i.e. Polymerase ζ) would 
be important for mediating PARP inhibitor 
resistance, REV3 depletion should have 
the same phenotype (HR restoration and 
PARP inhibitor resistance) as REV7 depletion 
in BRCA1-deficient cells. Unfortunately, 
REV3 depletion is poorly tolerated in most 
mammalian cells18. As an alternative to 
REV3 depletion, we made point mutations 
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Figure 6 Transient depletion of POGZ and CHAMP1 in G3 cells
(A) Western blot of G3 cells transfected with indicated siRNAs. Ku70 was used to ensure equal loading. 
(B) Quantification of the number of S-phase cells with more than 5 RAD51 foci. At least 100 nuclei were 
counted per sample. 
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in REV7 that have been reported to disturb 
the interaction with REV3 or REV1. The 
interaction of the C70R and 2A mutants with 
MBP-REV3 is indeed decreased, although not 
completely lost. The C70R mutant has been 
shown to completely lose interaction with a 
REV3 peptide19, but the interaction between 
full length REV7 and REV3 proteins might not 
be restricted to this region.
The REV7 point mutants show an 
intermediate phenotype for RAD51 focus 
formation or RPA recruitment on alpha 
tracks. This could be due to partial loss 
of the interaction with REV1 and REV3 or 
another process might be important for 
PARP inhibitor resistance as well. We found 
that the REV7 point mutants also lose their 
interaction with CHAMP1 and POGZ. The loss 
of this interaction could also contribute to 
the intermediate phenotype. Likewise, the 
phenotype of the repro-22 mouse in which 
the C70R mutation was found, is completely 
ascribed to the loss of the interaction 
between REV3 and REV7, but the loss of 
CHAMP1 and POGZ interaction could also 
contribute to infertility and the development 
of ovarian cancers19,32.
Partial depletion of POGZ in BRCA1-
deficient mouse cells did not lead to 
restoration of RAD51 focus formation after IR. 
Only in one single clone resistance to Olaparib 
comparable to REV7 depletion was observed. 
This could be due to an off-target effect or 
via an unknown mechanism. In this clone the 
expression of 53BP1 or REV7 was not affected 
and in the G3 cell line restoration of BRCA1 
expression is not possible because a large 
part of the BRCA1 coding region (exon 5-13) 
is deleted33. Additionally, no RAD51 foci were 
formed after irradiation, while this is the case 
for REV7 and 53BP1-depleted G3 cells. POGZ 
has been shown to be essential for normal 
mitotic progression26 and it is therefore 
possible that POGZ depletion is poorly 
tolerated. Knockout of POGZ or CHAMP1 in 
BRCA1-deficient cells using the CRISPR/Cas9 
system could help to solve the problem of 
poor knockdown, if loss of their expression 
is not lethal. Transient depletion of CHAMP1 
did not affect RAD51 focus formation either, 
suggesting that this interaction partner of 
REV7 is not important for restoring HR.
Several models could explain how REV7 
loss leads to restoration of homologous 
recombination. Boersma et al showed that 
REV7 promotes NHEJ mediated fusion of 
uncapped telomeres and inhibits 5’-end 
resection10. How REV7 inhibits resection 
remains unclear. REV7 could block access 
of nucleases, but in proteomics analysis no 
interaction between REV7 and any of the 
nucleases known to be involved in resection 
or any NHEJ proteins was found (data not 
shown). REV7 also did not interact directly 
with 53BP1. Another possibility is that 
Polymerase ζ reverses resection by filling in 
the ssDNA gap formed during resection. For 
this to be possible, a hairpin or a piece of 
dsDNA or RNA-DNA hybrid would be required 
to serve as a primer at the DNA end. To be 
able to distinguish between these models 
it is necessary to know what the phenotype 
of REV3 deletion in BRCA1-deficient cells is. 
Both BRCA1 and REV3 deletion are poorly 
tolerated in most mammalian cells. Chicken 
DT40 cells are an exception since both 
BRCA1 and REV3 knock-outs have been 
generated34,35. We tried to create BRCA1-/-
REV7-/- and BRCA1-/-REV3-/- DT40 cells. BRCA1 
knock-out REV7-/- cells were viable and loss of 
REV7 in BRCA1-deficient DT40 cells restored 
RAD51 focus formation (data not shown). 
BRCA1-/-REV3-/- cells could not be generated, 
suggesting that this double knockout might 
be lethal. A conditional deletion version of 
BRCA1 could circumvent this problem and 
more experiments are needed to determine 
whether REV3 loss in BRCA1-deficient cells 
restores homologous recombination. 
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Materials and Methods
Cell culture, transfections and treatments
HEK293FT cells were grown at 37°C in 5% CO2 in Dulbec-
co’s modified Eagle medium (DMEM) (Sigma) supple-
mented with 10% fetal bovine serum (Biowest), penicil-
lin, streptomycin, 1x non-essential amino acids (Lonza) 
and 1 mM sodium pyruvate (Lonza). U2OS cells were 
grown under the same conditions in a mixture of DMEM 
and Ham’s F10 (1:1) (Sigma) supplemented with 10% fe-
tal bovine serum (Biowest), penicilin and streptomycin. 
G3 cells 6 were cultured in DMEM/F12 (1:1) (Life tech-
nologies) supplemented with 10% fetal bovine serum 
(Biowest), penicillin and streptomycin, 5 mg/ml insulin 
(Sigma), 5 ng/ml epidermal growth factor (Life Technol-
ogies) and 5 ng/ml cholera toxin (Sigma) under low oxy-
gen conditions (3% O2, 5% CO2, 37°C). 
HEK cells were transfected using calcium phosphate pre-
cipitations and U2OS plasmid transections were carried 
out using Xtremegene HP (Roche). U2OS lines stably 
expressing mutants were generated by plasmid transfec-
tion and subsequent G418 di-sulphate selection (ForMe-
dium). 
For treatments with proTAME (I-440, Boston Biochem), 
G3 cells were incubated with 20 uM proTAME or equal 
amounts of DMSO (vehicle).
For clonogenic survivals, KP and G3 cells were seeded at 
low density and treated with Olaparib (AstraZeneca) the 
next day. Olaparib was refreshed every 4 days. Colonies 
were fixed and stained 10 days after seeding and count-
ed manually. 
siRNA transfections on G3 cells were carried out using 
Dharmafect 1 (Dharmacon) using a single transfection 
according to manufacturer’s instructions and cells were 
analysed 48 hours after transfection. Four siRNAs per 
gene were mixed at equimolar ratios and transfected as 
a pool for POGZ or CHAMP1. 
siRNAs (Dharmacon): siLuciferase sense sequence 
(CGUACGCGGAAUACUUCGAdTdT) siPOGZ ON-TAR-
GETplus set of 4, J059516-09 target sequence (GAG-
CAGAUUUAGACACGUU),  J059516-10 target sequence 
(CACCGAAGGUAGCGUCAGA), J059516-11 target se-
quence (CUUAAAUGUCCACGCUGUA), J059516-12 tar-
get sequence (CUGAGGAGGAGAUCGCAAA). siCHAMP1 
ON-TARGETplus set of 4, J056406-09 target sequence 
(CGGCUGAACACUUUCGAAA), J056406-10 target se-
quence (CCAGGACGGUGGACGGAAA), J056406-11 tar-
get sequence (GGAUUGUGCUGAACGUACA), J056406-12 
target sequence (ACGUAGAACUUGAUCAACA)
Lentiviral transduction with shRNA
ShRNA expression constructs were obtained from the 
Sigma mission library (TRC 1.5). Lentiviral packaging 
plasmids (pMDLg/pRRE, pRSV-REV and pMD2.G) and 
shRNA expression constructs were transfected into HEK-
293FT cells using calcium phosphate precipitations. 24h 
after transfection the medium was changed and 48h 
after transfection the supernatant of the HEK cells was 
added to U2OS, G3 or B11 cells. This process was repeat-
ed the next day. 48 hours after the second transduc-
tion, cells were selected using puromycin (Invivogen). 
Creation of G3 cell lines with shRNAs targeting REV7 or 
53BP1 has been described before9. The following shRNA 
constructs were used for lentiviral transduction in hu-
man or mouse cells.  Human: shNT32 no insert;  shREV7 
3’-UTR TRCN0000006569_CCCTGATTCCAAGTGCTCTTA 
Mouse: REV7 sh2 TCRN0000012846_CATCTTCCAGAAG-
CGCAAGAA;  53BP1 TCRN0000081778_GCTATTGTG-
GAGATTGTGTTT POGZ sh79 TRCN0000098926_GCCAA-
CAACAATGCTGGTAAT POGZ sh81 TRCN0000098928_ 
CGCACTCACTTGTCAGAAGAA
Cloning
Cloning of GFP-REV7 and the point mutants has been 
described before9. The MBP-REV3 construct was kindly 
provided by Wei Yang21.
FRAP
For FRAP experiments cells were seeded on 24 mm glass 
coverslips at low density, such hat single cells did not 
touch. All experiments were performed on a Leica SP5 
confocal microscope equipped with a 37°C chamber and 
CO2 supply (5% CO2). Cells were imaged and bleached 
with a 488 nm Argon laser using a 63x oil immersion 
objective. FRAP analysis was performed on a 16 pixel 
wide strip spanning the short axis of an ellipsoid nucle-
us. Pre-bleach, 200 frames were scanned using a 22ms 
interval, after which the ROI was bleached at maximum 
laser power for 100 ms. Subsequently the intensity in the 
ROI was measured with 22 ms intervals for 45 seconds 
to follow recovery of the fluorescence. A ROI outside the 
nucleus was measured to correct for the background. All 
curves were normalized to the pre-bleach intensity and 
averaged (n=20 cells).
FRAP data were analyzed using a Monte Carlo simula-
tion based program described before22. The error of the 
fit was calculated using the formula: Error= Σ(measured 
data-fitted data)2/(total number of points fitted). 
Immunofluorescence
Cells were grown on glass coverslips and fixed in 4% par-
aformaldehyde for 15 min. For RAD51 staining, cells were 
extracted before fixation for 1 min in cold Triton X-100 
buffer (0.5% Triton X-100, 20 mM Hepes-KOH pH 7.9, 50 
mM NaCl, 3 mM MgCl2, 300 mM Sucrose). PBS+0.1% Tri-
ton X-100 was used for all washing steps and PBS+ (0.5% 
BSA, 0.15% Glycine in PBS) was used for blocking and 
dilution of primary and Alexa conjugated secondary an-
tibodies (Invitrogen). Stained coverslips were mounted 
using vectashield+dapi (Vectorlabs). 
Alpha track experiments were performed as described 
previously9. 
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Antibodies
CHAMP1 (SAB1408469, Sigma), MBP (maltose-binding 
protein) (Ab 9084, Abcam), GFP (clones 7.1 and 13.1, Ro-
che), Ku70 (C-19, Sc1486, Santa Cruz), POGZ (ARP 39173_
P050, Aviva systems biology), RAD51 (2307, home-made 
36), REV7 (612266,BD transduction laboratories) and 
(EPR13657, Abcam), RPA (9H8, Abcam), 53BP1 (NB100-
304 Novus Biologicals). 
Immuno precipitation 
Cells were washed in PBS and lysed for 5 min on ice in 
NETT buffer (100 mM NaCl, 50 mM Tris-HCl  pH 7.5, 5 mM 
EDTA, 0.5% Triton X-100) supplemented with protease 
inhibitor cocktail (Roche) and Pefa-bloc (Roche). Lysates 
were cleared by centrifugation (1200 rcf, 15 min at 4°C), 
the supernatant was added to GFP-trap agarose beads 
(Chromo-Tek) in NETT buffer and incubated for 4-5h on 
a rotating wheel at 4°C. Beads were washed 3x in NETT 
buffer+ protease inhibitors+Pefa-bloc and eluted by 
boiling in 2x SDS-PAGE sample buffer.
Mass spectrometry
For SILAC labelling, cells were grown in DMEM medium 
for SILAC (Thermo Scientific) without lysine or arginine 
and supplemented with dialysed serum, L-arginine 
and L-lysine (Light: K0R0, Medium: K4R6, Heavy: K8R10) 
for 2 weeks. Amino acids for SILAC (K4: L-LYSINE:2HCL 
(4,4,5,5-D4, 96-98%), K8: L-LYSINE:2HCL (13C6, 99%), R6: 
L-ARGININE:HCL (13C6, 99%), R10: L-ARGININE:HCL (13C6, 
99%; 15N4, 99%) were obtained from Cambridge Isotope 
Laboratories. 
IPs were performed for each state separately in NETT 
buffer (100 mM NaCl, 50 mM Tris HCl pH 7.5, 5 mM EDTA, 
0.5% Triton X100) supplemented with protease inhibitor 
cocktail (Roche) and Pefa-bloc (Roche). After Immuno-
precipitation, bound proteins of all three stated were 
mixed and were digested ‘on-bead’. Briefly, beads were 
transferred to a Pierce spin column and washed at least 
five times with cold 50mM ammoniumbicarbonate (ABC). 
The columns were plugged and 100μl of 2.4mM sodium 
deoxycholate (SDC), 2.4mM sodium N-lauroylsarcosinate 
(SLS) in 0.1M Tris-HCl pH 8.5 was added. Proteins were 
reduced by addition of 5μl 100mM DTT and incubation 
at 50°C in a shaker for 30 minutes and subsequently alky-
lated by addition of 5μl 200mM 2-chloroacetamide (CAA) 
and incubation at room temperature for 30 minutes on 
a shaker in the dark. After addition of 100μl 50mM ABC 
and 2μl 100mM CaCl2 0.5μg trypsin (TPCK trypsin, Ther-
mo Fisher Scientific) was added. Proteins were digested 
at 30°C overnight on a shaker. After collection of the 
supernatant the beads were washed with 50μl 50mM 
ABC and trifluoric acid (TFA) was added to the digest to 
a final concentration of 0.5%. An equal volume of wa-
ter-saturated ethylacetate was added and after mixing 
vigorously for 1 minute and spinning the upper phase 
was removed and the same wash was repeated. Sample 
volume was reduced in a SpeedVac and pH was adjust-
ed with 10% TFA if necessary (pH < 4) and purified on a 
home-made C18 column (a 1.4mm diameter punch from 
a 3M Empore octadecyl C18 extraction disk in a 200ul 
tip) similar to the ZipTip C18 procedure (Sigma). The 
peptide eluate was dried in a SpeedVac and the residue 
was dissolved in 3% acetonitril (ACN), 0.5% formic acid 
(FA) and briefly sonicated.  A fraction was injected onto 
a Waters nanoAcquity LC equipped with a Waters 20mm 
x 180um nanoACQUITY UPLC Symmetry C18 Trap Col-
umn with 5μm particles and a home-made 40cm x 75μm 
fused silica analytical column with Waters 3.5μm Xbridge 
BEH C18 particles. Peptides were separated using a 90 or 
120 minute gradient from 99%A to 65%A (A= 0.1% FA, 
B=0.1% FA in ACN) at 0.3μl/min and 50°C and analyzed 
on a Thermo Orbitrap Fusion mass spectrometer using 
a nanoESI source and a TopSpeed DDA method with 3 
seconds cycle time, full scan detection at 120K resolution 
in the orbitrap, HCD fragmentation of selected peaks 
and fragment detection in the ion trap. Each sample was 
injected twice using either a maximal intensity first or a 
minimal intensity first DDA method. Data was analysed 
using MaxQuant and Perseus. 
Western blot
Cell extracts were prepared in 2x Leammli buffer (0.8% 
SDS, 4% glycerol, 280 mM β-mercaptoethanol, 25 mM 
Tris-HCl pH 6.8). Proteins were separated by SDS-PAGE 
and then transferred to either nitrocellulose or PVDF 
membrane. Blots were probed using the specified prima-
ry antibodies in blocking buffer (3% milk in PBS+ 0.05% 
Tween-20) and secondary antibodies coupled to HRP 
(Jackson Immunoreserach). Membranes were washed 
in PBS+0.05% Tween-20. Proteins were detected by ECL.
Fractionation
For fractionations, cells were washed in PBS and trypsin-
ized. Cells were counted and per sample 1 million cells 
were used. Fractionations were performed as described 
before38. 
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Table 1
Long Short
Immobile 
fraction
Residence 
time (sec)
Immobile 
fraction
Residence 
time (sec)
Diffusion 
constant (mm2/s)
Error best fit
WT 17% 79.88 10.5% 1.0 0.25 0.000173313
C70R 0.53% 29.56 0.25% 1.0 0.25 0.001596048
2A 0.53% 29.55 0.25% 1.0 0.25 0.001812122
3A 4.3% 103.12 1.46% 1.0 0.25 0.000838836
Long Short
Immobile 
fraction
Residence 
time (sec)
Immobile 
fraction
Residence 
time (sec)
Diffusion 
constant (mm2/s)
Error best fit
WT 21.3% 81.94 29.4% 1.0 1.0 0.000150538
C70R 3.1% 78.7 0.64% 1.0 1.0 0.000145077
2A 0.66% 110.11 1.04% 1.0 1.0 0.000159326
3A 8.4% 109.55 3.9% 1.0 1.0 0.000100401
Long Short
Immobile 
fraction
Residence 
time (sec)
Immobile 
fraction
Residence 
time (sec)
Diffusion 
constant (mm2/s)
Error best fit
WT 25.9% 52.2 35.5% 1.0 2.5 0.000171998
C70R 3.4% 14.88 5.9% 1.0 2.5 5.85241E-05
2A 10.8% 29.33 8.6% 1.0 2.5 9.69721E-05
3A 8.9% 57.33 19.3% 1.0 2.5 0.000103614
 Values for best fits per Dc. Residence time for the short immobile fraction was set to 1 sec in 
the model.
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Supplementary figure 1
(A) Western blot showing the expression of GFP-tagged REV7 wild type of mutants in BRCA1-deficient 
mouse G3 cells. The 2A mutant was not expressed. (B) Western blot showing the expression of GFP-
tagged REV7 wild type or mutants in U2OS cells. Cells were transduced with a shRNA targeting the 3’-UTR 
of endogenous REV7. PARP1 was used as a loading control.
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Supplementary figure 2
(A) Best fitting curves with a diffusion constant of 1 (dc=1.0) from Monte Carlo simulation of FRAP 
from data GFP-REV7 wild-type or mutants. Experimental data in blue, fitted data in purple and residual 
(difference between experimental en fitted data) in yellow. (B) Average values from 10 best fits for the 
short (imfSh) and long immobile (imfLo) fractions and residence time for three different values for the 
diffusion constant (dc=0.25;1.0;2.5). 
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Supplementary figure 3
Immunoblot of fractionated U2OS cells with depletion of REV7 or overexpression of GFP-REV7 using 
indicated antibodies. Depletion or overexpression of REV7 does not affect the localization of POGZ and 
CHAMP1.
Supplementary figure 4
Quantification of the number of EdU positive cells with more than 5 RAD51 foci. Cells were irradiated with 
5 Gy and incubated with EdU to label S-phase cells. At least 100 nuclei were counted in this experiment 
and the experiment was performed twice. 
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Supplementary Table 1: MS SILAC Ratio’s
Results of a SILAC experiment using U2OS cells expressing GFP-tagged wild-type or mutant REV7 to 
analyze their interacting proteins. The top 150 hits are shown. L: GFP-REV7 3A mutant, M: GFP-REV7 C70R 
mutant, H: GFP-REV7 wild type. All ratios in this table are Log2 converted. Data is sorted on normalized 
H/M ratio. A H/M ratio higher than 0 means that a protein is more abundant in the GFP-REV7 wild-type 
pull down than in the GFP-REV7 C70R pull-down. In essence, the protein interacts (indirectly or directly) 
more strongly with wild-type REV7 than the point mutant. 
Gene names Ratio M/L 
normalized
Ratio H/L 
normalized
Ratio H/M 
normalized 
Peptides Sequence 
coverage (%)
POGZ -1.746713 3.38405 8.718841 34 39.4
CBX3 -2.847466 2.598603 5.084489 6 42.6
CHAMP1 -1.183605 3.767231 5.010467 26 43.2
HDGFRP2 -1.299099 2.919264 4.085085 3 7.2
CBX1 -1.370564 1.186754 3.867106 4 26.6
H2AFV -5.018071 -1.300129 3.609046 4 31.2
DNMBP -0.7372301 2.518283 3.156332 13 12.6
HIST2H3PS2 -6.828445 -3.794197 2.940355 2 13.2
HIST1H4A -7.088786 -3.827625 2.924651 12 61.2
NIP7 -1.273727 1.775388 2.787516 3 28.9
SCAI -2.560472 0.3070788 2.672697 3 5.4
GLG1 -1.730919 1.000793 2.664415 3 5.3
CAPRIN1 -2.569522 -0.01547628 2.523311 3 8.4
GTF2I -2.00127 2.147437 2.512657 8 10.7
BIN3 -0.3341343 2.221289 2.448267 2 15.6
ADNP -2.752826 -0.2124004 2.435469 3 3.4
HIST1H2AC -6.088335 -3.547763 2.421318 5 35.4
HIST1H2BL -6.258701 -3.675415 2.36779 5 35.7
BANF1 -5.267455 -2.867121 2.258519 7 56.2
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Supplementary Table 1: MS SILAC Ratio’s continued
Gene names Ratio M/L 
normalized
Ratio H/L 
normalized
Ratio H/M 
normalized 
Peptides Sequence 
coverage (%)
OTUD5 1.373843 3.161678 2.198243 5 20.3
FXR1 -2.909743 -0.6412211 2.125585 5 12.8
VIM -5.690256 -3.48733 2.065124 46 82.4
PDCD11 -3.056971 -0.9113156 2.049247 12 10.9
BCAS2 -1.751708 0.2087669 1.844747 3 24
PSIP1 -4.035875 -2.031504 1.836369 7 16
RBM8A -4.762074 -2.894108 1.667892 3 32.2
CSNK2A1 -0.806897 0.9237196 1.639417 5 22.1
SMARCA4 -2.958925 -1.272925 1.571094 6 5.2
ELAVL1 -3.715448 -3.580474 1.493494 7 29.1
POLD2 -1.453597 0.1415635 1.482384 5 16.6
HNRNPUL2 -3.707115 -2.253532 1.367427 4 8
NHP2L1 -4.328957 -3.140253 1.343692 4 32
HNRNPC -5.257542 -3.991094 1.341872 12 33.2
FAM35A -0.05866828 1.108625 1.339935 5 9.3
RANBP2 -2.6631 -1.252192 1.297074 11 5.9
HMGA1 -4.670061 -3.303864 1.290837 3 41.1
HEATR1 -2.671991 -1.700404 1.273695 8 5.3
HIST1H1C -4.686053 -3.128093 1.251022 9 27.7
THY1 -3.329058 -1.973582 1.218719 2 19.7
RPL23A -0.8451834 0.5293712 1.206268 3 26.3
H1F0 -4.26141 -2.973922 1.173383 2 11.3
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Supplementary Table 1: MS SILAC Ratio’s continued
Gene names Ratio M/L 
normalized
Ratio H/L 
normalized
Ratio H/M 
normalized 
Peptides Sequence 
coverage (%)
LIMA1 -3.37713 -2.71577 1.1644 3 8.2
NOP58 -4.183821 -3.158558 1.080453 10 28.7
RBM25 -3.726615 -2.538178 1.05797 3 5.9
ACIN1 -3.004508 -1.826233 1.043205 6 7.6
ERH -3.742825 -2.720707 1.004753 3 41.3
NTPCR -0.5713217 0.4151096 0.9950141 5 35.8
NES -2.798968 -2.007638 0.9922609 12 10.4
FSCN1 -2.153414 -1.033097 0.9919707 1 3.2
DDB1 -0.9302154 -0.4999934 0.9835318 11 14.9
ALDH3A2 0.8196682 1.797013 0.9833128 4 14
NONO -4.320861 -3.311435 0.9705592 16 38.9
JUP -2.991255 -2.563625 0.9374951 17 35.8
CPSF1 -2.667859 -1.95506 0.9330438 8 7.4
NUMA1 -1.299418 -1.505246 0.9290335 23 17.5
NUP93 -1.055531 0.009920342 0.916553 8 16.6
DEK -2.549029 -2.081614 0.9143348 3 10.4
PNN -3.638061 -2.734371 0.9112697 4 7.7
RPL7L1 -3.323834 -2.475054 0.8970855 3 16.7
HIST1H1A -3.537106 -2.462833 0.8951474 8 27
BRIX1 -3.948419 -2.782993 0.891808 6 23.5
HNRNPA0 -2.363865 -1.48221 0.8850276 3 17
NUP155 -2.567297 -1.579491 0.8790784 3 4.9
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Supplementary Table 1: MS SILAC Ratio’s continued
Gene names Ratio M/L 
normalized
Ratio H/L 
normalized
Ratio H/M 
normalized 
Peptides Sequence 
coverage (%)
KPRP -4.359372 -3.03174 0.874679 11 33.9
RALY -3.935205 -3.238953 0.8603669 4 23.6
OCIAD2 0.07710631 0.7650254 0.8563882 1 5.8
KHDRBS1 -3.161395 -2.324383 0.8551924 3 6.1
HNRNPL -2.659996 -3.255529 0.8489584 12 36.8
TUBA4A -0.5610898 0.4487953 0.8459918 21 54.2
HNRPDL -3.681677 -3.086323 0.8401208 8 24.8
SNRPD1 -2.27425 -1.300093 0.8303365 2 28.6
POLR2B -1.612461 -1.044806 0.8277377 9 11.9
HLA-B -0.9783497 -0.4199896 0.8168864 4 19.3
PRPF8 -3.089881 -1.886299 0.8127036 20 12.6
RSL1D1 -3.613379 -3.330828 0.7962655 9 26.1
HIST1H1E -3.83218 -3.081186 0.7762725 10 26.9
POLR2H -2.94586 -2.043111 0.7584738 2 21.6
PRPF6 -2.401406 -1.539645 0.75745 2 2
NOC2L -2.77962 -1.949087 0.7302269 3 4.8
CSTB -2.2283 -1.590875 0.7167714 2 24.5
MYO1B -2.445283 -1.567981 0.716069 8 12.5
IMMT -1.564862 -1.175957 0.7144873 4 7.9
RPL8 -0.5256003 0.1894135 0.6999069 3 23.4
CKAP4 -0.4338765 0.2447654 0.6882251 6 13.6
DDX27 -1.909797 -1.693621 0.6651199 6 9.8
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Supplementary Table 1: MS SILAC Ratio’s continued
Gene names Ratio M/L 
normalized
Ratio H/L 
normalized
Ratio H/M 
normalized 
Peptides Sequence 
coverage (%)
GNAI2 -2.575873 -1.866857 0.6617496 9 34.1
CPSF6 -1.653991 -0.8935981 0.660381 2 7.5
CPSF7 -2.250577 -1.663465 0.6556266 3 14.2
TMPO -1.788813 -1.499973 0.6548937 5 22.5
CD44 -1.762583 -1.067243 0.6428402 1 6.6
DDX47 -1.849752 -1.925823 0.6391395 4 15.8
HNRNPF -2.166956 -1.365574 0.6374712 8 33.5
RANGAP1 -1.625845 -1.129513 0.6325474 3 6.8
RPL13A -0.5895721 -0.03269853 0.6305919 3 13.3
H2AFY -3.304149 -2.81624 0.6300327 9 39.5
DHX9 -3.413069 -2.850793 0.6277002 24 26.5
HNRNPA2B1 -4.03122 -3.728354 0.620211 14 50.4
PTBP1 -3.133021 -2.599637 0.6193661 12 42
RPL7A -0.765842 -0.1585904 0.6052098 7 26.3
LMNA -3.676909 -3.026558 0.6001746 18 35.2
RPS16 -0.7118895 -0.225565 0.5984604 4 30.1
HNRNPAB -3.061661 -2.620601 0.5971259 7 32.9
PLBD2 -0.2662986 -0.08303428 0.5967444 3 5.8
KIAA0020 -3.040972 -2.34161 0.5932103 4 8.3
RPL14 -0.6033802 -0.244839 0.587173 3 26.6
TPM4 -2.262088 -1.523338 0.5744406 9 43.1
SNRPA1 -0.02718976 0.5964581 0.5742468 8 32.9
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Supplementary Table 1: MS SILAC Ratio’s continued
Gene names Ratio M/L 
normalized
Ratio H/L 
normalized
Ratio H/M 
normalized 
Peptides Sequence 
coverage (%)
CSTF1 -2.458148 -1.771766 0.5736653 2 6.5
RCC1 -2.611667 -2.386619 0.5702686 9 36.1
ACTG1 -3.447501 -2.822962 0.5692967 21 70.7
RPSA; -0.7277378 -0.05790221 0.5558162 1 6.5
HNRNPU -2.304505 -1.731254 0.5479433 16 27.3
PES1 -3.672359 -2.846947 0.5459684 4 8.8
WDR12 -2.553596 -1.932967 0.5365503 3 10.9
HNRNPH1 -2.93115 -2.324094 0.5318679 8 28.5
NUP50 -2.331627 -1.595489 0.5285713 2 6.2
HDAC2 -1.940589 -1.331118 0.5245653 3 8.4
RPL10A -0.552389 0.06073913 0.5222567 6 33.2
HNRNPR; -3.679883 -3.069876 0.51924 18 31
ILF2 -3.05122 -2.561835 0.5189379 10 34.4
NOP16 -2.081553 -1.446698 0.5185351 3 27
AP2M1 -1.383642 -1.047517 0.5184344 5 17.7
HNRNPA1; -3.594156 -2.938652 0.5130864 17 52.8
RPL4 -0.8059381 -0.2853544 0.5080228 14 36.1
RPL27 -0.5771642 -0.1849329 0.506805 5 41.9
RPL13 -0.7359561 -0.1770333 0.5067034 5 24.2
S100A2 -0.4590007 0.1489992 0.503654 1 17.9
SPTAN1 -2.331699 -1.870545 0.5029415 11 7.3
MYO1C -2.779323 -2.107741 0.5003942 16 19.2
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Supplementary Table 1: MS SILAC Ratio’s continued
Gene names Ratio M/L 
normalized
Ratio H/L 
normalized
Ratio H/M 
normalized 
Peptides Sequence 
coverage (%)
MYBBP1A -2.077163 -1.614403 0.4998842 6 7.1
RPL18 -0.8865662 -0.3179661 0.498353 3 22.6
SAFB -3.428162 -2.797263 0.4968203 8 14.3
FBL -3.211699 -3.46234 0.4963089 8 30.8
HNRNPM -3.006942 -2.431209 0.4918019 15 28.6
RPL27A -0.7470032 -0.2211858 0.4882064 4 42.6
HIST1H2A 
variants
-4.293925 -3.525463 0.4873835 6 35.9
TPR -2.072179 -1.683576 0.485736 6 3
PPP2R1A 0.03689012 0.4882064 0.4817122 4 11.9
HNRNPK -2.910393 -2.374 0.4803685 12 44.5
CHD4 -2.278024 -1.793307 0.4766409 11 10
RPL36 -0.7881655 -0.2628324 0.4720718 3 21.9
HADHB -1.239702 -0.9098782 0.4673838 8 33.5
RPS26 -0.5186598 -0.05812744 0.4642501 2 23.5
ACTB -3.020575 -2.45419 0.4635179 21 70.7
SFPQ -3.222027 -3.410551 0.4616333 16 26.3
RPL6 -0.5810868 -0.1512339 0.4598512 7 33.7
RPL30 -0.4255206 -0.01791363 0.458067 4 51.8
DSP -3.16592 -1.857626 0.455439 22 10.7
REV3L -0.2832812 1.877116 0.4518573 15 6.9
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Abstract
We identified Heat Shock Factor 2 
Binding Protein (HSF2BP) as a novel protein 
directly interacting with the BRCA2 tumor 
suppressor. Overexpression, but not genetic 
deletion of HSF2BP, results in hypersensitivity 
to the interstrand DNA crosslinker mitomycin 
C (MMC) and increased MMC-induced 
chromosomal instability. This phenotype is 
similar to that of Fanconi anemia (FA) patient 
cells. HSF2BP, thus, represents an example 
where overexpression of a wild-type protein 
is associated with an FA-like phenotype. 
HSF2BP overexpression does not lead to 
homologous recombination deficiency as 
measured by functional assays but increases 
the kinetics of clearance of RAD51 foci 
induced by ionizing radiation. FANCD2 
ubiquitylation is not affected, indicating that 
the repair of interstrand crosslinks is disrupted 
at a downstream step. In conclusion, we 
demonstrate for the first time that ectopic 
expression of a wild-type protein, HSF2BP, 
can cause hypersensitivity to an interstrand 
DNA-crosslinker.
Introduction
Breast cancer type 2 susceptibility 
protein (BRCA2) is essential for the repair of 
DNA double strand breaks via homologous 
recombination (HR) and thereby maintenance 
of genomic stability1,2. BRCA2 binds RAD51 
and promotes the assembly of RAD51 onto 
single-stranded DNA (ssDNA)3–5, a critical 
obligatory intermediate in HR. Heterozygous 
mutations in BRCA2 predispose to breast and 
ovarian cancer, while certain hypomorphic 
homozygous mutations cause Fanconi 
anemia (FA), explaining the genetic defect in 
complementation group D16. 
FA is a rare genetic disease characterized 
by congenital skeletal and renal anomalies, 
growth retardation, haematological 
abnormalities, bone marrow failure and 
predisposition to leukaemia and a variety of 
other cancers7,8. The FA pathway is required 
for repair of interstrand DNA crosslinks (ICLs) 
and cells from FA patients are hypersensitive 
to interstrand crosslinking agents such as 
mitomycin C (MMC). Classically, FA was 
diagnosed by exposing patient cells to these 
agents, which results in increased levels of 
chromosomal aberrations compared to cells 
from a healthy control9, due to the defect in 
ICL repair. 
When a replication fork encounters 
an ICL, replication stalls and FANCM is 
recruited together with FAAP24 and 
MHF1/2. This triggers accumulation of the 
FA core complex, consisting of FANCA, B, C, 
E, F, G, L, M, FAAP20, FAAP24 and MHF1/2. 
Assembly of this complex is required for 
monoubiquitination of FANCD2 and FANCI 
by FANCL and Ube2T10,11, a critical and highly 
conserved step in ICL repair. Ubiquitinated 
FANCD2 acts as a recruitment platform for 
nucleases involved in ICL excision12. Incision 
on both sides of the ICL results in unhooking 
of the lesion, which can then be bypassed 
by translesion synthesis, which restores one 
of the broken DNA strands. Because the 
remaining broken DNA strand was part of a 
replication fork, the break can be repaired 
via HR. Resection of the break and RAD51 
nucleoprotein filament formation appears to 
be independent of the FA core complex13,14. 
The remaining unhooked ICL is no longer an 
obstacle for replication and can be removed 
by nucleotide excision repair. Both HR and 
the FA pathway are required for ICL repair 
and mutations in several HR proteins give an 
FA phenotype. For example FANCJ is BRIP1/
BACH115,16, FANCO is RAD51C17,18 and BRCA2 
is also known as FANCD16. 
Here we describe HSF2BP as a novel 
interactor of BRCA2. HSF2BP is expressed in 
human cancer cell lines and overexpression 
results in a phenotype that is similar to 
FA patient cells: hypersensitivity to DNA 
crosslinking agents and increased numbers of 
chromosomal aberrations after exposure to 
MMC. Because the reported FANCD2-BRCA2 
interaction domain partially overlaps with 
the BRCA2-HSF2BP interaction domain, we 
hypothesize that the MMC hypersensitivity 
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of cells overexpressing HSF2BP is due to 
the disturbance of the interaction between 
BRCA2 and FANCD2.
Results
HSF2BP interacts with BRCA2
HSF2BP was identified as a novel BRCA2 
interactor using semi-quantitative SILAC 
(stable isotope labeling by amino acids in cell 
culture) mass spectrometry (Fig 1A). BRCA2 
was immunoprecipated from BRCA2-GFP 
genomic knock-in mouse embryonic stem 
(ES) cells19. The abundance of HSF2BP in 
BRCA2-GFP immunoprecipitates correlated 
with the abundance of the BRCA2-GFP 
protein itself. As an example, changes in the 
abundance of proteins pulled down by anti-
GFP beads from Brca2GFP/GFP ES cells after 60 
minutes of mild hyperthermia treatment 
are shown in Fig 1A, which was measured 
in two independent label-swap experiments 
(log2 SILAC ratio). Hyperthermia treatment 
leads to BRCA2 protein degradation20, so its 
abundance in the immunoprecipitate from 
the hyperthermia-treated cells decreases 
(2.9x-4.4x). Similar changes in SILAC ratios 
were observed for HSF2BP and for proteins 
that bind to the beads via BRCA2-GFP, such as 
the known BRCA2 interactors RAD51, PALB2 
and MORF4L1. 
HSF2BP-GFP knock-in ES cells (Hsf2BPwt/
GFP) were created by fusing GFP to the 3’ end 
of one HSF2BP allele using a gene targeting 
approach. These cells were used to verify 
the interaction between BRCA2 and HSF2BP. 
BRCA2 and several of its interaction partners, 
such as RAD51 and PALB2, were efficiently 
immunoprecipitated via HSF2BP-GFP as 
analyzed by mass spectrometry (Fig 1B). 
RAD51-associated protein 1 (RAD51AP1)-
GFP knock-in cells (Rad51ap1GFP/GFP) were 
generated and used as a control, because 
RAD51AP1 is a nuclear protein with low 
expression, comparable to HSF2BP. 
To verify the BRCA2-HSF2BP interaction in 
human cells, HEK293T cells were transfected 
with MBP-BRCA2 and GFP-HSF2BP expression 
plasmids and an immunoprecipitation (IP) 
was performed on GFP-HSF2BP using anti-
GFP beads (Fig 1C). MBP-BRCA2 interacted 
with both mouse and human HSF2BP, but not 
with GFP. 
HSF2BP is expressed in human cell lines 
and mouse tissue
HSF2BP has originally been described 
as a testis–specific protein21. However, 
we identified HSF2BP in BRCA2 IPs from 
mouse ES cells. To test whether HSF2BP is 
expressed in human cell lines as well, RT-
PCR reactions were performed from several 
commonly used human cancer cell lines from 
different origins (HeLa – cervical carcinoma, 
U2OS – osteosarcoma, BLM –melanoma, 
MCF10A – mammary epithelium) with 
primer combinations amplifying the HSF2BP 
coding sequence. Amplification with primers 
targeting the 5’ or 3’ halves of the HSF2BP 
cDNAs resulted in a single PCR fragment for 
the 5’ part (Fig 1D) and several bands for the 
3’ end (Fig S1C), for most cell lines tested. 
This suggests that several forms of HSF2BP 
mRNA are constitutively produced in human 
cells, and might encode proteins that differ in 
the C-terminal part. Amplification of HSF2BP 
with the primer combination spanning the 
complete CDS resulted in multiple bands 
close to the predicted size of 1002bp (Fig S1B), 
which could indicate alternative splicing. 
Cloning and sequencing of the products 
allowed us to identify several shorter splice 
forms of HSF2BP. Supplementary figure S1A 
shows the exon model of the reference human 
HSF2BP cDNA sequence and identified splice 
forms. 
Expression of mouse HSF2BP in several 
mouse tissues was detectable by western 
blot using the antibody we raised against 
full-length mouse HSF2BP. As expected, 
a band matching the size of full-length 
HSF2BP was detected in testis. Importantly, 
bands of the same size were detected in the 
samples from kidney and heart and the band 
was not visible in our Hsf2BP knock-out ES 
cells (Fig 1E). A strong band running higher 
than mouse HSF2BP is also detectable in 
testis, however at this moment we cannot 
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Figure1 HSF2BP interacts with BRCA2 and its expression is not testis specific
(A) The abundance of HSF2BP correlated with the abundance of the BRCA2-GFP in BRCA2-GFP 
immunoprecipates in multiple quantitative mass-spectrometry experiments. Changes in the abundance 
of proteins pulled down by anti-GFP beads from Brca2GFP/GFP mES cells after 60 minutes of mild hyperthermia 
treatment is plotted, measured in two independent label-swap SILAC experiments (log2 SILAC ratio). (B) 
The abundance of proteins precipitated with anti-GFP beads from HSF2BP-GFP or RAD51AP1-GFP knock-
in mES cell lines. For visualization purposes the missing intensity values for proteins present in only one 
pull-down were imputed from a normal distribution with a downsift of 3 (i.e. below and left of the dashed 
line are proteins that were only identified in one pull-down experiment. For the purpose of visualization, 
a value was given automatically). Legend continued on next page.
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discriminate whether it is a larger splice form 
of HSF2BP or another testis-specific protein 
that is detected by the antibody. Neither 
endogenous nor overexpressed human 
HSF2B was detected with the antibody raised 
against the mouse protein (Fig S2A). 
Figure 1 continued 
Proteins used in the pull-down and known BRCA2 interactors are indicated. (C) GFP-IP of transiently 
overexpressed MBP-BRCA2 and GFP constructs.  Bound proteins were analysed by immunoblot using MBP 
and GFP antibodies. EV, empty vector; MBP, maltose binding protein. (D) Isolated total RNA was reverse-
transcribed into cDNA and the 5’ region of HSF2BP was amplified by PCR, generating a single band for all 
cell lines tested. A cDNA synthesis reaction without reverse transcriptase was used as negative control. 
(E) Immunoblot using HSF2BP and β-catenin antibodies showing the expression of HSF2BP in indicated 
mouse tissues and cell lines. Arrows indicate HSF2BP.
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Figure 2 HSF2BP overexpression sensitizes to MMC 
(A) Clonogenic survival using U2OS stably transfected with non-targeting shRNA or shRNA targeting 
HSF2BP treated with increasing doses of MMC. Data represents mean ±SD. (B) Clonogenic survival using 
GFP-HSF2BP expressing U2OS cells stably expressing non-targeting shRNA or shRNA targeting HSF2BP 
(shHSF2BP-29 and-32) treated with increasing doses of MMC. Data represents mean ±SD. (C) Clonogenic 
survival using HeLa cells overexpressing (o/e) an empty vector or untagged mouse or human HSF2BP 
with increasing doses of MMC. Data represents mean ±SD.
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Overexpression of HSF2BP sensitizes cells 
to MMC damage
Lentivirally-delivered stably expressed 
shRNAs were used to downregulate 
HSF2BP in human U2OS cells. Due to the 
lack of an antibody that could detect the 
endogenous protein in human cells, knock-
down efficiency could not be determined at 
the protein level. Instead, U2OS cells stably 
overexpressing GFP-HSF2BP were used to 
monitor the efficiency of the shRNAs using 
an anti-GFP antibody. Efficient knock-down 
of the GFP fusion could be achieved in U2OS 
cells using two independent shRNAs (Fig 
S2B). Anti-HSF2BP shRNA expression did not 
sensitize cells to IR and only marginally to 
MMC (Fig 2A, S2C). In order to exclude that 
incomplete knock-down of HSF2BP caused 
the lack of sensitivity, we inactivated the 
HSF2BP gene in HeLa cells using CRISPR/
Cas9 technology. Again, this did not lead to 
increased sensitivity to MMC, cisplatin or IR in 
two clones with complete disruption of the 
HSF2BP alleles (Fig S3A).
Strikingly, while depletion of HSF2BP 
did not cause any sensitivity to DNA 
damage, GFP-HSF2BP overexpression led 
to a profound sensitization to MMC (Fig 2B). 
Importantly, counteracting the GFP-HSF2BP 
overexpression using shRNA reverted the 
sensitivity close to wild type levels, showing 
that the phenotype was indeed caused by 
HSF2BP overexpression. Overexpression of 
untagged HSF2BP in HeLa cells yielded a 
similar sensitization (Fig 2C), demonstrating 
that the phenotype is not caused by the 
presence of the GFP tag and is not limited 
to the U2OS cell line. Cells overexpressing 
untagged HSF2BP also displayed cisplatin 
sensitivity, although to a lesser extent (Fig 
S2D). Like cells overexpressing GFP-HSF2BP 
they were not IR hypersensitive (Fig S2E). In 
the context of ICL-inducing agents, specific 
sensitivity to MMC has been observed 
previously for SNM122 and HELQ23,24 mutant 
cells, while deficiency in most FA genes 
results in comparable sensitivity to MMC and 
cisplatin25,26. 
HSF2BP overexpression causes a Fanconi 
anemia-like phenotype
GFP-HSF2BP localizes predominantly 
to the cytoplasm (Fig 3A). Although 
homology searches do not detect strong 
similarity between HSF2BP and any other 
known protein sequences, protein fold 
recognition software27 predicts the presence 
of armadillo repeats, commonly associated 
with cytoskeleton interaction and protein 
trafficking. We therefore investigated 
whether HSF2BP controls nuclear transport 
or cytoplasmic retention of BRCA2, similar to 
its recently described role in transport of its 
interacting transcription factor basonuclin 
(BNC1)28. However, biochemical fractionation 
did not reveal any differences in BRCA2 
distribution over cytoplasmic, nuclear and 
chromatin fractions between HSF2BP-
overexpressing and control HeLa cells (Fig 
3C) or detectable differences in BRCA2 
expression levels (Fig 3B), arguing against 
this hypothesis.  
Acute sensitivity to DNA cross-linking 
agents is a characteristic of cells deficient 
in the FA pathway, in which more than 17 
proteins have been implicated, including 
BRCA2 (identified as FANCD16). As FANCD2 
mono-ubiquitination is the key event in 
FA complex activation following cross-link 
recognition, we compared the efficiency of 
this protein modification in MMC-treated 
cells expressing HSF2BP at elevated or 
endogenous levels (Fig 4A). We did not find a 
difference in the extent to which FANCD2 was 
mono-ubiquitinated, suggesting that MMC 
sensitivity is not caused by disruption of the 
core FA complex, and is likely to be a direct 
consequence of BRCA2 dysfunction. 
FA cell lines show a characteristic pattern 
of increased chromosomal aberrations (i.e. 
increased formation of radials and chromatid 
breaks) after exposure to DNA crosslinking 
agents7. We therefore exposed HeLa cells 
overexpressing mouse or human HSF2BP to 
MMC and prepared metaphase spreads, which 
were scored for chromosomal aberrations. In 
untreated cells, HSF2BP overexpression had 
no effect on the number of chromatid type 
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breaks per metaphase, but MMC exposure led 
to an increase in the number of metaphases 
with 10 or more aberrations from 4% in the 
controls cells to 32% and 68% in HeLa cells 
overexpressing human or mouse HSF2BP, 
respectively (Fig 4B). 
HSF2BP overexpression results in a 
decrease in MMC-induced RAD51 and 
FANCD2 foci, but no obvious defect in HR 
As BRCA2 is required for RAD51 focus 
formation, a crucial step in HR2, HSF2BP 
overexpression might affect this process. 
To test whether HSF2BP overexpression 
had an effect on RAD51 focus formation 
after crosslinker-induced damage, HeLa 
cells containing an empty vector or stably 
overexpressing mouse or human HSF2BP 
were treated overnight with a low dose of 
MMC. Interestingly, HSF2BP overexpression 
indeed resulted in a reduction of the average 
number of FANCD2 and RAD51 foci per 
nucleus (Fig 5A, S4A). This was not due to 
differences in cell cycle distribution, as all 
cell lines showed similar cell cycle profiles 
irrespective of HSF2BP status (Fig S4B). 
Subsequently, we investigated whether 
the decrease in the amount of RAD51 foci 
correlated with a general reduction in HR 
capacity. HR efficiency was measured using 
a U2OS cell line with an integrated gene 
conversion reporter cassette, where GFP-
expression can be activated by HR-mediated 
repair of a double-strand break generated 
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Figure 3 HSF2BP overexpression does not change BRCA2 levels or localization
(A) Ectopically expressed GFP-HSF2BP predominantly localizes to the cytosol in HeLa cells. (B) Immunoblot 
using antibodies against BRCA2, PARP1 (loading control) and GFP. (C) Fractionation of HeLa cells stably 
overexpressing mouse HSF2BP or an empty vector. Immunoblot using antibodies against BRCA2, mouse 
HSF2BP, HSP90, MSH2 and Histone H2B. 
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by the I-SceI nuclease29. Overexpression of 
HSF2BP did not result in HR reduction in this 
assay (Fig 5B,C). To verify that recombination 
is reduced in cells in which proteins required 
for recombination are depleted, the reporter 
cells were transfected with siRNA targeting 
XRCC3. As expected, a reduction in the level 
of this protein (Fig S5A) resulted in a decrease 
in the number of GFP-positive cells 5 days 
after transfection of the double-strand break 
inducing I-SceI expression construct (Fig S5B).
Figure 4 HSF2BP overexpression gives a Fanconi Anemia-like phenotype
(A) HeLa cells stably overexpressing GFP-tagged or untagged HSF2BP were treated overnight with a 
low dose of MMC (100 nM) and cell extracts were analysed by immunoblot using a FANCD2 antibody. 
(B) Chromosomal breakage after MMC treatment of HeLa cells expressing an empty vector (EV) or 
overexpressing mouse or human HSF2BP. Cells were exposed to 50 nM MMC for 48h (blue bars) and 
compared to untreated cells (purple bars). Percentage of cells with indicated number of chromatid 
type breaks per cell is shown. 50 metaphases were scored per cell line and treatment. Arrows indicate 
chromosomal aberrations in example metaphases. o/e, overexpression.  
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HSF2BP interacts with the C-terminal 
domain of BRCA2
To map the domain that interacts with 
HSF2BP, BRCA2 was split into three flag-
tagged portions, the N-terminal (B2N, up to 
Thr939), middle (B2M, Gln940-Glu2198) and 
the C-terminal (B2C, from Thr2199) part. HeLa 
cells stably expressing the Flag-tagged BRCA2 
versions were transiently transfected with 
GFP or GFP-HSF2BP expression constructs 
and an IP was performed using anti-GFP 
beads. HSF2BP interacted most effectively 
with the C-terminal domain of BRCA2 (Fig 
6A).
Mass-spectrometry analysis of the proteins 
co-precipitating with the truncated forms of 
mouse BRCA2 from ES cells containing GFP-
tagged knock-in alleles of BRCA2 revealed 
that HSF2BP also interacts with BRCA2-GFP 
lacking the C-terminal DNA binding domain 
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Figure 5 HSF2BP overexpression results in a reduced number of RAD51 and FANCD2 foci per 
nucleus, but not in a defect in HR mediated repair
(A) The average number of RAD51 and FANCD2 foci per nucleus after MMC treatment (100 nM MMC 
overnight) in HeLa cells with indicated constructs. Cells were pre-extracted and stained for FANCD2 
and RAD51. The number of foci per nucleus is displayed for at least 290 nuclei per condition (from 3 
experiments). Line represents average ± SEM. *** indicates P value < 0.05 as calculated using the Kruskal-
Wallis test with Dunn’s post test comparing all columns EV, empty vector; ns, not significant. (B) HR function 
was measured in a U2OS cell line carrying a GFP reporter for gene conversion. Data was normalized to 
1 for U2OS #18 empty vector (EV). Bars represent averages of three experiments ± SD. U2OS EV cells do 
not contain the HR reporter (C) Immunoblot showing the overexpression of mouse HSF2BP in U2OS #18 
cells. o/e, overexpression. 
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(data not shown). The largest deletion (BRCA2-
∆DBD), in which mouse BRCA2 is truncated 
after Asp2400 (corresponding to Asp2479 in 
human BRCA2), could still precipitate mouse 
HSF2BP. We therefore hypothesized that 
the HSF2BP-BRCA2 interaction domain is 
situated between the N-terminal end of the 
B2C fragment (Thr 2199) and the C-terminus 
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Deletions
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Full  N    M    C Full  N    M    C
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Figure 6 HSF2BP interacts with the C-terminus of BRCA2 
(A) Pull-down on Flag-tagged BRCA2 full length or N,M, or C-terminal parts in HeLa cells stably expressing 
Flag constructs and transiently transfected with GFP or GFP-HSF2BP. Bound proteins were analysed by 
immunoblot using Flag and GFP antibodies. (B) Schematic overview of BRCA2 and its domains. Area 
between dashed lines indicates the overlap between HSF2BP-interacting fragments of BRCA2 identified 
from knock-in studies in mES cells and overexpression of Flag-tagged BRCA2 fragments in HeLa cells. 
Deleted domains in BRCA2 Δ1 and Δ2 constructs shown in red. (C) HeLa cells stably expressing GFP or 
GFP-HSF2BP were transiently transfected with Flag BRCA2 full length or the BRCA2 Δ1 and Δ2 constructs. 
After an IP using GFP beads, bound proteins were analysed by immunoblot using Flag and GFP antibodies. 
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of the BRCA2-∆DBD truncation (Asp2479 in 
human BRCA2). To test our hypothesis, we 
engineered constructs for the production 
of Flag-tagged versions of human BRCA2 
containing deletions in this region. In the 
construct Flag-BRCA2Δ1 the overlapping 
region between B2C and BRCA2-ΔDBD is 
completely deleted and in Flag-BRCA2Δ2 
only the part of it that overlaps the region 
previously shown to interact with FANCD230. 
Deletion of these regions resulted in a loss of 
interaction between BRCA2 and HSF2BP (Fig 
6C).  
Flag-tagged versions of the deleted 
domain of BRCA2 were also created to 
verify their interaction with HSF2BP (Table 
1, Fig S6B). The proteins were transiently 
overproduced in HeLa cells stably expressing 
GFP or GFP-HSF2BP and IPs were performed 
either on Flag or GFP. The larger BRCA2-F1 
fragment interacted with GFP-HSF2BP, but 
the short BRCA2-F2 fragment did not (Fig 7A).
The putative HSF2BP-BRCA2 interaction 
domain overlapped the N-terminal part 
of the BRCA2-FANCD2 interaction domain 
reported in a previous study30 (Fig 6B). 
Competition between the overproduced 
HSF2BP and the endogenous FANCD2 would 
provide a straightforward explanation to the 
FA-like phenotype we observed. However, 
we were unable to co-immunoprecipitate 
endogenous FANCD2 and BRCA2 (Fig S6B). 
In our mass spectrometry experiments, we 
did not detect FANCD2 in the GFP-BRCA2 
pull-downs either, although most, if not all, 
other previously reported BRCA2 interactors 
were detected in the precipitate. As an 
alternative approach to detect an interaction 
between FANCD2 and BRCA2, we engineered 
additional constructs to include the 
complete FANCD2-binding domain of BRCA2: 
BRCA2-F3 (BRCA2-F1 extended to include 
the whole of the FANCD2-binding domain); 
BRCA2-F4 (FANCD2-binding domain alone) 
and BRCA2-F5. The proteins were transiently 
overproduced in HeLa cells stably expressing 
GFP or GFP-HSF2BP and IPs were performed 
either on Flag or GFP. BRCA2-F3 and -F5 
fragments interacted with GFP-HSF2BP 
(S6A). Also in these IPs we did not detect an 
interaction between FANCD2 and any of the 
BRCA2 fragments (Fig S6A).
We also considered the possibility 
that HSF2BP overexpression disturbs the 
Figure 7 Mapping of the HSF2BP-BRCA2 interacting domain
(A) HeLa cells stably expressing GFP or GFP-HSF2BP were transiently transfected with a Flag empty vector 
(EV) or the Flag-tagged BRCA2 fragments. After collection of an input sample, the lysate was split in two 
parts and pull-downs were performed using anti-Flag and anti-GFP beads. Bound fractions were analysed 
by immunoblot using indicated antibodies. 
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interaction between BRCA2 and other 
proteins required for ICL repair. To test this 
notion we used an unbiased approach 
by performing a FLAG IP on HeLa cells 
transiently expressing Flag-B2-F1 labelled 
for 3-state SILAC (Schematic shown at the 
end of table S2). In one state (Light), HSF2BP 
was overexpressed as a control. Among the 
proteins that specifically bind to Flag-B2-F1, 
no FANC-proteins were identified (Table 
2). The experiment was repeated using the 
BRCA2-F3, but also in this experiment no 
FANCD2 was detected. Among the proteins 
that specifically interacted with the Flag-
tagged BRCA2 domains, apart from HSF2BP, 
we identified GAPDH and several histones 
including variants of H2A, H2B, H3 and H4, 
but not H1.
Changes in the kinetics of RAD51 focus 
formation 
As we did not find any connections with 
proteins directly involved in the repair of 
ICLs, we reconsidered the possibility that 
HSF2BP overexpression affected HR in a 
delicate manner via BRCA2, resulting in 
subtle changes in HR rather than a complete 
HR defect. Upon DNA damage induced by 
MMC or IR, HeLa cells overexpressing HSF2BP 
form RAD51 foci, but the percentage of cells 
with more than 10 RAD51 foci per nucleus is 
lower than in control cells (Fig 8A). To look at 
the kinetics of RAD51 focus formation, we 
used IR as damaging agent and quantified 
the number of S-phase cells with more than 
10 RAD51 foci at different time points (Fig 
8B). S-phase cells were labelled with EdU 
for 2 hours directly before fixation. HSF2BP 
overexpression did not significantly affect 
the fraction of cells scored as RAD51 focus 
positive (>10 foci per S-phase cell) at the first 
time point tested (2 hours after irradiation), 
but resulted in a reduction in this fraction at 
the later time points (4 and 8 hours). Also 24 
hours after IR, HSF2BP overexpressing cells 
show fewer nuclei with more than 10 RAD51 
foci (Fig 8C). For this time point all cells with 
more than 10 RAD51 foci were quantified, 
since EdU staining 24 hours after damage 
does not correlate with the cell cycle phase 
at the time of damage. These data suggest 
that HSF2BP overexpression results in a faster 
RAD51 focus clearance. 
Discussion
Here we identified HSF2BP as a new 
BRCA2-interacting protein. Most proteins 
reported to interact with BRCA2, such as 
RAD51 and PALB2 have a clear role in HR. 
However, for several other interactors, for 
example BRAF3531 and USP1132, their function 
or why they interact with BRCA2 is less clear. 
The interaction between BRCA2 and HSF2BP 
could be important for functions in HR as 
well as other pathways, since overexpression 
of HSF2BP results in a decrease in RAD51 foci 
after MMC and IR damage, but not in an overt 
recombination defect. 
HSF2BP overexpression results in MMC 
hypersensitivity and an increased number 
of chromatid breaks, reminiscent of a defect 
in the FA pathway. An essential step in this 
pathway is the ubiquitination of FANCD2 
by the core complex. However, this reaction 
was not affected by HSF2BP overexpression, 
suggesting that MMC sensitivity is not 
caused by disruption of the core FA complex, 
and is likely to be a direct consequence 
of BRCA2 dysfunction. This is consistent 
with previous reports showing that BRCA2 
involvement is downstream of FANCD2 
mono-ubiquitination33,34. 
HSF2BP interacts with BRCA2 in a region 
that partially overlaps with the reported 
FANCD2 interacting region of BRCA230. The 
most straightforward explanation for the 
observed phenotype (i.e. hypersensitivity to 
MMC and increased chromosomal aberrations 
after MMC exposure) is that overexpression 
of HSF2BP disturbs the interaction between 
BRCA2 and FANCD2. However, in our 
experiments we did not detect an interaction 
between endogenous FANCD2 and BRCA2 or 
flag-tagged BRCA2 fragments and we could 
not test this hypothesis directly.
An alternative model to explain the 
data is that HSF2BP disturbs a BRCA2-
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interaction partner other than FANCD2 that 
interacts with BRCA2 in the same region. 
In mass spectrometry experiments, we 
identified several proteins that specifically 
interact with the BRCA2-F1 and BRCA2-F3 
constructs. One of the strongest candidates 
is GAPDH (Glyceraldehyde-3-phosphate 
dehydrogenase). Although it is best 
known as a metabolic enzyme involved in 
glycolysis35, several other functions have 
been demonstrated for GAPDH, including 
regulated localisation to the nucleus, and 
involvement in telomere elongation and base 
excision repair36–39. GAPDH is an abundant 
protein, and was detected in all mass-
spectrometry experiments we performed, 
including in the negative control IPs. The 
quantative proteomics experiments with 
A
B
C
Figure 8 Mapping of the HSF2BP-BRCA2 interacting domain
(A) HeLa cells stably transfected with an empty vector, mouse or human HSF2BP expression constructs 
were irradiated with 5 Gy and fixed after 4 h or treated overnight with 100 nM MMC and fixed. After 
fixation cells were stained for RAD51 foci and the number of cells with more than 10 RAD51 foci was 
quantified. Bars represent mean of 3 experiments ± SEM. (B) HeLa cells stably transfected with an empty 
vector, mouse or human HSF2BP expression constructs were irradiated with 5 Gy, pre-extracted and fixed 
at indicated time points. 2 h before fixation, EdU was added to label S-phase cells. Cells were stained 
for EdU and RAD51 foci and the number of S-phase cells with more than 10 RAD51 foci was quantified. 
Bars represent mean ± SEM. (C) HeLa cells stably transfected with an empty vector or a human HSF2BP 
expression construct were irradiated with 5Gy, pre-extracted and fixed 24 hours later. Cells were stained 
for RAD51 foci and the number of cells with more than 10 RAD51 foci was quantified. Bars represent mean 
± SEM.
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BRCA2 fragments provides the first indication 
that what appeared as a non-specific 
contaminant may in fact be interacting with 
BRCA2 in the region to which we mapped 
HSF2BP binding. The Flag-BRCA2 domains 
also interact with histones and this interaction 
is most likely via other chromatin binding 
proteins since these domains lie outside the 
BRCA2 DNA binding domain. 
Cells overexpressing HSF2BP do not show 
a defect in an HR assay for intra chromatid 
gene conversion and although there seem 
to be fewer RAD51 foci present 2h after 
IR and after MMC, this defect is not of the 
same magnitude as for example the defect 
observed in BRCA1- or BRCA2-deficient cells. 
However, after IR, the number of nuclei with 
more than 10 RAD51 foci is decreased and 
their number also decreases more rapidly 
in HeLa cells overexpressing HSF2BP. This 
reduction could be due to the stimulation of 
HR by HSF2BP or the interference of HSF2BP 
with the function of proteins that are required 
for stable accumulation of RAD51 at sites of 
damage, such as BRCA240. Another possibility 
is that HSF2BP is involved in the disassembly 
of protein accumulations at sites of damage 
and that due to the overexpression of HSF2BP 
the disassembly takes place faster. Based 
on the current data, we cannot distinguish 
between reduced stability or increased 
disassembly of RAD51 foci. 
In several aspects, HSF2BP overexpression 
causes a FA-like phenotype. However, all FA 
subtypes described to date are caused by 
(homozygous) mutations and patients are 
usually screened by sequencing genomic 
DNA. In most cases, the mutation needs to be 
biallelic to cause FA26. Recently two dominant 
negative RAD51 mutations were identified 
in FA-like patients41,42. Expression of one of 
these mutants (T131P) results in a defect in 
ICL repair, but seems to affect HR to a lesser 
extent41. Additionally, it has been shown that 
overexpression of a FANCC mutant allele 
causes MMC hypersensitivity43. 
HSF2BP knock-out in HeLa cells does 
not result in increased sensitivity to DNA 
damaging agents, but overexpression clearly 
does. HSF2BP overexpression might therefore 
serve as a marker for MMC-sensitive tumours. 
In the GENT (Gene Expression across Normal 
and Tumour tissue) database44, we found 
that high expression of HSF2BP can occur in 
several tumour types compared to normal 
tissue (Fig S7). Thus mechanisms exist that 
can cause increased expression of HSF2BP.
Overexpression of testis-specific genes in 
cancer has been observed previously45. Due 
to the misregulation of expression, these 
cancer/testis (CT) antigens are expressed 
in a subset of tumours of different types. 
HSF2BP expression was reported to be testis-
specific and on western blot we see the 
highest expression in testis. HSF2BP mRNA is 
also detectable in several human cancer cell 
lines and high expression occurs in cancers. 
The question remains whether the ectopic 
expression of these genes is a cause or a 
consequence of tumorigenesis. 
To the best of our knowledge, HSF2BP is 
the first example where overexpression of a 
wild-type protein gives a FA-like phenotype. 
Currently it is still unknown whether there are 
any cases of HSF2BP overexpression among 
patients with an unclassified FA subtype. 
Standard methods such as sequencing 
of genomic DNA are not suitable to find 
overexpression of HSF2BP. RNA sequencing 
or microarray analysis need to be included in 
the mechanistic analysis of the unassigned 
FA cases to account for the new paradigm in 
the FA molecular etiology brought up by our 
findings on HSF2BP. 
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Materials and methods
Generation mES cell lines
Hsf2bpwt/GFP mES cells containing a knock-in allele were 
created by gene targeting using the approach we used 
previously to engineer the BRCA2-GFP knock-in lines19. 
The gene targeting construct was engineered by recom-
bineering46, starting with the BAC clone bMQ-430H02 
from the Sanger 129/Sv library47, homology arms were 
3.1 and 6.2 kb long, boundaries defined by the retriev-
al primers HSF2BP-CG-rtrL and HSF2BP-CG-rtrR, and the 
GFP-2A-neo cassette19 was inserted after the last codon 
of the Hsf2bp CDS, using the primers HSF2BP-CG-F and 
HSF2BP-CG-R. After the completion of selection with 
200 µg/ml G418 clones were isolated. Correct targeting 
was confirmed by Southern blotting on HindIII-digested 
genomic DNA the probe produced by PCR amplification 
with the primers HSF2BP-pr5-F and HSF2BP-pr5-R. Two 
out of the 14 screened clones were identified as Hsf2bpwt/
GFP (#7 and #14). Rad51ap1GFP/GFP cells used as a control in 
the MS experiment were produced by a similar gene tar-
geting procedure and will be described elsewhere.
Hsf2bp-/- mES cells were created using the “knock-out first 
conditional allele” strategy48 that allows converting the 
locus into two types of null alleles via an intermediate 
floxed conditional state using one gene targeting and a 
series of site specific recombination steps. Exon III was 
chosen as it is at the beginning of the gene and its de-
letion leads to a frame shift; the targeting construct is 
referred to Ce3 (conditional exon 3). The efficiency of 
the first GT step is facilitated by promotorless selection 
cassette and was ~25%. Eight independent clones that 
correctly recombined both homology arms were identi-
fied using Southerns with 3’ and 5’ probes and one clone 
(#18) was subjected to a set of recombination steps re-
quired to excise the selection cassettes and restore G418 
sensitivity, target the second allele, and by Cre recombi-
nation excise exon III.  Splicing between exon II and IV 
should lead to a frame-shift. HSF2PB elimination was 
confirmed by Western Blotting.
Generation of HSF2BP knock-out HeLa cells by CRIS-
PR-Cas9-assisted gene targeting
Oligonucleotides containing sequences for HSF2BP-tar-
geting guide RNAs were cloned into the AflII-digested 
gRNA expression vector49 using Gibson assembly. Two 
sgRNA expression constructs were generated targeting 
regions immediately upstream and immediately down-
stream of exon 2 (the first coding exon) of HSF2BP (recog-
nition sequences CGCGCCGACGCTCAGGCGAACGG  and 
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CTGAGGGGAGCGAATGGCGACGG, PAM underlined). The 
activity of gRNAs was verified by co-transfection with the 
Cas9 expression vector 49 into HEK293T, PCR-amplifica-
tion of the ~200 bp region surrounding the cut site, and 
mutation detection using Surveyor®  kit (Transgenom-
ics). Gene targeting constructs used as donors in CRIS-
PR-Cas9-stimulated gene targeting were engineered 
by recombineering, starting with a BAC (RP11-349I15). 
For exon 2 a donor construct was created that replaced 
the ~1 kb region adjacent to the sgRNA-targeted site(s) 
with the PGK-hygro selection cassette. Sequences of 
the oligonucleotides used for BAC recombineering and 
retrieval into the high copy vector are given in Table 
S1. The sgRNA expression plasmid(s), Cas9 (wt or cata-
lytically inactive) expression plasmid and the HR donor 
construct were co-transfected into HeLa cells. Selection 
with hygromycin B (200 µg/ml) was started one day after 
transfection and maintained for 8-10 days. Colonies were 
picked and genotyped using PCR to detect the presence 
of the wild-type HSF2BP allele. Clones in which no wild-
type allele was detected were further analyzed for the 
presence of the HSF2BP transcript by RT-PCR. 
Cell culture, clonogenic survivals and transfections
U2OS cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) and Ham’s F10 (1:1), supplemented 
with 10% (v/v) FCS (Biowest) and penicillin/streptomy-
cin. HeLa cells were grown in DMEM, supplemented 
with 10 %(v/v) FCS and penicillin/streptomycin. Mouse 
ES cells were cultured in a 1:1 mixture of DMEM (Lonza) 
and filtered buffalo rat liver (BRL)-conditioned medium, 
supplemented with 7.5% fetal calf serum (Biowest), 0.1 
mM nonessential amino acids (Lonza), 0.1 mM 2-mercap-
toethanol (Sigma-Aldrich), 1,000 U/ml leukemia inhibi-
tory factor, 2 mM ultraglutamine (Lonza) and penicillin/
streptomycin. Cells were grown on gelatin-coated (Sig-
ma-Aldrich) Petri dishes. All cells were grown at 37°C and 
5% CO2.
Sensitivity to DNA damaging agents was determined by 
using a clonogenic survival assay as described 50. 
For plasmid DNA transfections HeLa and U2OS cells 
were electroporated using a GenePulser XCell (Biorad). 
For the U2OS #18 HR assay, cells were tansfected us-
ing XtremeGene (Roche). For siRNA transfections Lipo-
fectamine RNAiMAX (Invitrogen) was used. All trans-
fection reagents were used as per the manufacturers 
instructions. siRNA and shRNA constructs are described 
in table S3. 
shRNA expression constructs were obtained from the 
Sigma mission library (TRC 1.5). Lentiviral packaging 
plasmids (pMDLg/pRRE, pRSV-REV and pMD2.G) and 
shRNA expression constructs were transfected into HEK-
293FT cells using calcium phosphate precipitations. 24h 
after transfection the medium was changed and 48h 
after transfection the supernatant of the HEK cells was 
added to U2OS cells. This process was repeated the next 
day. 48 hours after the second transduction, cells were 
selected using puromycin (Invivogen).
Cloning hHSF2BP, BRCA2 fragments
The list of constructs used in the study is presented in 
Table S2. Human and mouse HSF2BP CDS were amplified 
from first-strand cDNA synthesized with SuperScript II RT 
polymerase using oligo-dT primers from total RNA isolat-
ed from U2OS and IB10 cells. The RT-PCR products were 
cloned into pCR4 TOPO TA (Invitrogen) and sequenced. 
The clones containing sequences corresponding to 
full-length HSF2BP CDS present in the NCBI GenBank 
database (NM_007031 and NM_028902) were used as 
template for PCRs to re-clone the CDS into C- and N-ter-
minal GFP mammalian expression vectors (pEGFP-N1, 
pEGFP-C1) and his- or his-GST- bacterial expression vec-
tors (pETM-11 and pETM-30). To facilitate the generation 
of stable cell lines HSF2BP was cloned into selectable 
PiggyBac vectors described previously19 using Gibson as-
sembly. The same vectors were used to generate BRCA2 
fragment expression constructs. Flag-tagged full-length 
hBRCA2 expression construct and various internal dele-
tions were derived from pAZ11419 by excising a fragment 
encompassing the region that needs to be deleted using 
a pair of restriction enzymes uniquely cutting within the 
region and replacing it with a PCR-generated patch with 
the desired sequence.
HSF2BP expression detection by RT-PCRs
Total RNA was extracted from pelleted cells using RNe-
asy mini kit (QIAGEN). First strand cDNA was synthesized 
with SuperScript II enzyme (Invitrogen) using oligo-dT 
primer. PCR with primers amplifying either the complete 
or a part of HSF2BP CDS were performed with Platinum 
Taq polymerase (Invitrogen). 
Antibodies
RAD51 (2307, home-made51), FANCD2 (NB 100-316, No-
vus Biologicals), H2B (07-371, Millipore) MSH2 (Ab-2, On-
cogene), HSP90 (ab13492, Abcam) BRCA2 (Ab-1, OP95, 
Calbiochem), FLAG (M2 antibody, Sigma), GFP (clones 7.1 
and 13.1, Roche), ORC2 (551178,BD Pharmingen), XRCC3 
(ab6494, Abcam). 
Mouse HSF2BP: GST-His-mHSF2BP was expressed in bac-
teria using the his- or his-GST- bacterial expression vec-
tors (pETM-11 and pETM-30) and inclusion bodies were 
purified. Inclusion bodies were used to immunize rabbits 
(Eurogentec). Serum was affinity purified using His-mHS-
F2BP as described previously52.
Immunoblot 
To prepare lysates, cells were scraped in PBS and lysed 
in 2x Leammli buffer (120 mM Tris pH 6.8, 4% SDS, 10% 
Glycerol). Proteins were separated on acrylamide or 
tris-acetate gels (Novex) and blotted on nitrocellulose or 
PVDF. Membranes were blocked in 3% milk in PBS+0.05% 
Tween. After overnight incubation with the primary an-
tibody, membranes were washed in PBS+0.05% Tween 
and incubated with horseradish peroxidase-conjugated 
secondary antibodies (Jackson Immunoreserach). Blots 
were developed using homemade ECL and detected 
with the Alliance 4.7 (UVItec).
Fractionations
For fractionations 1 million cells were collected, washed 
once in ice-cold PBS and fractionated as described53.  
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Co-immunoprecipitation
Cells were washed twice in ice-cold PBS and lysed in 
NETT buffer (100 mM NaCl, 50 mM Tris pH 7.5, 5mM 
EDTA pH 8.0, 0.5% Triton-X100). After 30 min lysis on 
ice, mixtures were centrifuged and the supernatant (in-
put) was added to washed anti-GFP beads (Chromotec) 
or anti-Flag M2 affinity gel (A2220, Sigma)). Beads and 
lysates were incubated 2-4 hours at 4°C while rotating. 
Bound proteins were washed three times in NETT buffer 
and bound proteins were eluted by boiling in 2x Sam-
ple buffer. For Flag IPs on proteins smaller than 75 kDa 
Glycine elution according to the manufacturers protocol 
was used to prevent release of the M2 antibody from the 
affinity gel. 
Co-immunoprecipitation BRCA2 and FANCD2
Fractionations and immunoprecipitations were per-
formed as described34. Briefly, 5 million cells were used 
per 400 μl of buffer in every step of the fractionation. In 
the last step of the fractionation, the chromatin fraction 
was resuspended in 200μl Buffer A+ 250 mM Ammonium 
Sulphate + Protease inhibitor cocktail (PIC) + Pefa-bloc. 
The chromatin fraction was pre-cleared with 200 μl 50% 
protein A sepharose CL-4B beads (GE Healthcare) sus-
pension for 30 min on a rotating wheel at 4°C and the 
primary antibody was added overnight. Next, 200 μl 50% 
protA beads was added and incubated another 4 hours. 
Bound proteins were washed 3x in lysis buffer (20 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1mM EDTA, 0,5% NP40 
substitute)+PIC+pefabloc and eluted by boiling in 2x 
sample buffer. 
Mass Spectrometry
For SILAC labelling, cells were grown in DMEM medium 
for SILAC (Thermo Scientific) without lysine or arginine 
and supplemented with dialysed serum, L-arginine and 
L-lysine (Light: K0R0, Medium: K4R6, Heavy: K8R10) for 2 
weeks. Amino acids for SILAC (K4: L-LYSINE:2HCL (4,4,5,5-
D4, 96-98%), K6: L-LYSINE:2HCL (13C6, 99%), R6: L-AR-
GININE:HCL (13C6, 99%), R10: L-ARGININE:HCL (13C6, 
99%; 15N4, 99%) were obtained from Cambridge Isotope 
Laboratories. 
IPs were performed for each state separately in NETT 
buffer (100 mM NaCl, 50 mM Tris HCl pH 7.5, 5 mM EDTA, 
0.5% Triton X100) supplemented with protease inhibitor 
cocktail (Roche) and Pefa-bloc (Roche). After Immuno-
precipitation, bound proteins of all three stated were 
mixed and were digested ‘on-bead’, essentially as pub-
lished54. Details of this procedure are available upon re-
quest. Data was analysed using the Andromeda search 
engine within the MaxQuant software package version 
1.5.3.8 55,56. 
Recombination assay
Site specific recombination after DSB induction by I-SceI 
was measured as described29. 
IF Rad51 FANCD2 and confocal microscopy
For FANCD2 and Rad51 staining, cells were treated over-
night with 100 mM MMC. Cells were pre-extracted before 
fixation for 1 min in Triton X-100 buffer and stained as de-
scribed57. For the labelling of S-phase cells, cells were in-
cubated for 2 hours with 1 μM EdU before extraction and 
fixation. EdU staining was performed using the Click-iT® 
EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientif-
ic) according to the manufacturers protocol and before 
antibody staining. For quantification, experiments were 
performed in triplicate and per sample 100 nuclei were 
counted (except figure 8B and 8C, single experiments 
with at least 100 nuclei).   Pictures were taken using a 
Leica SP5 confocal microscope using a 63x objective 
and 405, 488 and 594nm lasers. Statistical analysis was 
peformed in Graphpad Prism using a Kruskal-Wallis test 
with Dunn’s post test comparing all columns. 
Cell cycle analysis
PI-BrdU labelling was performed as described58. Cell cy-
cle distributions were analysed on a FACS Fortessa (BD) 
and analysed using the FACSDiva software (BD).
Metaphase analysis for chromosomal aberrations
Metaphases analysis was performed as described59.
Table 1 Overview of Flag-tagged BRCA2 domains
Construct 
name
BRCA2 region MW
B2N Met 1-Thr 939 107.8 kDa
B2M Gln 940-Glu 2198 144.3 kDa
B2C Thr 2199-Ile 3418 141.4 kDa
Flag-BRCA2Δ1 Thr 2198-Asp2478 
deleted
345 kDa
Flag-BRCA2Δ2 Thr 2349-Asp 2478 
deleted
351 kDa
BRCA2-F1 Thr 2199-Asp2479 35 kDa
BRCA2-F2 Thr 2350-Asp 2479 18 kDa
BRCA2-F3 Thr2199-Ser2546 42.7 kDa
BRCA2-F4 Thr2350-Ser2546 25.6 kDa
BRCA2-F5 Gly2270-Ser2546 34.7 kDa
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Table 2 MS data Flag-BRCA2 domains
116
5
Chapter 5
117
Overexpression of HSF2BP, a new BRCA2 interactor, results in a Fanconi Anemia-like phenotype
5
118
5
Chapter 5
119
Overexpression of HSF2BP, a new BRCA2 interactor, results in a Fanconi Anemia-like phenotype
5
120
5
Chapter 5
121
Overexpression of HSF2BP, a new BRCA2 interactor, results in a Fanconi Anemia-like phenotype
5
122
5
Chapter 5
123
Overexpression of HSF2BP, a new BRCA2 interactor, results in a Fanconi Anemia-like phenotype
5
124
5
Chapter 5
125
Overexpression of HSF2BP, a new BRCA2 interactor, results in a Fanconi Anemia-like phenotype
5
126
5
Chapter 5
127
Overexpression of HSF2BP, a new BRCA2 interactor, results in a Fanconi Anemia-like phenotype
5
128
5
Chapter 5
Three mass-spectrometry experiments (see below) were performed with the FLAG-tagged BRCA2 
domain (F1 or F3) produced by transient transfection, and HSF2BP was stably over-produced by the host 
cell line from PiggyBac integrated construct. Proteins co-immunoprecipitating by anti-FLAG monoclonal 
antibody (M2) were quantified. The data was purged of contaminants and log2-transformed.  Data was 
sorted by whether proteins pass a treshold value of 0.4 in all 3 experiments and then by H/M ratio for 
experiment #1. NaN, not a number. In these cases the protein was not detected in one of the states and 
no ratio could be caluclated. 
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Figure S1 HSF2BP expression in human cell lines
(A) Exon model of the reference human HSF2BP cDNA sequences with the splice variants we identified 
by sequencing. Amplification of (B) full length (1002 bp) and (C) the 3’ end of HSF2BP from cDNA from 
indicated cell lines. cDNA synthesis reactions without reverse transcriptase enzyme were used as negative 
controls. 
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Figure S2 HSF2BP survivals
(A) Immunoblot showing the overexpression of mouse HSF2BP. Overexpression of human HSF2BP is not 
detectable with this antibody. (B) Immunoblot showing GFP-HSF2BP expression after stable induction 
with lentivirally delivered shRNAs targeting HSF2BP in U2OS cells. Coomassie stained gel as loading 
control. (C) Clonogenic survival using ionizing radiation as damaging agent using U2OS cells or U2OS 
cells stably overexpressing GFP-HSF2BP and stably transduced with a control non-targeting shRNA or 
shRNA targeting HSF2BP. Data represents mean ±SD (D) Clonogenic survival on HeLa cells expressing an 
empty vector or overexpressing mouse or human HSF2BP. Cells were damaged using increasing doses of 
cisplatin. Data represents mean ±SD. (E) Clonogenic survival on HeLa cells expressing an empty vector or 
overexpressing mouse or human HSF2BP. Cells were damaged using ionizing radiation. Data represents 
mean ±SD. 
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Figure S3 HSF2BP knock-out using CRISPR/Cas9
(A) Clonogenic survival using MMC, cisplatin and ionizing radiation as damaging agents using wild-type 
HeLa cells or clones (clone H1 and H4) in which HSF2BP is inactivated using the CRISPR/Cas9 system 
(targeting exon 2). Data represents mean ±SD (B) PCR on genomic DNA from indicated cell lines. Primers 
designed to span the gRNA target site in exon 2. PCR conditions were set up such that with integration of 
the donor, the primers were too far apart to allow amplification across the donor. Smaller band indicate 
loss of part of the sequence. (C) Amplification of full length HSF2BP from cDNA from indicated clones. 
cDNA synthesis reactions without reverse transcriptase enzyme were used as negative controls
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Figure S4 Effects of MMC treatment on Rad51 and FANCD2 foci and cell cycle distribution. 
(A) Examples of HeLa cells with an empty vector or overexpressing mouse or human HSF2BP showing 
Rad51 (Red) and FANCD2 (green) foci after treatment with MMC. Dapi in Blue. Scale bar represents 5 µm. 
(B) Cell cycle distribution of undamaged HeLa cells expressing an empty vector or overexpressing mouse 
or human HSF2BP with and without MMC treatment overnight. Cell cycles distribution was analysed by 
incubating the cells with BrdU. Cells were stained with an anti-BrdU-FITC antibody and PI and analysed 
by FACS.
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Figure S5 Recombination assay
(A) Immunoblot showing the knock-down of XRCC3. ORC2 was used as a loading control. (B) Recombination 
experiment in U2OS #18 cells treated with siRNA targeting XRCC3 or luciferase. Data was corrected for 
transfection efficiency and the number of GFP-positive cells in untransfected cells. 
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Figure S6 Mapping the BRCA2-HSF2BP interaction
(A) HeLa cells stably expressing GFP or GFP-HSF2BP were transiently transfected with a Flag empty 
vector (EV) or the flag-tagged BRCA2 fragments. Pull-downs were performed using anti-Flag beads. 
Bound fractions were analysed by immunoblot using indicated antibodies. (B) Fractionation and pull-
down of endogenous FANCD2 using a FANCD2 antibody or mouse IgG as a control from Hela cells stably 
expressing GFP or GFP-HSF2BP (G-H). Immunoblot using indicated antibodies. (C) Schematic overview of 
Flag-tagged BRCA2 fragments in table 1. 
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compared to normal tissue
Figure S7 HSF2BP is overexpressed in some human tumours compared to normal tissue
HSF2BP expression levels on microarray in normal and tumour tissue from the GENT (Gene Expression 
across Normal and Tumour tissue) database. The GENT database contains more than 34000 samples, 
profiled by Affymetrix U133A or U133plus2 platforms, allowing identification of outliers (value higher 
than ±750, black dashed line) in a subset of patients44. 
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Table S1 Oligonucleotide sequences
HSF2BP-CG-F gcccaggagctcctggaagacctccgcgccctggactgtaatgttGTGAGCAAGGGCGAGGAGCT
HSF2BP-CG-R tggaccactggcattttcaccgggctcctggtggtagagcacatctaTGGTCGACCTGCAGGCGGC
HSF2BP-CG-scrF ggtggtggtgattgtgttca
HSF2BP-CG-scrR ttccatgcattcaaaggtga
HSF2BP-CG-rtrL caaagtgagttccaggacagccaaggctacacagagaaaccctatctcaACGCGTgcggaacccctatttgtttat
HSF2BP-CG-rtrR taaggaatgtgggcaccaagaacaaccagcaagtgttgagcttacctctcACGCGTttccagtcgggaaacctgtc
HSF2BP-pr5-F CCAGTGGCCTTTTGCATATT
HSF2BP-pr5-R TGGGAATGCTAAATGTGTTCA
gRNA-hHe2u-F TTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCGCGCCGACGCTCAGGCGAA
gRNA-hHe2u-R GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTTCGCCTGAGCGTCGGCGCG
gRNA-hHe2d-F TTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCTGAGGGGAGCGAATGGCGA
gRNA-hHe2d-R GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTCGCCATTCGCTCCCCTCAG
gRNA-hHe5-F TTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCAGCAGTGAGGAAGTCGTCA
gRNA-hHe5-R GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTGACGACTTCCTCACTGCTG
hHe5-surv-F CAGTTGAATGAAGCGAAGCA
hHe5-surv-R TGAGTGAACAAAAGAAAATGGAAA
hHe2-surv-F GAATACTGCGCAAATTCTGG
hHe2-surv-R ACGCCGTTAGGGGAGGAA
hHSFko-e5-
recF1
GCAGAGTATTGTACAGAAATGGGAGCAGCAGCGTGTACCCTCTTGTGtggtcgacctgcaggcggc
hHSFko-e5-
recR1
ACAAGCAGTAATCAACAATATCTGGAGAGCCCACTGACCATACTTAacgtcgcatgctcccggcc
hHSFko-e5-
recR2
GCAGTATTTGCTTTACTGCAGTGGTCTGGAAGCAAACAGGCAACATacgtcgcatgctcccggcc
hHSFko-e5-rtrR ACCAGTTTTCTGTATCCTAAGCTAAAGCTGGAAATCAGAAATTTATTttccagtcgggaaacctgtc
136
5
Chapter 5
hHSFko-e5-rtrL CATATTGCAAACAAATTGCAACATATACATACCATGGAATATGAGGCAACGCGTgcggaaccccta tttgtttat
hHSFko-e2-
recF1
CGACCCCCGGCGTGGATTCGTTCCCGCGCTTTCTGGCGTGAGGGGTtggtcgacctgcaggcggc
hHSFko-e2-
recR1
CCCCAAGCACGCGACAGCGAGCCGTCTCCGAGCGCACGGGGCGAGGCacgtcgcatgctcccggcc
hHSFko-e2-
recR2
GTTTACAATTATTTACCTAGGGTAAATCTGCTAGAACAAATTACTGacgtcgcatgctcccggcc
hHSFko-e2-rtrL GGCCCAAAAGTCAGTTGACAGTTTTCTGATACTGGGCCCCTGTCAGCACGCGTgcggaacccctatttgtttat
hHSFko-e2-rtrR GAAGGTAGGAATGAATACAGGCAGGGAAGGAGTAGACCTGATTTGAttccagtcgggaaacctgtc
hHSF2BP-rt-F1 CGCAAATTCTGGGAGGTTT
hHSF2BP-rt-R1 GATCTGGGGAGAAGGGACAC
hHSF2BP-rt-F2 TGGCTTTTGAGTGATCCAGA
mHSF2BP-rt-F1 AGCTGAGGCAGCGGCTAT
mHSF2BP-rt-R1 GATGGACCACTGGCATTTTC
mHSF2BP-rt-F2 CCAAACTCAAAGTTCTAATGCTGA
hHSF2BP-
pETM-F
atctttattttcagggcgccATGGGCGAAGCGGGCGCC
hHSF2BP-
pETM-R
cttgtcgacggagctcgaattcCTACACATTATGCTCCAGAG
hHSF2BP-
EGFP-F
cagatctcgagctcaagcttcgGCCATGGGCGAAGCGGGCGC
hHSF2BP-
EGFPN-R
ggtggcgaccggtggatccCACATTATGCTCCAGAGTGC
hHSF2BP-
EGFPC-R
ttatctagatccggtggatcc TACACATTATGCTCCAGAGT
mHSF2BP-
GFPN-F
cagatctcgagctcaagcttcgGCTATGGCCGCAACCGTGG
mHSF2BP-
GFPN-R
ggtggcgaccggtggatccAACATTACAGTCCAGGGCGC
137
Overexpression of HSF2BP, a new BRCA2 interactor, results in a Fanconi Anemia-like phenotype
5
mHSF2BP-
GFPC-R
ttatctagatccggtggatccCTAAACATTACAGTCCAGGGCGC
mHSF2BP-
pETM-F
atctttattttcagggcgccATGGCCGCAACCGTGG
mHSF2BP-
pETM-R
cttgtcgacggagctcgaattcCTAAACATTACAGTCCAGGGCGC
GFP-HSFdcc-F ctcagatctcgagctcaagcttccattttgggaggagataaagctttgaag
GFP-HSFdcc-R tcagttatctagatccggtggatccctacacattatgctccagagtgcg  
GFP-HSFdArm-F ctcagatctcgagctcaagctttgggcgaagcgggcg           
GFP-HSFdArm-R tcagttatctagatccggtggatccCTAggccttgacgacttcctcac
Table S2 Constructs
Code Name Vector Comment
pAZ013 pCR4+mHSF2BP pCR4 mHSF2BP full-length CDS
pAZ014 pCR4+mHSF2BPde7 pCR4 mHSF2BP splice variant missing exon 7
pAZ015 pCR4+hHSF2BP pCR4 hHSF2BP CDS full-length
pAZ016 pCR4+hHSF2BPde7,8 pCR4 hHSF2BP CDS splice variant skipping exons 7,8
pAZ017 pETM30+hHSF2BP pETM30 his-GST-hHSF2BP
pAZ018 pETM11+hHSF2BP pETM11 his-hHSF2BP
pAZ019 pEGFPC1+hHSF2BP pEGFP-C1 GFP-hHSF2BP
pAZ020 pETM30+mHSF2BP pETM30 his-GST-mHSF2BP
pAZ021 pETM11+mHSF2BP pETM11 his-mHSF2BP
pAZ022 pEGFPN1+mHSF2BP pEGFP-N1 mHSF2BP-GFP
pAZ023 pEGFPC1+mHSF2BP pEGFP-C1 GFP-mHSF2BP
pAZ075 hHSF2BPe2u_gRNA pCR-BluntII CRISPR gRNA human HSF2BP exon 2 upstream
pAZ076 hHSF2BPe2d_gRNA pCR-BluntII CRISPR gRNA human HSF2BP exon 2 downstream
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pAZ077 hHSF2BPe5_gRNA pCR-BluntII CRISPR gRNA human HSF2BP exon 5
pAZ086 GFP-hHSF2BP∆Arm pEGFP-C1 hHSF2BP coiled coil domain (residues 1-)
pAZ088 GFP-hHSF2BP∆cc pEGFP-C1 GFP+hHSF2BP C-terminal armadillo domain
pAZ089 hHSF2BP-GFP pEGFP-N1
pAZ099 pGb-LPL-CMV-
>hHSF2BP
pGb-LPL over-expression of human hHSF2BP
pAZ100 pGb-LPL-CAG-
>mHsf2bp-GFP
pGb-LPL
pAZ102 pGb-LPL-CAG-
>mHsf2bp
pGb-LPL over-expression of mouse HSF2BP
pAZ103 pGb-LPL-CAG->GFP-
mHsf2BP
pGb-LPL
pAZ117 pBS+hHSF2BP-e5ins-
hygro
pBS CRISPR-assisted GT donor for hHSF2BP exon 5 (cassette 
insertion)
pAZ118 pBS+hHSF2BP-e5∆-
hygro
pBS CRISPR-assisted GT donor for hHSF2BP exon 5 (deletion)
pAZ119 pBS+hHSF2BP-e2∆-
hygro
pBS CRISPR-assisted GT donor for hHSF2BP exon 2 (deletion)
pAZ148 pGb-LPL-CAG 
Flag~BRCA2
pGB-LPL
pAZ147 pGb-LNL-CAG 
mHSF2BP
pAZ149 pGb-LPL-CAG 
Flag~BRCA2∆HSF
∆T2198-D2478
pAZ159 pGb-LNL-CAG BRCA2-
HSF-bigger
pAZ125 fragment of BRCA2 that binds HSF2BP (bigger variant 
T2198-D2478
pAZ160 pGb-LNL-CAG BRCA2-
HSF-smaller
pAZ125 fragment of BRCA2 that binds HSF2BP (smaller variant 
T2349-D2478
pAZ167 pGb-LNL-CAG 
BRCA2-F3 
pAZ125 HSF-bigger + full FANCD2 interaction domain
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shNT32 no insert
shNT 33 CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGT
GCTCTTCATCTTGTTGTTTTT
8029 human CCGGGCTGGAATTGTCACGAATGTTCTCGAGAACATT 
CGTGACAATTCCAGCTTTTT
TRCN0000017473
8030 human CCGGCGGGACTTCTTACCCAGAATACTCGAGTATTCT
GGGTAAGAAGTCCCGTTTTT
TRCN0000017474
8031 human CCGGCGGATGAAAGTCAGTTTGTTTCTCGAGAAACAA
ACTGACTTTCATCCGTTTTT
TRCN0000017475
8032 human CCGGGCTAATGCTGATGTCCCTATACTCGAGTATAGGG
ACATCAGCATTAGCTTTTT
TRCN0000017476
8033 human CCGGCGACAACATAAGAGAGAAGAACTCGAGTTCTTC
TCTCTTATGTTGTCGTTTTT
TRCN0000017477
8034 mouse CCGGTGCCGGAACATGGAATCTAAACTCGAGTTTAGA
TTCCATGTTCCGGCATTTTTG
TRCN0000239566
8035 mouse CCGGGCGGCAGGAGATGTCCATTTACTCGAGTAAATG
GACATCTCCTGCCGCTTTTTG
TRCN0000239567
8036 mouse CCGGGTATAATGTGAGCATCAATTCCTCGAGGAATTG 
ATGCTCACATTATACTTTTTG
TRCN0000239568
8037 mouse CCGGGGATGTCAAGGAGGTTGATTCCTCGAGGAATCA 
ACCTCCTTGACATCCTTTTTG
TRCN0000239569
8038 mouse CCGGGACGACGGAAGTGATGCAAATCTCGAGATTTGC 
ATCACTTCCGTCGTCTTTTTG
TRCN0000239570
Table S3 siRNA and shRNA
siRNA
shRNA targeting HSF2BP
siLuc sense sequence CGUACGCGGAAUACUUCGAdTdT
siXRCC3 sense sequence GGACCUGAAUCCCAGAAUUUU
pAZ168 pGb-LNL-CAG 
RCA2-F4
pAZ125 FANCD2 interaction domain alone 
pAZ169 pGb-LNL-CAG 
BRCA2-F5
pAZ125 C-terminal part of the HSF-bigger + full FANCD2 domain
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Part I – Results from this thesis
Over the last few decades the field of 
the DNA Damage Response (DDR) has been 
evolving rapidly. By now we have a general 
idea how most types of DNA damage are 
repaired, from bacteria to mammalian cells. 
However, there are many open questions 
regarding the finer details of these repair 
pathways and still new factors involved in 
DNA repair are discovered regularly. With 
the introduction of genome-wide screening 
methods using siRNA and shRNA, it became 
easier to identify drug sensitivities and 
resistance mechanisms, linking new proteins 
to DNA repair. Expression of GFP-tagged 
versions of proteins, efficient pull-downs 
and sensitive analysis by mass spectrometry 
allowed easy identification of new interaction 
partners. Since the advent of CRISPR/Cas9 
technology generating knockouts has 
become easier in any transfectable cell line 
and making knock-out mice is less time-
consuming1. While most main players in the 
DNA damage response have been known for 
several decades, new proteins are still being 
connected to the DDR. Recent examples 
are PAXX in non-homologous end-joining 
(NHEJ)2,3 and UVSSA in transcription coupled 
nucleotide excision repair4–6. Lately the focus 
is shifting more to chromatin remodelling 
and post-translational modifications such 
as phosphorylation, ubiquitylation and 
sumoylation. Additionally, new roles for 
proteins already known to be involved in 
DNA repair are identified. An example of that 
is REV7, which has been shown to affect DNA 
double strand break repair (Chapter 3 and 4).
DNA double strand breaks are among 
the most detrimental types of DNA damage. 
The main pathways to repair these breaks are 
NHEJ and homologous recombination (HR). 
A proper balance between these pathways 
is important for the maintenance of an 
uncompromised genome. Several proteins 
such as BRCA1 and 53BP1, are known to affect 
the balance between HR and NHEJ (Chapter 
2). Mutations in BRCA1 lead to defects in HR 
and repair via end-joining is likely to increase 
to compensate this deficiency. This defect 
in HR can be partially rescued by the loss of 
53BP17,8. Due to the defect in HR, BRCA1-
deficient cells are extremely sensitive to PARP 
inhibitors, but upon loss of 53BP1, the cells 
become resistant. In Chapter 3 we found that 
the same holds true for REV7. 
REV7 function in PARP inhibitor resistance
REV7 was originally identified as a gene 
involved in UV mutagenesis in yeast9 and 
was later shown to form a complex with 
REV310. It has now become clear that REV7 is 
a multi-functional protein that plays a role in 
cell cycle progression, translesion synthesis 
and transcriptional activation. As described 
in chapter 3, we found that loss of REV7 
leads to PARP inhibitor resistance in BRCA1-
deficient cells by restoring HR. Currently, it 
is still unclear why REV7 loss restores HR. 
The restoration of HR is specific to BRCA1-
deficient cells; loss of REV7 does not cause 
PARP inhibitor resistance in BRCA2-deficient 
cells. 
We considered the possibility that the 
role of REV7 in inhibition of the anaphase 
promoting complex/cyclosome (APC/C) 
is important. REV7 inhibits the activity 
of the APC/C-CDH1 complex to prevent 
premature activation of this complex before 
mitosis11. In the absence of  REV7, mitosis is 
accelerated and mitotic aberrations occur 
more frequently. It does not seem very likely 
that misregulation of mitosis would lead 
to restoration of HR, as this repair pathway 
functions mainly in the S and G2 phases of the 
cell cycle. Additionally, if changes in mitosis 
would rescue a HR defect, it is unlikely that 
this is specific for BRCA1-deficiency. However, 
to test this hypothesis, we inhibited the 
APC/C to see whether this had an effect on 
RAD51 foci formation after ionizing radiation 
in BRCA1-deficient cells (chapter 4). Although 
the inhibitor was active, there was no effect 
on RAD51 foci formation in BRCA1-deficient 
cells with REV7 depletion.
An alternative explanation is that REV7 
plays a role at the level of pathways choice 
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between HR and NHEJ. BRCA1 and BRCA2 
are both involved in HR, but BRCA1 has been 
shown to affect resection12,13, while the main 
function of BRCA2 in HR is to load RAD51 
onto these resected DNA ends14.
REV7 could directly stimulate end-joining. 
Boersma et al. showed that REV7 affects fusion 
of deprotected telomeres by inhibiting end 
resection15. Telomeres are protected by the 
Shelterin complex containing TRF2. Boersma 
et al. used MEFs expressing a temperature-
sensitive TRF2 variant. When these cells were 
exposed to elevated temperatures (39°C), the 
telomeres became uncapped and fused, a 
process that depends on end-joining. In the 
absence of REV7, the telomeres did not fuse 
and 3’ telomeric overhangs were elongated. 
Additionally, Flag-tagged REV7 co-localized 
with 53BP1 after telomere uncapping. This 
suggests that REV7 promotes NHEJ. The 
effect is dependent on 53BP1 and RIF1, but 
not PTIP. So far, no catalytic activity for REV7 
has been linked to NHEJ. REV7 does not seem 
to interact with either RIF1 or 53BP1 and 
why the phenotype is dependent on these 
proteins remains unclear. 
REV7 has also been linked to HR. Sharma 
et al. showed that HeLa cells transfected with 
siRNA targeting REV1, REV3 or REV7 showed 
more RAD51 foci 24 hours after damage than 
HeLa cells transfected with control siRNA16. 
REV1, REV3 and REV7 depleted cells also 
showed decreased recombination in the 
assay, an assay to measure intra chromatid 
gene conversion. The authors argue that 
this is because REV1 and Polymerase ζ are 
required to bypass damaged bases and 
aberrant structures in resected DNA (after 
strand invasion). Failure to bypass these 
lesions might results in stalled or delayed HR 
repair. On the other hand, there are several 
translesion polymerases, so it is not so likely 
that the bypass of the aberrant structures 
would exclusively depend on REV1 and 
Polymerase ζ.
Whether the interaction between REV3 
and REV7 is important for stimulating end 
joining and restoring HR in BRCA1-deficient 
cells is still under debate. In the screen 
performed by Boersma and colleagues, 
REV1 and REV3 depletion did not result in 
the same phenotype as REV7 depletion, but 
the C70R and the L186A mutants (defective 
in REV3 and REV1 interaction respectively), 
showed an intermediate phenotype in the 
telomere deprotection assay. Also in our 
experiments, the REV7 point mutants show 
an intermediate phenotype when comparing 
the results obtained in the alpha-track 
experiment or when comparing the efficiency 
of the formation of RAD51 foci in BRCA1-
deficient cells (Chapter 4). This indicates that 
the interaction with REV3 could play a role, 
but other processes or interaction partners 
might be important as well. The intermediate 
phenotype could also be due to incomplete 
loss of the interaction or loss of other binding 
partners (see below). 
There are several possible models for 
how REV7 could favour end joining (Figure 
1). One possibility is that it blocks resection 
by sitting on the DNA and preventing access 
of nucleases. Similar models have been 
proposed for 53BP1 and in fractionations 
REV7 is found in the chromatin fraction as 
well as the nucleus and the cytoplasm. REV7 
recruitment to sites of damage also depends 
on 53BP1. However, no direct interaction 
between REV7 and 53BP1 has been detected 
in our mass spectrometry experiments or 
immunoprecipitations. Also no interaction 
between REV7 and any of the nucleases 
known to be involved in resection was found. 
Another possibility is that REV3 and 
REV7 together fill in resected DNA, thereby 
reversing resection. DNA is resected from 5’ 
to 3’. All polymerases synthesize DNA from 
5’ to 3’, in the same direction as resection is 
taking place. A polymerase can therefore not 
directly fill in the resected DNA, assuming 
that resection starts at the end of the broken 
DNA. Recently it was shown in yeast that 
resection can start some distance away from 
the break. Cannavo and Cejka showed that 
in vitro, MRX (Mre11, Rad50, Xrs2) and Sae2 
(yeast homolog of CtIP), can make a nick in 
double stranded DNA 15-20 base pairs from a 
break17. At this site, resection then takes place 
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in both directions. If the same would be the 
case in mammalian cells and a small piece of 
double strand DNA would stay on the end 
of the DNA, Polymerase ζ might be able to 
fill the gap and reverse resection. The DNA 
synthesis could also start from a small DNA or 
RNA primer or a microhomology at the end 
could fold back on itself to form a hairpin, 
which could serve as a primer. 
Currently it is unknown whether REV3 
loss also causes PARP inhibitor resistance 
in BRCA1-deficient cells. REV3 depletion 
is poorly tolerated and attempts to knock 
down REV3 using shRNA were not efficient. 
In chicken DT40 cells deletion of REV3 is 
tolerated18 and also BRCA1 knock-out DT40 
cells are viable19. To find out whether REV3 
deletion restores HR in BRCA1 knock out 
cells, we set out to make BRCA1-/-REV7-/- 
and BRCA1-/-REV3-/- double knock out cells. 
BRCA1-/-REV7-/- cells were viable and REV7 
loss restored RAD51 foci formation in BRCA1 
knock-out cells (data not shown). BRCA1-/-
REV3-/- cells could not be obtained. This might 
indicate that the combination is lethal. We 
are currently making cells with a conditional 
BRCA1 deletion allele combined with REV3 
deletion. It is, however, possible that REV3 
function is essential and that REV3 loss 
would never lead to PARP inhibitor resistance 
because REV3 loss results in cell death, even 
if the REV3 polymerase activity is needed for 
this phenotype.
As an alternative approach and to 
circumvent the problem of the lethality of 
REV3 loss, we made point mutations in REV7 
to disrupt the interaction with REV1 or REV3 
(Chapter 4). When looking at PARP inhibitor 
resistance and RAD51 foci formation, the 
mutants show an intermediate phenotype 
compared to wild-type REV7. The explanation 
for this intermediate phenotype could either 
be that the interaction between REV7 and 
REV3 or REV7 and REV1 is not completely 
lost or that other factors play a role in this 
interaction as well. Binding partners of 
wild-type REV7 and two point mutants 
were analysed by mass spectrometry to see 
whether any interaction partners other than 
REV1 and REV3 change as well.  
The point mutations in REV7 also affect 
the interaction with CHAMP1 and POGZ. 
A complex with REV7, POGZ and CHAMP1 
was identified in a screen for readers of 
histone marks20. POGZ, CHAMP1 and REV7 
interacted with HP1 isoforms CBX1, CBX3 and 
CBX5, which bind to the repressive histone 
modification H3K9me3. CHAMP1 (C13orf8, 
Znf828) has been reported to regulate 
kinetochore microtubule attachment during 
mitosis upstream of CENP-E and CENP-F21. 
CHAMP1 localizes to chromosomes and 
CHAMP1-depleted cells show chromosome 
misalignment. POGZ, a domesticated 
transposase, contains a DDE domain that 
can be used for DNA cleavage, strand nicking 
and ligation22. Nozawa et al. showed that 
POGZ is important for the dissociation of 
heterochromatin protein 1 alpha (HP1α) 
and Aurora B kinase from chromosome arms 
during mitosis23. 
REV7, POGZ and CHAMP1 have all been 
linked to mitosis, so the complex might play 
a role there. For CHAMP1 and POGZ there is 
no link to DNA repair yet. However, these two 
proteins have not been studied as thoroughly 
as REV7. POGZ contains a DDE domain that 
might be used to connect two DNA ends in a 
manner that is similar to the joining reaction in 
transposition24. It is possible that this activity 
could be used in alternative end-joining 
and that REV7 facilitates end-joining via this 
complex. However, it is not known whether 
the DDE domain in POGZ has maintained any 
transposase-like activity. In our experiments, 
depletion of POGZ and CHAMP1 with siRNA 
(and shRNA for POGZ) was inefficient and 
there was no effect on the formation of 
RAD51 foci. One BRCA1-deficient G3 clone 
with stable depletion of POGZ was Olaparib 
resistant comparable to G3 cells with shRNA 
targeting 53BP1 or REV7. However, since 
none of the other clones showed resistance 
and there was no formation of RAD51 foci 
after irradiation, it could well be off target 
effect. The currently available data on the role 
of POGZ and CHAMP1 in HR is inconclusive 
and these proteins cannot be linked yet to 
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1. REV7 blocks resection
2. REV3 and REV7 fill in resected DNA
3. CHAMP1, POGZ and REV7 form an end-joining complex
Nuclease
REV7
Rev7
New DNA
REV7
REV3
Resected DNA for HR
Resected DNA for HR
New DNA
Substrate for end joining
REV7 POGZ
CHAMP1
End joining
Resection
Resected DNA for HR
REV7 present REV7 absent
Nuclease
Nuclease Nuclease
Nuclease
Nuclease Nuclease
Figure 1  Models for the role of REV7 in DNA repair
1. REV7 blocks resection. REV7 could be DNA bound and block access of nucleases to prevent resection. In 
the absence of REV7, nucleases are no longer blocked and resection can proceed, generating a substrate 
suitable for HR. 2. REV3 and REV7 fill in resected DNA. If resection does not start from the end of broken 
DNA, but some distance from it and a small piece of double stranded DNA remains at the end (orange), 
Polymerase ζ might be able to fill in the resected DNA (pink). This would reverse resection and create 
a DNA end that is suitable for repair via NHEJ. After loss of REV7, the resected DNA is no longer filled 
in by Polymerase ζ and is suitable for repair via HR. 3. CHAMP1, POGZ and REV7 form an end-joining 
complex. In the absence of REV7, end-joining of deprotected telomeres decreases. REV7 therefore might 
stimulate end joining and the DDE domain of POGZ might be able to perform a transposition/integration 
like reaction. It is possible that this complex is involved in an alternative form of end-joining. This complex 
could prevent resection by joining the broken DNA ends before resection takes place. In the absence of 
REV7 this end-joining reaction does not take place and the DNA ends are processed for HR. 
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restoration of HR. More experiments with 
complete deletion of CHAMP1 and POGZ, 
for example using CRISPR/Cas9 technology, 
would be required to determine whether 
these proteins affect HR in BRCA1-deficient 
cells.
How to treat PARP inhibitor resistant 
tumours
Finding out how REV7 loss leads to 
restoration of HR is important for the 
treatment of patients whose tumours have 
become resistant to PARP inhibitors due to 
REV7 loss. Once the mechanism is known, 
other drugs can be used to target resistant 
cells or to prevent resistance by using a 
combination of drugs. For example, PARP 
inhibitor resistance due to overexpression 
of a multi-drug resistance transporter could 
be prevented by using a PARP inhibitor that 
is a poor substrate for this protein25 or by 
inhibiting this multi-drug transporter using 
Tariquidar26. In cell culture experiments, 
the formation of RAD51 foci and increased 
Olaparib resistance of BRCA1-deficient cells 
with depletion of REV7 could be abrogated 
by the addition of an ATM inhibitor. Whether 
this also works on tumour bearing mice has 
not been tested yet. 
For the treatment of (resistant) tumours, 
especially the possibilities and drawbacks 
of drug combinations are important. 
Ovarian cancers with BRCA2 mutations are 
very sensitive to cisplatin treatment. This 
patient group could also benefit from PARP 
inhibitor treatment, but it has been shown 
that cisplatin resistance due to genetic 
reversion correlates with PARP inhibitor 
resistance in a BRCA2-mutated breast-cancer 
cell line, HCC142827. Also in patients with 
hereditary ovarian carcinoma, cisplatin and 
PARP inhibitor resistance were correlated28, 
although the number of patients in this study 
was small. 
Tumours that have become resistant 
to treatment with PARP inhibitors through 
genetic reversion might still be sensitive 
to other chemotherapeutics that inflict a 
different type of DNA damage. Issaeva and 
colleagues showed such cells and tumours 
are still sensitive to treatments with the 
chemotherapeutic 6TG (6-thioguanine)29. 
HR is required for the repair of 6TG-induced 
damage and one explanation for the 
sensitivity to 6TG is that the restoration of HR 
in PARP inhibitor resistant cells is insufficient 
to cope with this type of damage. 
HSF2BP and crosslinker sensitivity
Certain repair deficiencies make cells very 
sensitive to specific types of DNA damage. 
As described above, HR-deficient cells are 
very sensitive to the treatments with PARP 
inhibitors. These repair deficiencies are 
usually caused by mutations. In Chapter 5 
we describe a novel mechanism for repair 
deficiency: overexpression of a wild-type 
protein. Overexpression of HSF2BP sensitizes 
HeLa and U2OS cells to Mitomycin C. HSF2BP 
was identified as a protein interacting with 
BRCA2. BRCA2 is essential for HR and the 
formation of RAD51 foci30. Overexpression 
of HSF2BP does not lead to a HR defect but 
the formation of RAD51 and FANCD2 foci 
after MMC exposure is decreased. Also, the 
number of chromosomal aberrations after 
MMC exposure is dramatically increased in 
HeLa cells overexpressing HSF2BP compared 
to HeLa cells expressing an empty vector. 
These phenotypes are very similar to the 
phenotype observed for Fanconi Anemia 
patient cells31. 
HSF2BP interacts with the C-terminus 
of BRCA2. In this region FANCD2 has also 
been reported to interact with BRCA2. We 
hypothesized that the interaction between 
HSF2BP and BRCA2 prevents or weakens the 
interaction between BRCA2 and FANCD2. 
However, in immunoprecipitations we could 
not show an interaction between FANCD2 
and BRCA2 and therefore we could not test 
this hypothesis.
Another possibility is that another 
interaction between BRCA2 and an interaction 
partner required for the repair of interstrand 
crosslinks is disrupted by the overexpression 
of HSF2BP. To investigate this, we used 
quantitative mass spectrometry to identify 
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proteins that specifically interact with the 
flag-tagged BRCA2 domain that interacts with 
HSF2BP and a larger BRCA2 domain that also 
contains the reported FANCD2 interaction 
domain. In these experiments we could not 
identify an interaction with FANCD2 either. 
Among the proteins that interacted with 
the BRCA2 domains and not with the Flag 
peptide itself and whose interaction changed 
upon overexpression of HSF2BP was GAPDH. 
Other proteins the BRCA2 domains strongly 
interacted with were histones and histone 
variants. No other proteins that could directly 
be linked to the repair of DNA interstrand 
crosslinks were found. Therefore, at the 
moment, the disturbance of the interaction 
between BRCA2 and FANCD2 by HSF2BP 
overexpression seems to be the most logical 
explanation. However, we cannot exclude 
that the interaction between HSF2BP and 
BRCA2 results in an overall change in BRCA2 
structure, affecting interactions in other parts 
of BRCA2. 
Fanconi Anemia due to overexpression
As described above, the phenotype of 
cells overexpressing HSF2BP is reminiscent 
of Fanconi Anemia (FA) patient cells. 
Historically, these patient cell lines have 
been analysed by screening metaphase 
spreads for chromosomal aberrations after 
MMC exposure31. To identity the specific 
genetic defect and for a definitive diagnosis, 
a genetic complementation analysis was 
performed. So far at least 16 genes have been 
identified in which mutations cause Fanconi 
Anemia. Some of these genes had already 
been identified in other DNA repair pathways, 
such as PALB2/FANCN32 and FANCQ/ERCC433. 
The most recently identified Fanconi Anemia 
subtypes are FA-S (mutations in BRCA1)34 
and FA-T (mutations in de E2 ubiquitin ligase 
UBE2T that is required for the ubiquitination 
of FANCD2 and FANCI)35,36. Both of these 
subtypes were discovered by searching for 
bi-allelic mutations in patients with typical 
FA features that had no mutations in other 
known FA genes. 
All FA subtypes described to date are 
caused by mutations. HSF2BP is the first 
example where overexpression of a wild-
type protein gives a Fanconi Anemia-like 
phenotype. Currently it is still unknown 
whether there are any cases of HSF2BP 
overexpression among patients with an 
unclassified FA subtype. Standard methods 
such as sequencing of genomic DNA are not 
suitable to find overexpression of HSF2BP. 
RNA sequencing or microarray analysis 
would be more suitable. In the future these 
methods should be used on all patients with 
an unclassified type of Fanconi Anemia.
Part II –  How can we apply our 
findings in the clinic?
Genome-wide screens for drug 
sensitivities as well as bioinformatics analysis 
on sequenced tumours and their therapy 
response regularly reveal new prognostic 
markers for all types of tumours. In this thesis 
a resistance mechanism and a sensitization 
mechanism are described. This type of 
information is very valuable for mechanistic 
insight and knowledge on how cells repair 
DNA damage, but it is not very easy to 
apply this knowledge to the treatment of 
patients. Main questions when trying to 
apply ‘fundamental’ findings to the clinic are 
the following: How relevant is the finding for 
patients? Does it only happen in cultured cells 
or also in (human) tumours? In which types of 
tumours does it occur? In how many patients 
does this happen? How big is the effect? 
To find quantitative and statistically 
significant answers to these questions, 
material from many patients needs to be 
tested on a large scale. This material could be 
acquired from clinical trials or by collecting 
material from surgery. Sequencing of large 
numbers of tumours, as was done for the 
Cancer Genome Atlas (TCGA) provides the 
data to answer these questions. Currently the 
TCGA project has collected approximately 
11000 samples for 33 tumour types and in 
the future more cancer types will be analysed 
(www.cancergenome.nih.gov). For breast 
cancer, DNA methylation, exome sequencing, 
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messenger RNA arrays and several other 
techniques were used to analyse the 
tumours37. Genomic analysis of these tumours 
is just the first step. To be able to predict 
treatment outcome based on sequencing 
information, the data from all these tumours 
should be related to parameters such as 
treatment response and overall survival. 
Once such data on a large cohort of 
tumours is available, the next step is to 
characterize patient material for diagnosis. To 
characterize tumours based on morphology 
or expression of a single receptor, standard 
immuno-histological methods suffice. For 
example, breast cancers can easily be stained 
for the HER2-receptor or Estrogen-receptor to 
determine whether any targeted treatments 
(Herceptin or Tamoxifen respectively) will be 
suitable. Also sequencing of the BRCA1 and 
BRCA2 genes is very useful to test whether the 
tumour is likely to be HR-deficient. However, 
for a thorough analysis for many markers, 
other methods are more suitable. 
Sequencing of patients’ tumours (whole 
genome sequencing) is already feasible. 
With this data, one can look for possible 
disease causing mutations or mutational 
signatures. However, there are often very 
many mutations detected in tumour material 
compared to normal tissue and it is difficult 
to determine which mutations are the driver 
mutations. 
Driver mutations are genetic changes 
that give selective advantages to cancer 
cells and thereby drive cancer development. 
Mutational signatures can be indicative of 
specific types of DNA damage and/or repair 
mechanisms that have been taking place in 
the genome38. A disadvantage of looking 
at those signatures is that they reflect the 
history of the tumour and not necessarily 
the current status. For example, a BRCA1-
deficient tumour can show specific genomic 
scars, but if the tumour has restored BRCA1 
expression by genetic reversion or restored 
HR via the loss of 53BP1, the scars will remain 
but the tumour is no longer HR-deficient and 
will respond accordingly to therapy. 
Methods that would better reflect the 
tumours’ current status are microarray 
analysis and RNA sequencing. A disadvantage 
of microarray analysis is that the number 
of probes per gene is limited and that the 
probes need to be specifically designed. 
You will only detect what you are looking 
for. This method has been used to classify 
molecular subtypes to identify BRCA1 and 
BRCA2 mutation carriers39. RNA sequencing 
is unbiased and mutations, different splice 
forms and other variations can be detected. 
For RNA sequencing, one can focus on the 
exome to look at expressed genes or also 
sequence small and non-coding RNAs. The 
latter provide a wealth of data, but are not 
easy to interpret and relatively little is known 
about their role in cancer. One of the current 
challenges for RNA seq is the quantification of 
expression levels and accurate identification 
and quantification of different splice forms40. 
A completely different strategy to test 
how a tumour will respond to therapy is to 
treat tumours ex vivo. This can either be done 
by culturing slices of tumours collected after 
surgery41, dissociating tumour samples into 
single cells42 or by growing organoids from 
patient material. So far, only an organoid 
biobank for material from colorectal cancer 
patients has been established43, but this 
might be achievable for other tumour types 
as well. An advantage of organoid cultures 
over tissue slices is that organoids can be 
expanded and more treatments can be 
tested. However, in tissue slices the tumour 
morphology remains intact and the analysis 
does not require time-consuming expansion 
of the material. 
Although there are many techniques 
available to characterize a patient’s 
tumour, tumour heterogeneity remains a 
challenge for all techniques. Tumours often 
consist of different clones, which might 
harbour different mutations and respond 
differently to treatment. In ex vivo assays 
using tissue slices, tumour heterogeneity 
can be observed after treatment, but for 
subsequent genetic analysis the material is 
analysed as a mix of the total tumour. Single 
cells sequencing methods might help to 
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overcome this problem, but these tools are 
still being developed44. Another challenge 
for all techniques mentioned above is the 
contamination of tumour tissue with normal 
tissue. This problem could also be resolved 
by using single cell sequencing methods, but 
this technology needs further development 
before it can be used for routine analysis. 
Lastly, these sequencing techniques generate 
large amounts of data and the storage, but 
most of all the analysis and interpretation of 
data remains challenging. The sequencing 
data should be related to the current 
literature for accurate analysis. One question 
that remains is how can we integrate all data 
that has been acquired so far? 
 
Data integration and interpretation
The sensitivity of a tumour to a drug is 
determined by the total composition, not 
only the expression or mutation of a single 
protein. Therefore new models and methods 
are required to integrate all data. An example 
of such an approach is the Cancer Cell Map 
Initiative45. The goal of this project is to chart 
the interaction networks and pathways that 
operate in cancer and healthy cells. Tumours 
often have a variety of mutations but these 
mutations might hijack the same pathways. 
For the interpretation of sequencing data it is 
therefore important to take these pathways 
into account. 
In 2011, Roychowdhury and colleagues 
used whole-genome sequencing of the 
tumour, targeted whole-exome sequencing of 
tumour and normal DNA, and transcriptome 
sequencing (RNA-Seq) of the tumour to find 
clinically relevant genetic defects in two 
patients46. For the interpretation of the results 
they made use of a multidisciplinary team 
with experts on clinical oncology, pathology, 
cancer biology, bioethics, bioinformatics, 
and clinical genetics. In the future, computer 
models that interpret all data might perform 
this task. However, a team of experts should 
still verify the results or outcome of the model. 
If a bioinformatics model is developed to take 
over this task, it will need continuous updates 
to integrate new findings and clinical data to 
obtain the best results. 
Ideally, the model for data interpretation 
should be understandable and usable for 
oncologists in the clinic. This will enable 
them to make the optimal therapeutic choice 
for their patients. Johnson et al. described 
an example of a decision support platform 
for oncologists using next generation 
sequencing data47. In this approach, the first 
step is to determine whether a DNA variant 
found in tumour material is actionable (i.e. 
could a treatment based on this aberration 
benefit the patient?). If this is the case, the 
team tries to find a clinically available drug 
that targets this aberration. Also here the 
decision is made by a team of experts and 
based on the literature and a functional 
genomics platform. 
Deciding whether a mutation has 
functional consequences for a protein 
is, even for a team of experts, often not 
straightforward. For mutations in the known 
catalytic site of a protein it is likely that they 
will inactivate the protein and mutations 
that change an amino acids to a proline will 
probably change the folding of the protein. 
However, most missense mutations or small 
insertions and deletions, it is difficult to 
predict what the effect will be. Therefore 
laborious functional experiments with these 
mutants, preferably in cells, are required to 
determine the effect of a mutation on protein 
function. Another factor complicating the 
interpretation of tumour data is the effect 
epigenetic modifications have on protein 
expression. Although a gene might show 
no mutations, promotor hypermethylation 
or other histone modifications could still 
affect the expression. For example, tumours 
showing hypermethylation of the BRCA1 
promotor are HR-deficient, although there 
are no mutations in the BRCA1 gene41. For 
the optimal analysis of tumours, these factors 
should be taken into account as well. 
The availability of a computer program or 
platform that helps oncologist to interpret 
the sequencing data from patients will allow 
them to make the best therapeutic choice for 
their patients. This should increase treatment 
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efficiency and overall survival of cancer 
patients. If more is known about resistance 
mechanisms, unnecessary treatment can be 
prevented as well and patients would not 
have to suffer from the side effects without 
benefit. However, there are also other 
steps that can be taken to improve cancer 
treatment in the future. 
The future of cancer treatment
To be able to treat cancer better, there 
are several aspects that can be improved. 
One of them is early detection of tumours. 
The earlier a tumour is detected, the smaller 
the chances that the tumour has already 
metastasized and the better the chances of 
curing the patient. Ideally one would detect 
tumours while they are still on the scale of 
just a few thousand cells using for example 
tumour-specific antibodies or other markers. 
However, it is unlikely that a tumour of this 
size will cause symptoms in the patient. Still, 
investing in strategies for early detection 
of tumours will be beneficial, also to detect 
residual cancer cells. On the other hand, not 
all lesions that will de detected are malignant 
and some might never grow out. To avoid 
over-treating patients, and potentially 
causing secondary cancers due to treatments 
with DNA-damaging agents, methods are 
required to determine how likely a lesion is to 
grow out. Unfortunately, such methods are 
currently not available yet. 
The second aspect is to make cancer 
treatment more personalized. Several 
strategies to characterize a patients’ tumour 
and to determine which treatment will be 
best are described above. Personalized 
treatments generally aim at giving the 
patient the best treatment by looking for 
sensitivities. However, detection of resistance 
may prevent unnecessary treatment and 
patient suffering from treatment side effects 
needlessly. 
Another part of personalized medicine is 
the development of drugs that target specific 
genetic defects. Examples of this type of drugs 
are the BRAF kinase inhibitor Vemurafenib, 
which is used to treat melanomas with a V600 
mutation in BRAF48 and the PARP inhibitor 
Olaparib49,50. Both of these drugs have 
been approved for clinical use for certain 
types of tumours. For example Olaparib has 
only been approved for the treatment of 
advanced ovarian cancer associated with 
BRCA-defective genes. Olaparib might also 
be a very effective treatment for other HR-
deficient tumours such as gastric cancers 
with low ATM expression51 and that is 
currently being tested in clinical trials52. Once 
it has been demonstrated that for those HR-
deficient tumours PARP inhibitor treatment is 
better than the current standard treatment, 
effort should be made to approve the drug 
for those tumour locations as fast as possible 
to make sure that patients can benefit. 
Extensive clinical trials to verify the safety of 
the drug might not be necessary, since this 
has already been done for the initial approval 
of the treatment of ovarian cancer. 
Strategies contrasting personalized 
medicine aim for a drug to treat all types of 
cancer. One example of a general cancer 
drug is the MTH1 inhibitor. MTH1 is required 
to hydrolyse oxidized nucleotides to prevent 
the incorporation of these damaged bases. 
For many cancers, this process is essential 
for survival, while normal cells are less 
dependent on it. MTH1 inhibition leads to 
DNA damage and eventually cell death53,54. 
Normal cells also depend on MTH1 and 
inhibition of this enzyme will lead to DNA 
damage54. Furthermore, MTH1 knock-out 
mice have an increased long–term tumour 
burden55. Whether the benefit of the drug 
outweighs the toxic effect of the DNA 
damage in healthy cells is not yet clear. MTH1 
inhibitors are currently being developed and 
tested in mice, but not yet on patients. 
Lastly, the treatment should be focussed 
on completely eradicating the tumour. 
The remaining (treatment resistant) cells 
are likely to grow out again eventually 
and can metastasize, turning cancer into a 
sort of chronic disease. At the moment the 
treatments also aim at complete eradication 
of the tumour, but the treatment choice is 
mostly based on the type or location of the 
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tumour and a few biomarkers (for example 
hormone status for breast cancer). With 
the use of personalized treatments based 
on sequencing of individual tumours, the 
treatment could be optimized to eliminate 
all individual sub-clones of a tumour. To be 
able to do that, detailed characterization 
of a patient’s tumour is required and the 
treatments will differ between patients. 
Maybe a combination of treatments would 
be required to completely eliminate a 
heterogeneous tumour. Once sequencing on 
biopsies is possible, samples could be taken 
from treated tumours to see which treatment 
should be used next. 
The price to pay
Personalized medicine is very promising 
for the treatment of cancer, but is this new 
technology affordable? Can these techniques 
be used on a large scale in hospitals? Ex vivo 
treatment of organoids grown from a patients 
tumour is very exciting, but also time-
consuming and labour intensive. Specific 
growth conditions are required to keep the 
organoids alive and the results should be 
obtainable in a clinically relevant time span 
to make a decision on the best treatment for 
the patient.  
Drugs targeting a specific genetic defect 
are very effective, but only useful for a 
relatively small group of patients. Patients 
clearly benefit from these treatments, not 
only because of the efficacy but also because 
the side effects are less severe than for 
conventional chemotherapy. However, the 
development of these drugs is very costly 
and the resulting drugs are very expensive. 
Additionally, resistance occurs and in many 
cases, the treatment results in an increase of 
life span of several months, not a cure56.
The tests to characterize tumours such 
as whole genome sequencing and exome 
sequencing are very expensive as well. In 
the future, sequencing will become cheaper, 
as the technology progresses. Also the 
integration of data and the accessibility of 
the knowledge should improve over time, 
although the interpretation of tumour data 
will remain complex. Sequencing and data 
analysis should also become faster to allow 
oncologists to design treatment plans based 
on the results. 
As described above, a program or 
model for clinicians that helps to guide 
their treatment plan and that takes current 
literature and new drugs into account would 
be very valuable. Another aspect that such 
a program could address is the cost of the 
treatment and the net health benefit. The 
price of cancer care is increasing rapidly 
and to address this problem the American 
Society of Clinical Oncology (ASCO) has set 
up “a framework to assess the value of cancer 
treatment options” 57. This tool should help 
patients and oncologist to decide which 
treatment to take. 
Conclusion
The field of cancer treatment is rapidly 
developing, both on the fundamental and the 
clinical side. To transfer all new knowledge 
from bench to bedside, models should be 
developed to integrate all data and to make it 
accessible for clinicians. With the introduction 
of more targeted treatments and precision 
oncology, more cancers will become treatable 
and more patients will survive. Combinations 
of treatments will hopefully lead to complete 
eradication of tumours, killing the whole 
heterogeneous tumour. In the future cancer 
should not become a chronic disease, but 
one that can be cured. 
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Summary
All information a cell needs to live and 
survive is stored in the DNA. Most DNA 
molecules consist of two complementary 
chains of linked nucleic acids that twist into a 
helix. During replication the helix is unwound 
and new complementary bases are placed 
opposite the ‘old’ bases, resulting in two 
identical daughter helices. The place where 
the DNA is unwound and replicated is called 
the replication fork. 
Maintenance of an intact and 
uncompromised genome is of vital 
importance for cell survival. Damaged DNA 
can block transcription and replication, 
processes essential for cell viability. 
Additionally, once a permanent change such 
as a point mutation or translocation has been 
made in the DNA, it will be inherited by the 
daughter cells. Persistent DNA damage can 
result in cell death or the accumulation of 
mutations, which may lead to accelerated 
ageing or malignant transformation (i.e. 
cancer). 
The DNA is constantly attacked by 
endogenous as well as exogenous agents 
that cause DNA damage. For example, UV 
light from the sun can damage the DNA by 
crosslinking two adjacent bases and ionizing 
radiation can either break one or both 
strands of the DNA. Chemotherapeutics such 
as Mitomycin C and cisplatin make crosslinks 
in the DNA and between DNA and nearby 
proteins. To counteract the deleterious effects 
of DNA damage, cells evolved an intricate 
network of pathways to detect and repair 
DNA damage, the DNA Damage Response 
(DDR). These pathways can recognize specific 
types of damage and also halt cell cycle 
progression to gain time to repair the damage 
before the next cells division. Chapter 1 gives 
a general introduction into the topic of DNA 
repair. 
The nucleotide excision repair pathway 
repairs damaged bases that distort the DNA 
helix, such as bases damaged by UV light. 
Mismatches between two opposing bases 
can arise during replication, because the 
polymerases that replicate the DNA sometimes 
incorporate the wrong nucleotide. Mismatch 
repair deals with these mistakes by removing 
the wrong base. Another polymerase then 
replaces the missing base. For the repair of 
DNA double strand breaks there are two 
pathways, homologous recombination and 
non-homologous end joining. Assays to 
measure the repair via these pathways and 
the importance of a proper balance between 
the two are reviewed in chapter 2. 
DNA interstrand crosslinks connect two 
opposing strand of DNA, preventing the 
transcription and replication machinery 
from opening the helix. This type of 
damage is recognized and repaired via the 
Fanconi Anemia (FA) pathway, homologous 
recombination, translesion synthesis and 
nucleotide excision repair. Unlike most 
other DNA repair pathways, the translesion 
synthesis (TLS) pathway is a DNA damage 
tolerance pathway. When a replication 
fork stalls at a damaged base, translesion 
polymerases can take over to bypass the 
damage. The damaged base is then removed 
at a later stage, for example by the nucleotide 
excision repair pathway. 
Mutations in proteins involved in DNA 
repair can predispose to specific types 
of cancer. For example, women with a 
heterozygous mutation in the homologous 
recombination proteins BRCA1 and BRCA2 
are more prone to develop breast and ovarian 
cancer. Usually the wild-type copy of BRCA1 
or BRCA2 is inactivated in the tumour and 
only the mutated variant is expressed. These 
cells are then no longer able to repair DNA 
breaks via homologous recombination. This 
defect makes the cells exquisitely sensitive 
to PARP inhibitors, such as Olaparib. PARP1 
is required for the efficient repair of single-
strand breaks in the DNA. When these breaks 
are repaired inefficiently due to inhibition of 
PARP1, replication forks collapse at these sites 
of damage, resulting in DNA double strand 
breaks. To repair these breaks, BRCA1 and 
BRCA2 are required. In tumours where these 
proteins are not functioning properly, DNA 
damage accumulates, eventually leading to 
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cell death.
The treatment of homologous 
recombination deficient tumours with PARP 
inhibitors is very promising, but a fraction of 
the tumours eventually becomes resistant 
to the treatment. Resistance can be due 
to overexpression of a drug-efflux pump, 
reversion of the mutation in BRCA1 or BRCA2 
or restoration of homologous recombination 
due to the loss of 53BP1 expression. However, 
these mechanisms do not explain all cases of 
resistance. In chapter 3 we therefore set out 
to identify novel mechanism of resistance in 
BRCA1 deficient mouse mammary tumour 
cells. 
To identify mechanism of PARP inhibitor 
resistance in BRCA1deficient cells, a loss-of-
function shRNA screen was performed on 
mouse mammary tumour cells. Resistant 
clones were selected with a high dose of 
the PARP inhibitor Olaparib. One of the hits 
from the screen was 53BP1. For 53BP1 it had 
already been demonstrated that its loss in 
BRCA1 deficient cells results in restoration 
of homologous recombination and PARP 
inhibitor resistance. A new hit from the 
screen was Rev7 and Rev7 loss also resulted 
in Olaparib resistance. In the absence of Rev7, 
Rad51 foci formation was restored and CtIP 
dependent-resection was increased in BRCA1 
deficient cells. 
From the initial study it was still unclear 
why loss of Rev7 led to restoration of HR in 
BRCA1 deficient cells. Rev7 plays a role in 
translesion synthesis together with Rev3 and 
Rev1, but Rev7 has also been implicated in 
regulation of cell cycle progression via the 
anaphase-promoting complex and in several 
other processes. In chapter 4 we investigate 
the importance of the different roles of 
Rev7 in the restoration of homologous 
recombination and mediating PARP inhibitor 
resistance. The role of Rev7 in cell cycle 
progression does not seem to be important 
for restoration of homologous recombination 
in BRCA1 deficient cells, but the interaction 
between Rev3 and Rev7 is. 
In chapter 5 we studied BRCA2 and its 
interactions partners. BRCA2 is, like BRCA1, 
essential for homologous recombination 
and BRCA2 deficient cells are also extremely 
sensitive to PARP inhibition. In a mass 
spectrometry screen, a new BRCA2 interacting 
protein, HSF2BP (Heat Shock Factor 2 Binding 
Protein), was identified. Although HSF2BP 
expression was reported to be testis specific, 
we showed that it is expressed in mouse 
embryonic stem cells, mouse tissue and 
several human cancer cell lines. HSF2BP 
overexpression resulted in hypersensitivity 
to the interstrand-crosslinking agent 
mitomycin C (MMC). Additionally, exposure 
to MMC resulted in increased numbers 
of chromosomal aberrations in cells 
overexpressing HSF2BP. Both of these 
phenotypes are also characteristic for Fanconi 
Anemia patient cells, which have a defect 
in the pathway that repairs DNA interstrand 
crosslinks. 
HSF2BP interacts with the C-terminal part 
of BRCA2, in the same region as FANCD2. Our 
current model is that the MMC hypersensitivity 
upon overexpression of HSF2BP is caused by 
disturbing the interaction between FANCD2 
and BRCA2. 
Chapter 6, the general discussion, 
examines the results and implications of this 
thesis for the treatment of cancer and also 
how new findings can be implemented in the 
clinic or which steps should be taken before 
this can be done. Finally, the future of cancer 
treatment and the implications for the costs 
are considered. 
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Samenvatting
Alle informatie die een cel nodig heeft om 
te kunnen (over)leven is opgeslagen in het 
DNA. De gangbare conformatie van DNA is 
een dubbele helix bestaande uit nucleotiden 
die om elkaar heen gewonden zijn. Tijdens 
de replicatie, het kopiëren, van DNA worden 
nieuwe basen, de bouwstenen van het DNA, 
tegenover een vaste partner in het ‘oude’ DNA 
geplaatst. Zo wordt een exacte kopie van de 
originele streng gemaakt. De plek waar de 
oude strengen gescheiden worden en het 
DNA gekopieerd wordt, heet de replicatie 
vork. 
Het in stand houden van intact en 
onbeschadigd DNA is voor een cel van 
levensbelang. Beschadigd DNA kan de 
transcriptie en replicatie blokkeren en 
deze processen zijn van essentieel belang 
voor cellen. Daarnaast zullen mutaties 
en translocaties, wanneer deze eenmaal 
ontstaan zijn, overgeërfd worden in het 
nageslacht. Bovendien kan de permanente 
aanwezigheid van beschadigd DNA leiden 
tot het ophopen van mutaties,  versnelde 
veroudering en kanker.  
Het DNA is constant blootgesteld aan 
interne en externe factoren die DNA schade 
kunnen veroorzaken. UV licht van de zon kan 
er voor zorgen dat twee naast elkaar liggende 
bases aan elkaar vast komen te zitten 
terwijl ioniserende straling enkelstrengs- 
en dubbelstrengsbreuken in het DNA 
kan veroorzaken. Chemotherapeutische 
medicijnen, zoals Mitomycine C en cisplatine, 
maken dwarsverbindingen (crosslinks) 
tussen DNA strengen onderling en naburige 
eiwitten, waardoor het DNA niet geopend kan 
worden voor transcriptie en replicatie. Om 
DNA schade efficiënt te kunnen detecteren 
en repareren beschikken cellen over een 
arsenaal aan DNA reparatiemechanismen: 
de DNA schade respons (DNA damage 
response, DDR). Deze reparatiemechanismen 
herkennen specifieke soorten DNA schade 
en kunnen de celcyclus stil leggen zodat er 
voldoende tijd is om de schade te repareren 
voor de volgende mitose (celdeling). 
Hoofdstuk 1 is een algemene introductie 
over DNA reparatie.  
Basen die de DNA helix verstoren, zoals 
basen beschadigd door UV licht, worden 
gerepareerd via het nucleotide excisie 
reparatiemechanisme (NER). Soms plaatst 
een polymerase tijdens het kopiëren van 
DNA per ongeluk een verkeerde base. 
Wanneer twee verkeerde basen tegenover 
elkaar zitten, worden deze verwijderd door 
een mechanisme dat verkeerde combinaties 
(mismatches) herkent. De verkeerde base 
wordt verwijderd en een polymerase plaatst 
de juiste base terug. Voor de reparatie van 
DNA dubbelstrengsbreuken zijn er twee 
verschillende mechanismen: homologous 
recombination (HR) en non homologous end-
joining (NHEJ). Testen om de activiteit van 
deze twee reparatiemechanismen te meten 
en het belang van een gezonde balans tussen 
de twee mechanismen worden besproken in 
hoofdstuk 2. 
DNA crosslinks verbinden twee 
tegenoverliggende strengen van DNA, 
waardoor de DNA helix niet geopend kan 
worden tijdens de replicatie. Dit type DNA 
schade wordt herkend door het Fanconi 
Anemie mechanisme (FA), door HR, door 
trans-laesie synthese (TLS) en door NER. TLS 
is een bijzonder mechanisme, omdat het niet 
zo zeer voor reparatie van de schade zorgt, 
maar voorkomt dat replicatie vastloopt. Het 
zorgt ervoor dat schade getolereerd wordt 
door een base tegenover een beschadigde 
base te zetten met een flexibele polymerase, 
zodat de cel kan overleven en de schade later 
gerepareerd kan worden.
Mutaties in eiwitten die betrokken zijn 
bij DNA reparatie verhogen de kans op 
specifieke soorten kanker. Vrouwen met een 
mutatie in de eiwitten BRCA1 en BRCA2, 
betrokken bij HR, hebben een verhoogde 
kans op borst- en eierstok kanker. In de 
meeste gevallen is in de tumor het gezonde 
allel uitgeschakeld en komt alleen de 
gemuteerde versie van het eiwit tot expressie. 
De cellen zijn dan niet langer in staat om 
DNA dubbelstrengsbreuken te repareren 
via HR. Dit defect maakt de cellen extreem 
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gevoelig voor PARP inhibitors zoals Olaparib. 
Het enzym PARP1 is noodzakelijk voor de 
efficiënte reparatie van enkelstrengs breuken. 
Wanneer deze breuken niet gerepareerd 
worden voor de replicatie, dan ontspoort 
de replicatievork wanneer deze bij een 
breuk komt. De ontspoorde vork vormt een 
dubbelstrengs breuk met een enkel uiteinde 
en voor de reparatie hiervan is HR nodig. 
Wanneer HR geïnactiveerd is door mutaties 
in bijvoorbeeld BRCA1 of BRCA2, hoopt de 
DNA schade zich op in de aanwezigheid van 
de PARP inhibitor. Dit leidt uiteindelijk tot de 
dood van de kankercel. 
PARP inhibitors zoals Olaparib zijn 
veelbelovend voor de behandeling van 
tumoren met defecten in HR, maar een deel 
van de tumoren wordt uiteindelijk resistent. 
De resistentie kan veroorzaakt worden door 
overexpressie van een membraanpomp die 
de PARP inhibitor uit de cel pompt, door het 
terug muteren van de mutatie in BRCA1 of 
BRCA2 waardoor er geen HR defect meer is, 
of door het verlies van de expressie van het 
eiwit 53BP1. Echter, niet alle gevallen van 
resistentie kunnen via deze mechanismen 
verklaard worden. Hoofdstuk 3 beschrijft 
dan ook een zoektocht naar andere 
resistentiemechanismen in BRCA1 deficiënte 
borstkankercellen van de muis. 
Om nieuwe resistentie mechanismen 
te identificeren, voerden we een ‘loss-
of-function’- shRNA screen uit in de 
muizencellen. Resistente kolonies werden 
geselecteerd door middel van een hoge 
concentratie PARP inhibitor. Een van de ‘hits’ 
uit de screen was 53BP1. Van dit eiwit was 
al bekend dat verlies van expressie leidt tot 
PARP inhibitor resistente in BRCA1 deficiënte 
cellen. Een nieuwe hit uit de screen was REV7 
en het verlies van REV7 expressie, leidde ook 
tot PARP inhibitor resistentie. In afwezigheid 
van REV7 konden RAD51 foci weer gevormd 
worden en was resectie hersteld in BRCA1 
deficiënte cellen. 
Aan de hand van de eerste studie was 
nog niet duidelijk waarom het verlies van 
REV7 leidt tot herstel van HR in BRCA1 
deficiënte cellen. REV7 is van belang voor TLS, 
samen met REV3, maar REV7 is vooral van 
belang voor de celcyclus en diverse andere 
processen. In hoofdstuk 4 wordt beschreven 
op welke wijze REV7 van belang is voor de 
PARP inhibitor resistentie. De rol van REV7 in 
de celcyclus lijkt niet van belang te zijn, maar 
de interactie met REV3 is wel belangrijk voor 
het herstel van HR. 
Hoofdstuk 5 gaat over BRCA2 en haar 
interactie partners. BRCA2 is, net als BRCA1, 
essentieel voor HR en BRCA2 deficiënte cellen 
zijn ook heel gevoelig voor PARP inhibitors. 
In een massaspectrometrie experiment 
ontdekten we een nieuwe interactie partner 
van BRCA2: HSF2BP. Volgens de literatuur 
komt HSF2BP alleen tot expressie in de testis, 
maar wij zagen ook expressie in embryonale 
stamcellen van de muis en in verschillende 
humane kankercellijnen. Overexpressie, maar 
niet depletie, van HSF2BP zorgde ervoor dat 
cellen extreem gevoelig werden voor de 
crosslinker MMC. Ook leidde overexpressie 
van HSF2BP tot meer chromosomale 
afwijkingen na blootstelling aan MMC. Deze 
eigenschappen zijn ook karakteristiek voor 
cellen van Fanconi Anemie patiënten. Deze 
patientencellen cellen hebben een defect in 
de reparatie van DNA crosslinks. 
HSF2BP bindt aan BRCA2 in dezelfde 
regio als FANCD2 aan BRCA2 bindt. Ook leidt 
overexpressie van HSF2BP tot een afname 
in FANCD2 en RAD51 foci, nadat cellen 
blootgesteld zijn aan MMC. We hebben de 
regio van BRCA2 waar HSF2BP aan bindt 
exact bepaald.
Hoofdstuk 6 is de algemene discussie, 
waarin zowel de resultaten van deze thesis 
als de implicaties voor de behandeling van 
kanker in de toekomst besproken worden. 
Er wordt bovendien aandacht besteed 
aan de vraag hoe de nieuwe bevindingen 
optimaal geïmplementeerd zouden kunnen 
worden in de kliniek en welke stappen 
genomen zouden moeten worden voordat 
de implementatie mogelijk is. Ook worden 
ontwikkelingen op het gebied van nieuwe 
medicatie voor de behandeling van kanker en 
de daarmee gemoeide kosten en bijkomende 
consequenties besproken. 
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